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“The morbid alterations to which attention is subject, may all be reduced under the three following 
heads: 
1st. The incapacity of attending with a necessary degree of constancy to any one object. 
2dly. A total suspension of its effects on the brain.” 
 
“The incapacity with a necessary degree of constancy to any one object, almost always arises from 
an unnatural or morbid sensibility of the nerves, by which means this faculty is incessantly 
withdrawn from one impression to another.” (….)”When born within a person it becomes evident at a 
very early period of life, and has a very bad effect, inasmuch as it renders him incapable of 
attending with constancy to any one object of education” 
Crichton (1798), p. 270-271 
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GENERAL INTRODUCTION  
Attention problems are a core feature in adolescents with Attention Deficit /Hyperactivity 
Disorder (ADHD) as well as in adolescents with comorbid autism spectrum disorders (ASD) and 
ADHD (ASD+ADHD). To what extent psychophysiological constructs related to attention 
problems overlap or differ between ADHD and combined ASD+ADHD is yet unknown. 
Accordingly, it remains unclear whether current treatment strategies, that are effective in reducing 
ADHD-symptomatology in ADHD, might have a different effect on psychophysiological 
parameters in combined ASD+ADHD and as a consequence might be less effective.  
Neurofeedback is proposed as an intervention that is potentially effective in reducing 
ADHD- symptomatology. Neurofeedback aims to alter brain activity by operant conditioning and 
simultaneously reduce ADHD symptoms, mainly to improve attention. However, results to date 
have been inconsistent and large scale randomized clinical trials are scarce, and the additional 
effects of neurofeedback in adolescents with ADHD and comorbid disorders have not been 
investigated. Therefore, this thesis consists of two parts. The first part focuses on 
psychophysiological overlap and differences between adolescents with ADHD and combined 
ASD+ADHD. The focus of the second part is on whether it is possible to improve behavioral and 
neurocognitive functioning in these adolescents with neurofeedback.  
 
ADHD and Autism Spectrum Disorders 
In the 18th century, Sir Alexander Crichton was the first to describe a disorder similar to Attention 
Deficit/Hyperactivity Disorder (ADHD) (Lange, Reichl, Lange, Tucha, & Tucha, 2010). 
Nowadays, ADHD is defined as patterns of frequent inattention and/or hyperactivity-impulsivity 
symptoms that interfere with developmentally appropriate social, academic, or occupational 
functioning (American Psychiatric Association, 2013). ADHD is the most common 
neurodevelopmental disorder with a worldwide prevalence of around 5% (Polanczyk, de Lima, 
Horta, Biederman, & Rohde, 2007; Willcutt, 2012). Comorbid neurodevelopmental conditions such 
as learning disabilities, conduct disorder, depression and anxiety are seen more often in youngsters 
with ADHD than in youngsters without ADHD (Larson, Russ, Kahn, & Halfon, 2011). 
Additionally, in ASD, which are characterized by persistent problems with social interaction, 
communication and/or display stereotyped behavior, interests and activities (American Psychiatric 
Association, 2013), estimations of ADHD comorbidity range between 30% and 78% (Gjevik, 
Eldevik, Fjaeran-Granum, & Sponheim, 2011; Lee & Ousley, 2006; Simonoff et al., 2008). 
Notwithstanding the high rates of ADHD comorbidity in ASD, in the Diagnostic and Statistical 
Manual of Mental Disorders, the DSM-IV (American Psychiatric Association, 2000), ADHD could 
not be classified as a comorbid disorder of ASD, but ADHD symptoms were considered part of 
ASD. In order to prevent children with ASD and ADHD symptoms being excluded from 
potentially beneficial treatment for ADHD (American Psychiatric Association, 2012), the DSM-V 
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now states that when criteria of ASD and ADHD are met, both diagnoses should be assigned 
(American Psychiatric Association, 2013).  
Currently, best practices for treatment of ADHD symptoms consist of stimulant-
medication, and/or behavioral therapy. Evidence of effectiveness of non-pharmacological 
interventions as behavioral therapies is limited (Sonuga-Barke et al., 2013). Behavioral therapies 
seem effective for reducing ADHD problems when evaluated by parents or others aware of the 
received treatment (Sonuga-Barke et al., 2013). However, with blinded assessments these effects 
disappear (Sonuga-Barke et al., 2013). Stimulant-medication is effective in reducing ADHD 
symptoms in youngsters with ADHD (Faraone & Buitelaar, 2010; Greenhill et al., 2001). It is 
effective treatment for ADHD in youngsters with combined ADHD and ASD, although possible 
to a lesser extent (Cortese, Castelnau, Morcillo, Roux, & Bonnet-Brilhault, 2012; Research Units on 
Pediatric Psychopharmacology (RUPP) Autism Network, 2005). Moreover, previous studies are 
inconclusive on whether psychophysiological correlates are different for ASD+ADHD compared 
to ADHD. Consequently, it is not known whether stimulant medication that seems effective for 
ADHD treatment (Faraone & Buitelaar, 2010; Greenhill et al., 2001) results in comparable 
psychophysiological effects in combined ASD+ADHD. Differences in psychophysiology indicate 
that stimulant-medication might exert its effect differently in combined ASD+ADHD and could 
possibly help to explain why stimulant-medication seems to be less effective in ASD+ADHD than 
in ADHD.  
 Even though stimulant medication seems effective in reducing ADHD symptoms for a 
large number of youngsters with ADHD (Cortese et al., 2012; Faraone & Buitelaar, 2010; Greenhill 
et al., 2001; RUPP, 2005), dose-dependent mild adverse effects of stimulant-medication, such as 
decreased appetite, difficulty falling asleep and headaches, are reported relatively often (Cortese et 
al., 2012; Graham & Coghill, 2008; RUPP, 2005). Moreover, eventually, the majority of adolescents 
above the age of 15 discontinue stimulant-medication use, despite the persistent course of the 
disorder (Zetterqvist, Asherson, Halldner, Langstrom, & Larsson, 2012). Therefore, additional 
interventions to the current treatment as usual (TAU) to further reduce ADHD symptoms 
enduringly are warranted. In this respect, neurofeedback has been suggested as a potential effective 
intervention in reducing ADHD symptoms by modifying brain activity in ADHD (Lofthouse, 
Arnold, Hersch, Hurt, & DeBeus, 2012; Moriyama et al., 2012) and ASD (Holtmann et al., 2011). 
Since working mechanisms of interventions, such as stimulant medication and neurofeedback, are 
(hypothesized to be) based on adapting deviant physiological patterns, it is of importance to 
understand how physiology is related to ADHD symptoms.  
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Psychophysiology and ADHD symptomatology 
Physiological measures have previously been related to ADHD symptomatology. For example, 
cardiac reactivity has been related to different psychological processes such as attention, behavioral 
inhibition and social engagement (Porges, 2007) and consequently to key symptoms of ADHD. 
Specifically, indications for increased parasympathetic activation with lower heart rate (Negrao, 
Bipath, van der Westhuizen, & Viljoen, 2011) and increased heart rate variability (Borger & van der 
Meere, 2000; Borger et al., 1999; Negrao et al., 2011) were found in youngsters with ADHD. In 
addition, electro-encephalogram (EEG) power spectra in ADHD revealed increased theta power 
(Cortese, 2012; Loo & Makeig, 2012; Snyder & Hall, 2006), and to a lesser extent, decreased beta 
activity (Cortese, 2012; Snyder & Hall, 2006). At the behavioral level, theta (4-7 Hz) has been 
negatively related to vigilance and beta (13-30Hz) positively related to attention (Banaschewski & 
Brandeis, 2007). Accordingly, theta and beta measures lend support for cortical underarousal in 
ADHD. Similarly, deviant patterns of event-related potential (ERP) activity are seen in youngsters 
with ADHD (Du et al., 2006; Groom et al., 2010; Hermens et al., 2005; Johnstone, Barry, & Clarke, 
2013; Pliszka et al., 2007). Compared to typically developing youngsters, ERP components related 
to attention processing are diminished in amplitude in youngsters with ADHD (Barry, Johnstone, 
& Clarke, 2003; Johnstone et al., 2013), including the N2, which is associated with stimulus 
orienting and discrimination (Näätänen, Simpson, & Loveless, 1982), and the P3, which is 
associated with selective attention and (working) memory capacity (Polich & Herbst, 2000) 
Collectively, diminished cortical activation levels seem apparent in ADHD across different 
physiological measures.  
Stimulant medication that is effective in reducing ADHD symptoms in youngsters with 
ADHD (Faraone & Buitelaar, 2010; Greenhill et al., 2001) also seems to partly normalize the 
aforementioned deviant physiological measures in ADHD. Heart rate increases due to stimulant 
medication (Hammerness, Perrin, Shelley-Abrahamson, & Wilens, 2011) and becomes more similar 
in stimulant-medicated youngsters with ADHD and typically developing youngsters (Negrao et al., 
2011). Stimulant medication decreases the elevated theta activity as seen in ADHD, while 
simultaneously increasing beta activity (Clarke, Barry, Bond, McCarthy, & Selikowitz, 2002; Clarke 
et al., 2003; Hermens et al., 2005; Loo & Barkley, 2005). Similarly, stimulant medication appears to 
regulate ERP activity, with increased N2 (Pliszka et al., 2007) and P3 (Groom et al., 2010; Hermens 
et al., 2005) amplitudes after stimulant medication use in adolescents with ADHD. Overall, it seems 
that stimulant medication use by youngsters with ADHD leads to physiological measures that 
appear to resemble more those of typically developing youngsters, but do not reach identical 
activity levels. 
 It is not clear whether physiological patterns in youngsters with combined ASD and 
ADHD overlap with physiological patterns seen in ADHD. If physiological measures overlap, this 
could indicate that treatments that reduce ADHD-symptomatology might work similarly in 
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youngsters with combined ASD+ADHD. However, in the case that physiological measures related 
to ADHD-symptomatology differ for youngsters with combined ASD+ADHD, this could indicate 
that ADHD treatments might work differently or be less effective in youngsters with combined 
ASD+ADHD.  
 
Neurofeedback: an overview  
Neurofeedback is an intervention that intends to alter brain activity by giving feedback of 
electroencephalogram (EEG) activity to patients. Neurofeedback as an intervention for ADHD 
was originally derived from animal research with cats. In the sixties, Sterman and Wyrwicka (1967) 
trained hungry cats to inhibit behavior in order to obtain food. During the period behavior was 
inhibited, EEG recordings showed increased 12 to 20 Hz activity at the sensorimotor cortex. 
Therefore, this activity was named sensorimotor rhythm (SMR) (Roth, Sterman, & Clemente, 1967; 
Sterman & Wyrwicka, 1967). Consequently, by training the cats to inhibit behavior they indirectly 
increased SMR activity, mainly between 12 to 16 Hz (Roth et al., 1967). In a new experiment, the 
cats were not trained to inhibit behavior, but the hungry cats received food when the recorded 
EEG showed SMR activity (Sterman, Wyrwicka, & Roth, 1969). In this way, Sterman, Wyrwicka, et 
al. (1969) intended to train the SMR activity more directly, instead of training behavior and 
consequently SMR activity. Note that the cats started to show sets of behavior with typical 
inhibited postures simultaneously with the SMR activity, in order to obtain food. In a subsequent 
experiment, three cats that were trained to produce SMR activity, together with three cats that did 
not receive this training, were poisoned with monomethylhydrazine in an experiment for NASA on 
the toxic effects of rocket fuel (Sterman, LoPresti, & Fairchild, 1969). Compared to the untrained 
cats, more monomethylhydrazine was needed for the SMR-trained cats to show epileptic activity. 
Accordingly, it was concluded that SMR training has protective properties. Moreover, it was 
hypothesized that it may be possible to train brain regulation enduringly by operant conditioning in 
humans as well.  
Considering the possible protective properties, the first studies of SMR training in humans 
included epileptic subjects (Sterman & Friar, 1972; Sterman, Macdonald, & Stone, 1974). After 
long-term (more than two to three months) biofeedback training of the SMR activity, the patients 
showed a decrease in epileptic activity and displayed SMR activity more often than before the 
training (Sterman et al., 1974). Taken together, the results indicated that SMR activity (12-16Hz) is 
related to cortical inhibition (Roth et al., 1967; Sterman & Wyrwicka, 1967; Sterman, Wyrwicka, et 
al., 1969) and could be trained in humans (Sterman & Friar, 1972; Sterman et al., 1974). 
Correspondingly, it was reasoned by Lubar  and Shouse (1976) that training aimed at increasing 
SMR activity would improve inhibition problems in children with ADHD. In addition, the training 
aimed to reduce theta activity that is negatively related to vigilance. After positive results in this case 
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study, other studies followed with more participants. Until now, the effects of neurofeedback have 
been investigated and applied mostly in youngster with ADHD. 
The most frequently applied neurofeedback protocol for reducing ADHD symptoms is the 
theta/beta training, which aims to decrease theta (4-7Hz) and increase SMR (12-15Hz) or beta (12-
20Hz) (Lofthouse et al., 2012; Loo & Makeig, 2012; Moriyama et al., 2012). This training protocol 
is based on the assumption that children with ADHD show increased theta activity and decreased 
beta activity compared with typically developing children (Snyder & Hall, 2006). Theta and beta 
activity are related to vigilance and attention respectively (Banaschewski & Brandeis, 2007). 
Correspondingly, the rationale is that a decrease in theta activity would result in improved vigilance 
and an increase in beta would result in improved attention.  
In practice, a neurofeedback training session starts with the attachment of electrodes on 
the scalp, mostly on the vertex (Cz) with references linked mastoid. The signals are amplified and 
sent to a computer. Software developed for neurofeedback training converts the incoming signal 
and the converted signal is made visible on the monitor of the neurofeedback trainer. The trainer 
looks at the raw EEG-signal and the signal separated in frequency bands between 4Hz and 32 Hz. 
Several frequency bands can be trained simultaneously. Accordingly, for theta/beta training the 
software is programmed to reinforce the SMR or beta activity and to inhibit theta activity or other 
frequency bands. Based on the incoming EEG-signal, the limits per frequency band are 
determined. When the signal is within the set limits of each frequency bands, then the signal is 
considered appropriate and the patient is rewarded with positive feedback. At the same time, the 
patient watches a monitor that displays a visual representation of his/her own brain activity. This 
visual representation can be presented as a movie or a game like situation. In the case of a movie, 
the quality of the film as well as the sound, rely on the produced brainwaves. In the game like 
situation, graphics, sound and score depend on the produced brainwaves. In this way the different 
frequency bands are reinforced or inhibited by means of operant conditioning in 20 to 40 sessions. 
A special kind of neurofeedback is the training of slow cortical potentials (SCPs). SCPs are 
stimuli related very slow potentials (<0.1 Hz). A negative (downwards curving) very slow brainwave 
is associated with increased cortical activation and related to more efficient behavioral responses. A 
positive (upwards curving) very slow brain wave is associated with a decrease of cortical activation 
and less efficient behavioral responses (Birbaumer, Elbert, Canavan, & Rockstroh, 1990). The idea 
is basically that the patient gets control to increase and decrease the activation level of the brain. 





Effectiveness of neurofeedback in ADHD treatment 
The first non-randomized effectiveness studies in youngsters with ADHD compared care as usual, 
including stimulant medication, with neurofeedback, sometimes as additional training to care as 
usual. Overall, these studies showed comparable improvement in attention, as measured by 
behavioral questionnaires and neuropsychological tests, for youngsters receiving neurofeedback 
compared to youngsters receiving stimulant medication (Fuchs, Birbaumer, Lutzenberger, 
Gruzelier, & Kaiser, 2003; Rossiter & La Vaque, 1995). In addition, neurofeedback seemed of 
additional value to stimulant medication (Monastra, Monastra, & George, 2002). Compared to a 
combined treatment of stimulant medication with parent- and school-education, youngsters with 
ADHD who also received neurofeedback displayed increased brain activity, improved attention and 
less hyperactive/impulsive behavior at home and at school. The study by Monastra et al. (2002) 
showed that the youngsters who received neurofeedback one-year post neurofeedback training still 
displayed less ADHD symptomatology compared to the youngster who received standard 
treatment. 
The randomized studies that followed also showed positive effects after neurofeedback 
training. The largest randomized study with 94 children between the ages of 8 and 12 years old 
showed that neurofeedback training (n=59) was more effective in reducing ADHD-
symptomatology than computerized attention training (n=35) up to a half-year post treatment 
(Gevensleben et al., 2010; Gevensleben, Holl, Albrecht, Vogel, et al., 2009). Moreover, the study 
found changes in brain functioning as reflected in a decrease of posterior-midline theta activity. In 
addition, the decrease in theta activity was related to the decrease in ADHD symptoms as reported 
by parents (Gevensleben, Holl, Albrecht, Schlamp, et al., 2009). The study of Duric, Assmus, 
Gundersen, and Elgen (2012) showed similar improvement in attention on behavioral 
questionnaires over time for children with ADHD who were treated with neurofeedback (n=30), 
stimulant medication (n=31) or combined neurofeedback and stimulant medication (n=30). 
Comparably, a smaller study with a RCT design also showed similar improvement in attention for 
neurofeedback (n=12) and stimulant medication (n=11) (Meisel, Servera, Garcia-Banda, Cardo, & 
Moreno, 2013). In line with the positive outcomes of the uncontrolled studies, these RCTs showed 
comparable improvement for neurofeedback compared to stimulant-medication.  
 In contrast, blinded RCT’s, overall, do not show superiority or neurofeedback over sham-
neurofeedback in reducing ADHD-symptoms (Arnold et al., 2012; Perreau-Linck, Lessard, 
Levesque, & Beauregard, 2010; van Dongen-Boomsma, Vollebregt, Slaats-Willemse, & Buitelaar, 
2013; Vollebregt, van Dongen-Boomsma, Buitelaar, & Slaats-Willemse, 2013). The most optimistic 
outcome is of one single-blinded study, in which children with ADHD who received 
neurofeedback (n=18) improved more in attention as reported by parents and on 
neuropsychological measures of reaction time and accuracy than those receiving electromyography 
(EMG) biofeedback (n=17) (Bakhshayesh, Hansch, Wyschkon, Rezai, & Esser, 2011). The other 
Chapter 1 – Introduction 16 
blinded studies failed to find larger reductions of ADHD-symptoms for neurofeedback than for 
placebo-neurofeedback in youngsters with ADHD (Arnold et al., 2012; Perreau-Linck et al., 2010; 
van Dongen-Boomsma et al., 2013). Note, however, that the sample sizes of these groups were 
relatively small, with included participants per condition for neurofeedback versus placebo-
neurofeedback respectively, n=4 versus n=4 (Perreau-Linck et al., 2010), n=25 versus n=11 (Arnold 
et al., 2012) and n=22 versus n=19 (van Dongen-Boomsma et al., 2013). Notwithstanding the small 
sample sizes, these results indicate that the previously reported positive outcomes of the non-
placebo controlled studies in ADHD were possibly the result of non-specific effects of the 
treatment such as motivation and expectations by parents and youngsters, the high-tech setting 
with a medical appearance and the large number of training sessions with a clinical expert.  
There are fewer clinical effectiveness studies of neurofeedback in ASD than there are in 
ADHD. The most applied neurofeedback protocols in ASD consist of frequency training protocols 
(Holtmann et al., 2011) either similar to those applied in ADHD with inhibition of theta (4-7 Hz) 
and reinforcement of SMR (12-15 Hz) (Coben, Linden, & Myers, 2010) or suppression of the Mu 
rhythm (8-13Hz) (Coben et al., 2010; Holtmann et al., 2011). The review by Holtmann et al. (2011) 
states that although neurofeedback does not seem effective for ASD-features, it might be effective 
in reducing comorbid ADHD-symptomatology.  
 Overall, claims on the effectiveness of neurofeedback for ADHD symptoms range from 
‘efficacious and specific’ (Arns, de Ridder, Strehl, Breteler, & Coenen, 2009) and ‘probably 
effective’ (Lofthouse et al., 2012; Moriyama et al., 2012), to not effective when examined within 
blinded designs (Sonuga-Barke et al., 2013). The range of effectiveness estimations is so broad 
because several methodological shortcomings have hampered many of the included studies: the 
majority of the studies were not randomized, sample sizes were small, and/or non-specific 
treatment effects were not controlled for. Therefore, more conservative estimations were reported 
recently (Gevensleben, Rothenberger, Moll, & Heinrich, 2012; Lofthouse et al., 2012; Loo & 
Makeig, 2012; Moriyama et al., 2012; Sonuga-Barke et al., 2013). All in all, previous shortcomings in 
study design and unknown (negative) side effects preclude strong conclusions. To address these 
shortcomings, more controlled research is necessary to see if there are specific patient groups that 
will profit from neurofeedback and if this depends on the kind of neurofeedback training protocol 
that is applied (Gevensleben et al., 2012; Lofthouse et al., 2012). In addition, research is needed to 
see whether neurofeedback can be of additional value to multimodal treatment protocols 
(Gevensleben et al., 2012). Furthermore, the value of neurofeedback in clinical practice needs to be 
invested, where more heterogeneous populations of youngsters with ADHD are seen. Accordingly, 
in order to resemble implementation in clinical practice, youngster with ADHD and comorbid 




The aims of this thesis  
This thesis has two aims. The first aim of this thesis is to explore psychophysiology in adolescents 
with ADHD and combined ASD+ADHD in relation to possible clinical implications. The second 
aim of this thesis is to investigate whether neurofeedback has additional value for TAU to improve 
behavior and neurocognitive functioning for adolescents with ADHD. Therefore, this thesis is 
divided into two parts. In the first part of this thesis, the overlap and differences in 
psychophysiological measures between adolescents with ADHD and adolescents with combined 
ASD+ADHD are explored (Chapter 2-4). In the second part of this thesis, the additional effects 
of neurofeedback for TAU for adolescents with ADHD are investigated (Chapter 5-7). 
 
Study design and thesis layout 
In order to investigate the additional value of neurofeedback to the current TAU, adolescents were 
recruited from three different mental healthcare centers for child and adolescent psychiatry in the 
south of the Netherlands: GGzE (Eindhoven), GGz Breburg (Breda and Tilburg) and the Reinier 
van Arkel group (‘s-Hertogenbosch). Eligible participants were male adolescents with Dutch as 
their native language, ages 12 through 24 years old, with a clinical DSM-IV-TR primary diagnosis of 
ADHD and a full-scale total intelligence quotient (TIQ)>80. Adolescents diagnosed with ASD 
(including: Autism, Asperger disorder and PDD-NOS) with notification of clinical ADHD 
symptoms equal to a full ADHD diagnosis were also included. Exclusion criteria were neurological 
disorders, schizophrenia and other psychotic disorders. 
 At pre-intervention, participants were seen on three occasions for 1) the administration of 
behavioral questionnaires and neurocognitive tests, 2) the WAIS or WISC intelligence test, and 3) 
physiological measurements. In cases where participants were on medication, medication intake was 
also continued on the day of assessment. Interventions took place between December 2009 and 
July 2012. Duration of the intervention period was approximately 25 weeks. Interventions included 
either TAU as prescribed by the main therapist of the participating center for child and adolescent 
psychiatry or combined neurofeedback with TAU. Post-intervention assessment included 
behavioral questionnaires and neurocognitive tests. One year follow-up assessment included 
behavioral, neurocognitive and physiological measures.  
 The first part of this thesis explores potential physiological overlap and differences 
between adolescents with ADHD and combined ASD+ADHD, on and off stimulant medication, 
in cardiac reactivity (Chapter 2), theta/ beta power spectra (Chapter 3) and event-related 
potentials (Chapter 4) at pre-intervention. Two diagnostic groups were compared: adolescent with 
ADHD versus combined ASD+ADHD. The first group consisted of adolescents with a clinical 
DSM-IV-TR primary diagnosis of ADHD, including: combined subtype, inattentive subtype, 
hyperactive /impulsive subtype. The second group consisted of adolescents with a primary 
diagnosis of ASD, including: Asperger disorder and Pervasive developmental disorder – not 
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otherwise specified (PDD-NOS). Adolescents with ASD also showed ADHD symptomatology 
equal to a full DSM-IV-TR ADHD diagnosis. To improve comparability on the investigated 
physiological measures, we also excluded adolescents with depression, attachment disorder, anxiety 
disorder, use of cannabis 24 hours prior to physiological assessment or medication use other than 
stimulant medication for these analyses.  
 In the second part of the thesis, the additional value of neurofeedback for TAU is 
investigated by comparisons of the pre-intervention and direct post-intervention assessments on 
behavior and side effects (Chapter 5) and neurocognitive functioning (Chapter 6) between 
adolescents with ADHD who received TAU and adolescents who received combined 
neurofeedback and TAU. Approximately half of the adolescents used stimulant medication and one 
third had an ASD diagnosis. Therefore, possible effects of stimulant medication use as well as 
having an ASD diagnosis were taken into account. Finally, additional effects of neurofeedback on 
behavior and neurocognitive functioning one-year after the intervention period are explored 
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ABSTRACT 
A large number of youngsters with autism spectrum disorders (ASD) display comorbid attention 
deficit/hyperactivity disorder (ADHD) symptoms. However, previous studies are not conclusive 
whether psychophysiological correlates, like cardiac reactivity, are different for ASD with comorbid 
ADHD (ASD+) compared to ADHD. Therefore, the current study investigated (dis)similarities in 
cardiac reactivity and attention task performance. In a clinical sample, adolescents diagnosed with 
ASD+ (n=20) versus ADHD (n=36) and stimulant medication use (56%) were compared during a 
baseline with eyes closed and task performance. Results for cardiac reactivity were similar for both 
diagnostic groups. Stimulant-medicated adolescents showed decreased adaptation of LF/HF ratio and 
faster reaction times than stimulant-free adolescents. The current study underlines the 




Adolescents with autism spectrum disorders (ASD) show severe and persistent problems with social 
interaction, communication and/or display stereotyped behavior, interests and activities (American 
Psychiatric Association, 2000). More than half of youngsters with ASD also experience comorbid 
symptoms of Attention Deficit Hyperactivity Disorder (ADHD) at a clinical level (Gadow, DeVincent, 
& Pomeroy, 2006; Holtmann, Bolte, & Poustka, 2007). However, in the DSM-IV-TR (American 
Psychiatric Association, 2000) ADHD was excluded as a diagnosis in ASD. In order to prevent that 
children with ASD and ADHD symptoms are excluded from potentially beneficial treatment for 
ADHD, the DSM-V taskforce has removed ASD from the exclusion criteria of ADHD (American 
Psychiatric Association, 2012). Nevertheless, previous studies are not conclusive whether 
psychophysiological correlates are different for ADHD in ASD compared to ADHD (American 
Psychiatric Association, 2012). Consequently, it is uncertain whether treatment for ADHD, like 
stimulant medication, work equally well in children with ASD and comorbid ADHD (ASD+) as in 
children with ADHD. Stimulant medication showed improved attention and diminished hyperactivity 
and impulsivity symptoms in children with ADHD (Gorman, Klorman, Thatcher, & Borgstedt, 2006). 
ADHD symptom reduction by stimulant medication seems dose dependent, with better responses in 
children with predominant hyperactive/impulsivity (HI) symptoms to higher doses and in children 
with predominant inattentive (I) symptoms to lower doses (Barkley, DuPaul, & McMurray, 1991; Stein 
et al., 2003). Comparison of two large corporate studies that investigated reactions to stimulant 
medication in children with ADHD (Greenhill et al., 2001) and children with ASD+ (Research Units 
on Pediatric Psychopharmacology (RUPP) Autism Network, 2005) indicates that there are differences 
for the two groups. For example, where stimulant medication improves behavior in nearly three-
quarters of children with ADHD (Greenhill et al., 2001), this is only 49 percent in ASD+ (RUPP, 
2005). Moreover, adverse effects, such as irritability, decreased appetite, and difficulty falling asleep are 
more often seen in stimulant medicated ASD+ patients. In fact, 18 percent of the children with ASD+ 
had to stop stimulant medication because of adverse effects (RUPP, 2005), compared to only 1.5 
percent in children with ADHD (Greenhill et al., 2001). The lower response rate and higher prevalence 
of adverse effects reported for stimulant medication in the ASD+ group may reflect differential 
psychophysiological mechanisms underlying ADHD symptoms in ADHD versus ASD+.  
 Cardiac reactivity has been related to different psychological processes as attention, behavioral 
inhibition and social engagement (Porges, 2007) and consequently to key symptoms of both ADHD 
and ASD. To date, several studies indeed differentiate in cardiac reactivity for youngsters with ASD 
compared to typically developing (TD) youngsters (Althaus, Mulder, Mulder, Aarnoudse, & Minderaa, 
1999; Van Hecke et al., 2009) and in youngsters with ADHD compared to TD youngsters (Borger & 
van der Meere, 2000; Borger et al., 1999; Luman, Oosterlaan, Hyde, van Meel, & Sergeant, 2007). 
However, cardiac reactivity has not been compared between ASD+ and ADHD. Therefore, the aim of 
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this study is to explore (dis)similarities in cardiac reactivity and attention task performance in 
stimulant-medicated and stimulant-free adolescents, diagnosed with ASD+ versus ADHD. 
 In the last two decades, cardiac activity in heart rate (HR) and heart rate variability (HRV) has 
been increasingly studied in relation to behavior and cognition. HRV represents the variation of beat-
to-beat intervals in an electrocardiogram (ECG) and reflects the interchange between sympathetic and 
parasympathetic impact on the cardiac pacemaker. Task effort and stress have been shown to induce 
an adaptation of cardiac activity (Jorna, 1992). Previous studies have found mixed results for cardiac 
activity during resting baseline. Compared to TD children, children with ASD showed higher heart 
rates and less HRV in rest conditions, that indicates increased sympathetic activation in children with 
ASD (Bal et al., 2010; Daluwatte et al., 2012; Van Hecke et al., 2009). Other studies, however, failed to 
find any differences during rest conditions between TD children and adolescents and those with 
ASD(+) (Althaus et al., 1999; Toichi & Kamio, 2003).  
Whereas increased sympathetic activation is supposed in ASD (Bal et al., 2010; Daluwatte et al., 2012; 
Van Hecke et al., 2009), indications for increased parasympathetic activation were found in stimulant-
free children with ADHD across different studies (Borger & van der Meere, 2000; Borger et al., 1999; 
Negrao, Bipath, van der Westhuizen, & Viljoen, 2011). More specific, increased HRV was found 
during attention task performance in stimulant-free children with ADHD compared to TD children 
(Borger & van der Meere, 2000; Borger et al., 1999). In addition, increased HRV and lower HR during 
resting baseline were found for stimulant-free children with ADHD compared to TD children (Negrao 
et al., 2011). However, HRV and HR were similar for stimulant-medicated children with ADHD and 
TD children (Negrao et al., 2011). Accordingly, Negrao et al. (2011) postulated the assumption that 
stimulant medication decreases the parasympathetic activation and thereby normalizes the autonomic 
balance. This idea is in line with the majority of research that shows elevation of HR due to stimulant 
medication (Hammerness, Perrin, Shelley-Abrahamson, & Wilens, 2011). Nevertheless, similar to the 
pattern observed during rest conditions in children with ASD, other cardiac studies in children with 
ADHD failed to find differences in cardiac activity between stimulant-free children with ADHD and 
TD children (Beauchaine, Katkin, Strassberg, & Snarr, 2001; Jennings, van der Molen, Pelham, Debski, 
& Hoza, 1997). In contrast, there are even studies that indicate elevated HR and decreased 
parasympathetic activation in children with ADHD and that medication reduces HR and increases 
parasympathetic activation (Buchhorn et al., 2012; Rash & Aguirre-Camacho, 2012). However, 
Beauchaine et al. (2001), showed that only children with ADHD and comorbid conduct disorder show 
significant decreased parasympathetic activation compared to children with ADHD and TD children. 
This assumes that the comorbid symptoms of conduct disorder are related to decreased 
parasympathetic activation rather than to ADHD symptoms.  
 Findings have been more consistent with respect to differential patterns of cardiac adaptation 
to tasks. In the early nineties, Porges (1995, 2007) described the common presentation of a decrease in 
HRV in healthy subjects when they perform an attention-demanding task compared to a resting 
baseline condition. Moreover, a positive relation was observed for cardiac adaption and task 
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performance (Porges, 2007). In line with this theory, task-related cardiac adaptation with decreased 
HRV was observed in TD children and stimulant-free children with ADHD (Borger & van der Meere, 
2000; Jennings et al., 1997; Luman et al., 2007; Negrao et al., 2011). However, task-related cardiac 
adaptation was not observed in stimulant-medicated children with ADHD (Negrao et al., 2011). 
Likewise, children and young adults with ASD also seem to show less task-related cardiac adaptation 
than TD controls (Althaus et al., 1999; Toichi & Kamio, 2003). Therefore, it seems that ASD and 
stimulant medication use are both related to a reduced task-related cardiac adaptation.  
 Attention symptoms that occur in youngsters with ADHD or ASD may result in diminished 
attention task performance. Several studies showed that children with ADHD display longer reaction 
times and more variability in reaction times than TD children (Banaschewski et al., 2003; Borger & van 
der Meere, 2000; Groen et al., 2008; Jennings et al., 1997). The study of Althaus et al. (1999) also 
presented longer reaction times in youngsters with ASD and ASD+ compared to TD controls. 
However, a study by Groen et al. (2008) did not find such differences in reaction times for ASD 
compared to TD children. More specifically, the study showed that only stimulant-free children with 
ADHD display more variability in reaction times than stimulant-medicated children with ADHD, 
children with ASD and TD children. Results with regard to accuracy are ambiguous. For example, 
Groen et al. (2008) did show that children with ADHD or ASD made more errors than TD children 
during attention task performance. Whereas, Althaus et al. (1999) showed that children with ASD+, 
but not children with ASD, made more errors than TD children. In addition, some studies did not 
even find significant differences between ADHD and TD children (Banaschewski et al., 2003; Borger 
& van der Meere, 2000). Group differences of accuracy in the studies, might have been suppressed by 
a ceiling effect due to the low amount of errors during sustained attention tasks.  
 To summarize, ADHD symptoms are present in a large number of patients diagnosed with 
ASD. At this time, it is not clear whether psychophysiological characteristics are similar in ASD+ 
patients and ADHD patients. Therefore, the aim of this study is to explore (dis)similarities in cardiac 
reactivity and attention task performance in stimulant-medicated and stimulant-free adolescents, 
diagnosed with ASD+ versus ADHD. 
 It was expected that psychophysiological measures are dependent on diagnostic group (ASD+ 
versus ADHD, stimulant medication use, stimulant-free versus stimulant-medicated adolescents) and 
the interaction of diagnostic group and stimulant medication use. More specifically, with respect to 
cardiac reactivity it was expected that: (1) ASD+ adolescents display higher HR, less HRV and less task 
related cardiac adaptation than ADHD adolescents, (2) stimulant-medicated adolescents will display 
higher HR, less HRV and less task-related cardiac adaptation than the stimulant-free adolescents, and 
(3) the interaction of cardiac activity and stimulant medication use is smaller in the ASD+ group than 
in the ADHD group. With respect to cognitive performance on the attention task it was expected that, 
stimulant-medicated adolescents would show enhanced performance compared to stimulant-free 
adolescents in both diagnostic groups. 
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METHOD 
Participants 
Eligible participants were native Dutch speaking male adolescents, between 12 and 24 years old, a 
clinical DSM-IV-TR primary diagnosis of ADHD or ASD (including: PDD-NOS and Asperger 
disorder) with notification of clinical ADHD, symptoms equal to a full ADHD diagnosis, a full-scale 
total intelligence quotient (TIQ) > 80 on the Wechsler Intelligence Scale for Children (WISC-III) or 
the Wechsler Adult Intelligence Scale (WAIS-III) (Wechsler, 1991, 1997). ADHD symptoms were 
verified by a DSM-IV based Dutch semi-structured ADHD interview for adults (Kooij, 2002) and the 
Mini International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998; Sheehan et al., 1997). 
Exclusion criteria were neurological disorders, schizophrenia or another psychotic disorder, 
depression, attachment disorder or anxiety disorder. Presence of other comorbid disorders was 
allowed. 
Stimulant medication use was allowed. Adherence to prescribed stimulant medication was verified by 
asking the participants whether they took their medication on the day of assessment. Participants were 
excluded for analysis if they forgot to take the prescribed medication on the day of assessment, used 
antidepressant medication, used atomexetine, and/or used recreational drugs in the last 24 hours prior 
to assessment.   
 Fifty-six participants were divided in two diagnostic groups. These groups are presented in 
Figure 1. The final group characteristics are listed in Table 1. The first group consisted of 20 
adolescents with a primary DSM-IV-TR diagnosis of ASD with ADHD symptoms (ASD+ group). 
Although the diagnoses ASD and ADHD are mutually exclusive according to the DSM-IV-TR, 13 
(65%) participants received a secondary diagnosis of ADHD. In addition to the inclusion criteria, the 
seven (35%) participants who did not have a secondary ADHD diagnosis, had to score (sub)clinical on 
two subscales of the ADHD-rating scale (See further description below; Kooij et al., 2008; Kooij et al., 
2005). The second group consisted of 36 adolescents with a primary DSM-IV-TR diagnosis of ADHD 
(ADHD group). 
 In total 31 (55%) participants used stimulant medication. In the ASD+ group, 11 (55%) used 
stimulant medication: one used immediate release methylphenidate, 10 used sustained release 
methylphenidate. Two adolescents in the ASD+ group used low doses (0.5 mg and 1.5 mg per day) of 
antipsychotic medication (Risperdal®) in addition to their stimulant medication. Because of the low 
doses, possible impact on the cardiac measures was considered minimal. In the ADHD group, 20 

























ASD symptoms were screened with the Autism-Spectrum Quotient (AQ)-adolescent version, which is 
a questionnaire for individuals with normal intelligence (Baron-Cohen, Hoekstra, Knickmeyer, & 
Wheelwright, 2006; Baron-Cohen, Wheelwright, Skinner, Martin, & Clubley, 2001). The AQ-
adolescent version is a parent report and was completed by parents or significant others. Dichotomous 
scoring was applied and all item scores were summed. In the AQ validity study of Baron-Cohen et al. 
(2006) 87% of the male ASD adolescents seem to score 30 points or more on the AQ-adolescent 
versus none of the TD adolescents. Therefore, the advised critical minimum to screen for ASD is 30 
points or more (Baron-Cohen et al., 2006).  
 The ADHD-rating scale is a DSM-IV-based self-report for adults (Kooij et al., 2008; Kooij et 
al., 2005) We used the adapted form (DuPaul et al., 1998) which contains 23 items rated on a 4-point 
scale ranging from ‘rarely or never’ to ‘very often’. Items are completed for occurrence over the last six 
months and childhood. Participants were instructed to consider the 23 items over childhood for the 
primary school period. Each 23-item list is divided in two nine-item subscales: inattention and 
hyperactivity/ impulsivity (HI) (Kooij et al., 2008; Kooij et al., 2005). 
 The Child Behavior Checklist (CBCL) and the Youth Self Report (YSR) (Achenbach, 1991) 
are questionnaires that cover behavioral and emotional problems in children and adolescents up to 18 
years old. In this study, the subscale attention problems, the two broadband scales internalizing and 
ASD+ (n=20) 
♦ PDD-NOS (14) 
♦ Asperger (6) 
 
Subtype ADHD (20) 
♦ Combined (5) 
♦ Inattentive (4) 
♦ Hyperactive/Impulsive (2) 
♦ ADHD NOS (2) 
♦ ADHD symptoms and (sub) 
clinical score on two 
subscales of the ADHD-
rating scale (7)   
 
Comorbid disorders (2) 
♦ Conduct disorders (1) 
 ♦ Reading disorder (1) 
 
Stimulant-medicated: 11 (55%) 
ADHD (n=36) 
Subtype ADHD (36) 
♦ Combined (17) 
♦ Inattentive (18) 
♦ Hyperactive/Impulsive (1) 
 
Comorbid disorders (8) 
♦ Substance related disorders 
(2) 
♦ Conduct disorders (3) 
♦ Reading disorder (2) 
♦ Learning disorder (1) 
 






Diagnostic Group (n=56) 
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externalizing problems and the global scale total problems were used. The CBCL and YSR were 
administered to all participants from 12 to 24 years old, because most of the participants older than 18 
years old were still in school and living with their parents. 
 Corresponding with the age of the participants, the Wechsler Intelligence Scale for Children 
(WISC-III) or the Wechsler Adult Intelligence Scale (WAIS-III) was administered (Wechsler, 1991, 
1997). Full-scale total intelligence quotient (TIQ), verbal intelligence quotient (VIQ), and performance 
intelligence quotient (PIQ) were calculated. When available, WAIS or WISC scores from less than a 
year old of the participant were obtained from the mental healthcare institution. 
 
Physiological measures 
The electrocardiogram (ECG) was recorded between 10 and 11 o'clock in the morning. If applicable, 
stimulant medication was taken during breakfast before the measurement. No caffeine or nicotine 
intake was allowed two hours prior to physiological measurement. The ECG recording was part of an 
EEG-recording in combination with a subset of the brain resource company (BRC, Ultimo, Australia) 
test battery. This included a baseline condition in which the adolescent had to sit quietly with closed 
eyes for two minutes. Subsequently, they performed the task condition that consisted of an auditory 
oddball task lasting six minutes.  
 Electrocardiogram (ECG) was recorded with two Ag/AgCl electrodes attached between the 
collarbones over the jugular notch of the sternum and at the fifth intercostal space at the left anterior 
axillary line (V5). A NuAmps amplifier amplified the signals and Neuroscan software recorded the 
signals with a sampling rate of 500 Hz. The occurrence of R-peaks was detected automatically by using 
BioSig software (Schlögl, 2009). The location of R-peaks was visually checked and manually adapted if 
necessary. Thereafter, the ECG data was further automatically analyzed by Kubios software (Niskanen, 
Tarvainen, Ranta-Aho, & Karjalainen, 2004; Tarvainen & Niskanen, 2008).  
 The following time domain measures of HRV were taken into account: (1) Mean time in ms 
between two successive R-peaks (RR), (2) the standard deviation of RR (RR SD), (3) mean heart rate 
(HR) in beats per minute (bpm), (4) the standard deviation of HR (HR SD), and (5) the root mean 
square of differences of successive RR intervals (RMSSD) as an estimate of short-term components of 
HRV (Malliani, Pagani, Lombardi, & Cerutti, 1991; Task Force, 1996). 
 The other measurements are in the frequency domain. The power spectral density (PSD) was 
calculated from the RR series parametrically based on an autoregressive (AR) model of order 16. For 
the present study, the following measures were further analyzed: (1) low frequency power (LF, 0.04-
0.15 Hz), (2) high frequency power (HF, 0.15-0.4 Hz), and (3) the low frequency-high frequency ratio 
(LFHF). Because of the short analysis period for the baseline measure (2 min), it was not possible to 
interpret the very low frequency band (VLF, 0.0-0.04 Hz; Task Force 1996). HF and LF power can be 
seen as an indicator of parasympathetic modulation, and the LFHF ratio is thought to reflect 
autonomic cardiovascular modulation (Reyes del Paso, Langewitz, Mulder, van Roon, & Duschek, 
2013).  
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Auditory oddball task 
The auditory oddball task is an attention test in which relevant stimuli need to be processed and 
irrelevant stimuli need to be ignored. In this task, every second a tone of 75 dB (A) for the duration of 
50 ms is presented binaurally. Low tones of 500 Hz were presented interchanged with infrequent high 
tones of 1000 Hz in quasi-random order. Rise and fall times of all the tones was 5 ms. The adolescents 
were asked to press the answer box with both their index fingers as fast as they could when they heard 
the high 1000 Hz tone. In total, the low tones were presented 280 times and the high tones 60 times in 
6 minutes. Response measures used were: mean reaction time to the odd high tones, standard 
deviation of the mean reaction time, number of incorrectly ignored high tone stimuli (omission errors), 
number of incorrectly not ignored low tone stimuli (inhibition errors). 
 
Procedure 
Participants were recruited for an intervention study for adolescents with clinical ADHD symptoms. 
Prior the start of the study approval was obtained from the medical ethics committee for mental health 
institutions in the Netherlands (Ref. no: NL 24776.097.08 CCMO). The study took place in three large 
secondary care centers of child and adolescent psychiatry (GGzE, GGz Breburg, Reinier van Arkel 
group) in the Southern part of the Netherlands. After the study was explained (verbally and in writing), 
written informed consent was obtained from each participant. For those younger than 18, parents also 
completed a written informed consent.  
 DSM classification and information about medication use were obtained from the clinical 
professionals of the corresponding center of child and adolescent psychiatry. Complete DSM 
classification was retrieved from the electronic patient record. Medication use was monitored through 
an intervention questionnaire based on the “Dutch national basic ADHD program for children and 
adolescents” (Vink & Van Wamel, 2007). Stimulant medication use included immediate release 
methylphenidate and sustained release methylphenidate (Concerta®, Equasym®, Medikinet®).  
 Participants were seen on three occasions. During the first appointment inclusion criteria were 
checked using an interview and behavioral questionnaires. During the second appointment, intellectual 
functioning was estimated, using the WAIS or WISC (Wechsler, 1991, 1997). Finally, during the third 
appointment, physiological measurements were noted. For one participant, the auditory oddball stimuli 
responses were not recorded correctly during physiological measurement and data were irretrievably 
lost. Eleven participants used marihuana in the 24-hours prior to physiological assessment, two 
participants used atomexetine, one participant used citalopram and two other participants who 
normally took prescribed stimulant medication but not on the day of physiological assessment. These 
17 cases were excluded from analysis.  
 Parents or significant others received the CBCL and AQ-adolescent by mail, with the request 
to complete and return them on the assessment day or by mail. For two participants, AQ-adolescent 
and CBCL-scores were not retrieved and for three other cases the AQ-adolescent was not completed. 
These five cases were also excluded from analysis.  
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Data Analyses 
All analyses were performed using SPSS version 19.0. There were violations of normality for the 
cardiac measures and reaction time measures; these were converted with a log10 function to obtain 
more normally distributed values. After the log10 transformations, assumptions of normality for 
cardiac measures were not violated.  
 Differences in group characteristics were analyzed with a one-way ANOVA. Separate 
Generalized Linear Model (GLM) ANCOVA’s were conducted for each cardiac variable (time and 
frequency domain) during baseline and oddball task performance with diagnostic group (ASD+ or 
ADHD) and stimulant use (stimulant-medicated and stimulant-free) as within subject factor and the 
covariates age and PIQ. Stimuli response variables of the oddball task were analyzed with only age as 
the covariate.  
 Post hoc analyses were performed with redistribution of the participants. The first 
redistribution was based on the critical minimum of 30 points on the AQ-adolescent as indicated by 
Baron-Cohen et al. (2006), to compare participants with a score less than 30 points to participants with 
a score of 30 points or higher. The second redistribution was made to compare only the participants 
within the ASD+ diagnostic group and an AQ-adolescent score above 30 to the participants within the 
ADHD diagnostic group and an AQ-adolescent score less than 30. This means that participants 
diagnosed with ASD+ with AQ-adolescents scores under the critical minimum were excluded as well 
as participants diagnosed with ADHD with AQ-adolescents scores above the critical minimum.  
 Task-related cardiac adaptation was investigated using a Generalized Linear Model (GLM) 
with between and within-subjects factors. The analysis was applied to all the cardiac measures 
separately with diagnostic group and stimulant use as between subject factors and task (e.g., between 
baseline eyes closed condition and auditory oddball task) as within subjects factor. The full factorial 
models were tested. Within-subjects effects of the cardiac measures for task from the GLM were used 
to assess the validity of the cardiac measures. All task-related cardiac adaptation effects were evaluated 
using multivariate test criteria, which is known to be robust in case of violations of sphericity (Vasey & 
Thayer, 1987).  
 The adjusted least significant difference (LSD) and 95% confidence interval [95% CI] for 
diagnostic group (ADHD, ASD+ADHD), medication use (stimulant-free, stimulant-medicated) and 
task (baseline, task) were noted. Values of p<.05 were considered statistically significant. Because of 
the exploratory nature of the current study, no alpha correction for multiple testing has been applied. 




Group characteristics are summarized in Table 1. There were no differences for diagnostic group 
characteristics between the ASD+ group and the ADHD group in age (M=15.45, SD=3.02 years) [F 
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(1, 54)=.08, p>.05] and stimulant medication use [χ2(1, 54)=.00, p>.05]. In addition, the mean 
prescribed doses in mg for the stimulant-medicated adolescents was similar in the ASD+ group 
(N=11, M=35.27, SD=17.35, 95%-CI =25.84, 44.71) as in the ADHD group (N=20, M=34.45, 
SD=14.11, 95%-CI= 27.45, 41.45) [F(1, 29)=.02, p>.05, ηp2=.00]. However, there was a trend for 
stimulant-free adolescents (M=16.32, SD=3.24 years) to be older than the stimulant-medicated 
adolescents (M = 14.74, SD = 2.67 years) [F(1,54)=4.0, p=.05]. Stimulant-free and stimulant-
medicated adolescents did not differ significantly on other group characteristics.  
 The diagnostic groups did not differ on scores of Global Assessment of Functioning. ADHD 
symptoms as measured by MINI scores for inattention and hyperactivity/impulsivity (H/I), the 
ADHD-rating scale for inattention and H/I over the last six months as well as the childhood 
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Age in Years 15.45 (3.02) 15.60 (2.62) [14.37, 16.83] 15.36 (3.24) [14.26, 17.09] .08 .00 
GAF-score 55.25 (6.39) 54.50 (6.10) [51.65, 57.35] 55.67 (6.59) [53.44, 57.90] .42 .01 
AQ-adolescent version2 25.62 (7.83) 32.45 (5.36) [29.94, 34.96] 21.82 (6.25) [19.70, 23.94] 40.96*** .43 
ADHD-rating scale3        
 Inattention 4.84 (2.34) 4.90 (2.25) [3.85, 5.95] 4.81 (2.42) [3.99, 5.63] .02 .00 
 H/I 3.32 (1.93) 3.70 (2.06) [2.74, 4.66] 3.11 (1.85) [2.49, 3.74] 1.21 .02 
 Child Inattention 6.04 (2.62) 5.65 (2.83) [4.32, 6.98] 6.25 (2.51) [5.40, 7.10] .67 .01 
 Child H/I 4.93 (2.77) 4.20 (2.75) [2.92, 5.48] 5.33 (2.74) [4.41, 6.26] 2.20 .04 
MINI ADHD Inattention 5.39 (2.49) 5.00 (2.53) [3.81, 6.19] 5.61 (2.48) [4.77, 6.45] .77 .01 
MINI ADHD H/I 3.73 (2.39) 3.60 (2.39) [2.48, 4.72] 3.81 (2.41) [2.99, 4.62] .09 .00 
CBCL Total Problems 61.82 (28.28) 72.95 (28.27) [59.72, 86.18] 55.64 (26.70) [46.61, 64.67] 5.19* .09 
 Internalizing Problems 14.02 (9.44) 17.55 (10.37) [12.69, 22.41] 12.06 (8.40) [9.21, 14.90] 4.64* .08 
 Externalizing Problems 18.55 (11.48) 21.80 (11.06) [16.62, 26.98] 16.75 (11.46) [12.87, 20.63] 2.56 .05 
 Attention Problems 11.88 (3.41) 12.80 (3.62) [11.11, 14.49] 11.36 (3.22) [10.27, 12.45] 2.35 .04 
YSR Total Problems 47.07 (20.01) 54.30 (21.43) [44.27, 64.33] 43.06 (18.26) [36.88, 49.23] 4.31* .07 
 Internalizing Problems 8.98 (5.82) 10.90 (6.09) [8.05, 13.75] 7.92 (5.46) [6.07, 9.76] 3.53 .06 
 Externalizing Problems 15.32 (9.55) 17.85 (9.89) [13.22, 22.48] 13.92 (9.19) [10.81, 17.03] 2.23 .04 
 Attention Problems 9.50 (3.10) 8.85 (3.59) [7.17, 10.53] 9.86 (2.79) [8.92, 10.80] 1.37 .02 
TIQ 101.39(10.87) 104.90(11.60) [99.47, 110.33] 99.44 (10.09) [96.03, 102.86] 3.38 .06 
 VIQ 102.55(11.39) 106.75(12.07) [101.10, 112.4] 100.22(10.45) [96.69, 103.76] 4.49* .08 
 PIQ 100.54(13.12) 102.45(11.80) [96.93, 107.97] 99.47 (13.85) [94.79, 104.16] .66 .01 
Note: 1data are means (SD); Df (1,54); *p<.05, **p<.01, ***p<.001; 2Autism Spectrum Quotient (AQ)- 
adolescent version is a parent report; 3the ADHD-rating subscales are self-reported over the last six months, the 
child subscales are retrospective self-reported for the primary school period.  
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 The AQ-adolescent confirmed that the ASD+ group exhibited more autism symptoms than 
the ADHD group [F(1,54) =40.96, p<.001] with a range of 23-42 for the ASD+ group and 10-36 for 
the ADHD group. For the ASD+ group, parents reported on the CBCL more total behavioral 
problems, specifically more internalizing problems. On the YSR the adolescents in the ASD+ group 
reported also more total problems, with a trend for internalizing problems [F(1,54) =3.53, p=.07]. 
Externalizing problems and attention problems were similar for both groups on the CBCL and the 
YSR. The ASD+ group had a higher VIQ compared than the ADHD group and there was a trend for 
TIQ to be higher [F(1,54) =3.37, p=.07]. PIQ scores were similar for both groups. 
 
Physiological Measures 
Cardiac activity  
Cardiac measures are summarized in Table 2. Raw HR (bpm) data is listed italicized on the first line of 
both conditions (baseline and task). All other cardiac measures are presented with log-transformed 
data. Untransformed HR was M = 74, SD = 12 bpm during baseline and M=77, SD=14 bpm during 
task performance (see also Table 3).  
 The cardiac measures showed no effects of diagnostic group during baseline or task 
performance.  LFHF ratio differed between stimulant-medicated and stimulant-free adolescents: 
stimulant-medicated adolescents showed relative higher LF power to lower HF power and the 
stimulant-free adolescents relative higher HF power to lower LF power [F(5,50)= 6,46, p<.05, 
ηp2=.11]. There was no differentiation between stimulant-medicated and stimulant-free adolescents on 
the other cardiac measures. Furthermore, there was no interaction of diagnostic group and stimulant 
medication use on any of the cardiac measures.  
 The older adolescents showed less HRV during baseline; older adolescents showed decreased 
HR SD, HR and increased RR intervals compared to younger adolescents. In addition, older 
adolescents showed decreased HF power and increased LFHF ratio than younger adolescents. During 
task performance age revealed a decrease in HR SD and an increase in LFHF ratio. The other cardiac 
measures revealed no effect of age during task.  
 PIQ is negative related to RR SD and LF power during baseline and task performance. 
Adolescents with higher PIQ scores show decreased RR SD and LF power, compared to adolescents 
with lower PIQ scores.  
 Post hoc analyses with redistribution of the diagnostic groups based on the AQ-adolescent 
critical minimum (Baron-Cohen et al., 2006) revealed no differences in cardiac measures between the 
group with a score less than 30 points (n=39) and the group with a score 30 points or higher (n=17) 
and no interactions between group and stimulant medication use. Furthermore, comparing the 
adolescents with ASD+ and an AQ-adolescents score above the critical minimum of 30 points (n=13) 
to the adolescents with ADHD and an AQ-adolescent score less than 30 points (n=32) showed no 
differences in cardiac measures and no interactions between group and stimulant medication use.  
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Task related cardiac adaptation  
Cardiac adaptation measures are summarized in Table 3. Task related cardiac adaptation for the total 
group was observed as expected, with a decrease in mean RR, an increase HR and HR SD, a decrease 
in high frequency power (HF), and increase in LFHF ratio between baseline condition and auditory 
oddball task performance. 
 There was an interaction between task related cardiac adaptation and stimulant medication for 
LFHF ratio [F (3, 52) = 4.75, p<.05, ηp2= .08 ]. The stimulant-free group showed a greater task related 
increase in LFHF ratio (baseline M=-.16, SD=.35 and task M=.12, SD= .35), while a more modest 
increase is seen for the stimulant-medicated group (baseline M=.05, SD= .38 and task M=.15, 
SD=.34) (see Figure 2). Note that even though equality of error variances was not violated, the 
standard deviations for the LFHF ratio were relatively high. The other measures revealed no 
interactions of stimulant medication use and task-related cardiac adaptation. Cardiac adaptation was 
similar for the diagnostic groups (ASD+ or ADHD) on all the cardiac measures. Furthermore, no 
interactions between stimulant medication and diagnostic group were found for task-related cardiac 
adaptation. 
 
Figure  2 .  Interaction of cardiac adaptation and stimulant medication use for LFHF ratio 
 
Note: mean log 10 LFHF ratios with standard error bars are displayed during baseline and  
task for the stimulant-free and the stimulant-medicated group. The interaction between  
stimulant medication use and cardiac adaptation for LFHF ratio was significant  
[F (3, 52) = 4.75, p<.05, ηp2= .08]. 
 
Auditory Oddball Task 
The adolescents on stimulant medication responded faster and with less variability than stimulant-free 
adolescents (see Table 4). Stimulant medication appeared unrelated to inhibition or omission errors. 
Diagnostic group (ASD+ or ADHD) or interaction between diagnostic group and medication had no 
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DISCUSSION 
This study is the first to explore the psychophysiological overlap and differences in a clinical sample of 
adolescents diagnosed with ASD+ versus ADHD. In addition, the impact of stimulant medication use 
was investigated. Cardiac activity was measured during a baseline condition with eyes closed and while 
performing an attention task. Overall, no differences in cardiac activity or task performance were 
found between the ASD+ and the ADHD group. Adolescents who used stimulant medication showed 
increased LF/HF ratio during baseline with eyes closed, decreased LF/HF ratio adaptation from 
baseline to task performance and faster reaction times during task performance compared to stimulant-
free adolescents.  
 Cardiac activity and task-related cardiac adaptation were similar for the adolescents with 
ASD+ and the adolescents with ADHD. Because of the supposed increased sympathetic activation 
associated with ASD (Bal et al., 2010; Daluwatte et al., 2012; Van Hecke et al., 2009), the expectation 
was that the ASD+ group would show signs of more sympathetic and less parasympathetic activation 
than ADHD adolescents. However, no such trend was observed in the present study. In addition, no 
interaction was found between medication use and diagnostic group; differences in cardiac activation 
and task-related cardiac adaptation between stimulant-medicated and stimulant-free adolescents, were 
the same within the ASD+ group and the ADHD group. This may imply that there are 
psychophysiological constructs related to the ADHD symptomatology, responsible for the overlap in 
cardiac activity between the ASD+ group and the ADHD group. However, interpreting the results it 
should be taken into account that sympathetic activation levels by HRV are difficult to reliably estimate 
(Reyes del Paso et al., 2013). The expectation was that the ASD+ group would show more sympathetic 
activation. Consequently, as sympathetic activation is not reflected by HRV, this also contributes to the 
lack of differentiation between the diagnostic groups in HRV. Furthermore, primary diagnostic groups 
were based on clinical diagnoses of the adolescents. Nevertheless, some adolescents with ADHD 
without an ASD diagnosis may experience ASD symptoms. These ASD symptoms might effect 
physiological measurements and thereby diminishing differences between the diagnostic groups. 
However, post hoc analyses with redistributed diagnostic groups based on the AQ-adolescent critical 
minimum score did not reveal significant differences in cardiac activity either.  
 The expectation that stimulant-medicated adolescents would have a higher heart rate than 
stimulant-free adolescents was not confirmed. Even though HR was 70 bpm for the stimulant-free 
adolescents and 78 bpm for the stimulant-medicated adolescents during rest condition, this difference 
in HR failed to reach significance after correcting for age. This in contrast to the majority of studies 
that show significant increases in HR of up to 10 bpm in stimulant-medicated youngsters with ADHD 
(Hammerness et al., 2011). This might be due to the fact that the stimulant-medicated adolescents were 
somewhat younger than the stimulant-free adolescents in the present study. The average HR in rest 
condition in the current study was 74 bpm and thereby more comparable to a HR around the 73 bpm 
in stimulant-free (young) adults with ADHD (Cox et al., 2012; Lackschewitz, Huther, & Kroner-
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Herwig, 2008) than to the HR of approximately 85 bpm of stimulant-free school-aged children with 
ADHD (Donner, Michaels, & Ambrosini, 2007; Negrao et al., 2011; Wilens, Biederman, & Lerner, 
2004). In addition, HR deceleration with age has been found in TD and ASD youngsters during the 
first years of adolescence (Daluwatte et al., 2012). Similarly, in the current study younger adolescents 
also displayed higher HR than the older adolescents. All in all, being a younger adolescent and using 
stimulant medication are both related to higher HR. Consequently, in the current study it is hard to 
separate the effect of stimulant medication and age.  
 Results from this study show that the adolescents who use stimulant medication display higher 
LFHF ratios during baseline rest condition with eyes closed than the stimulant-free adolescents. In 
addition, all adolescents in the present study showed task-related cardiac adaptation as expected with 
increased heart rate (HR, HR SD) and decreased time between two successive R-peaks (RR), decreased 
HF power and increased LFHF ratio, while performing the attention task compared to baseline. The 
only interaction for task-related cardiac adaptation and stimulant medication use was a decreased 
LFHF ratio adaptation in stimulant-medicated adolescents compared to the stimulant-free adolescents. 
This is in line with the study by Negrao et al. (2011) who showed that when on stimulant medication 
significant cardiac adaptation was no longer apparent. Although both studies point to decreased 
autonomic modulation for stimulant-medicated youngsters, Negrao et al. found these results for all 
cardiac measures, whereas the current study only found results for LFHF ratio. Whereas decreased 
parasympathetic activation is generally viewed as a shift to normalization, a decrease in autonomic 
modulation could be less favorable. It is not clear what the implications are for everyday life when 
stimulant-medicated youngsters are less able to shift physiologically between rest conditions and 
demanding cognitive activities.  
 The observed age effect on cardiac activity is comparable with the few available studies among 
healthy adolescents, in which older adolescents showed less HRV during resting baseline compared to 
younger adolescents (Faulkner, Hathaway, & Tolley, 2003; Tanaka et al., 2000). However, healthy 
adolescents show a decline in LF power, HF power and parasympathetic modulation with aging from 
pre-adolescent to adolescent (Faulkner et al., 2003; Tanaka et al., 2000). In contrast, our study showed 
increased LFHF ratio or autonomic modulation for older adolescents than for younger adolescents, 
due to decreased HF power. On the assumption that ADHD means higher levels of parasympathetic 
activation, this faster decline in HF power might be interpreted as normalization.  
In the current study, attention task performance was alike for the adolescents with ASD+ and ADHD. 
However, task performance did differ depending on stimulant medication use. Stimulant-medicated 
adolescents responded faster and with less variability than the stimulant-free adolescents, regardless of 
diagnostic group. This is in line with research showing that stimulant medication primarily decreases 
reaction time variability in children diagnosed with ADHD (Epstein et al., 2011; Groen et al., 2008). 
However, previous research showed less variability in reaction time for children with ASD only versus 
stimulant-free children with ADHD (Groen et al., 2008). In line with a study by Althaus et al. (1999), 
results of the present study showed that adolescents diagnosed with ASD+ and ADHD displayed 
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similar reaction times. This might indicate that reaction time variability in both groups is related to the 
same (ADHD) symptomatology. Accuracy on the attention task did not differ between the diagnostic 
groups or between stimulant-medicated and stimulant-free adolescents. The amount of errors during 
the task for all participants was so low, that there was most likely a ceiling effect.  
The current results suggest that ASD+ and ADHD adolescents may have more in common than one 
would expect based on previous research. Cardiac adaptation from baseline to attention task, effects of 
medication and effects of age were mostly as expected. Therefore, the cardiac measurement seems to 
be adequate to show variances in cardiac activity. Consequently, the absence of differentiation between 
ASD+ and ADHD is not likely to be explained by the quality of the measurement. Although results 
from the present study show psychophysiological overlap between ASD+ and ADHD, additional 
research is necessary. First, replication with a design with further controlled groups and larger sample 
size is warranted. The current study investigated a clinical sample of adolescents with severe ADHD 
symptoms. Moreover, diagnostic groups were based on clinical appointed DSM-IV diagnoses which 
increase the ecological validity of the study. However, further standardized information about the 
diagnostic process with respect to ASD is lacking. Including the Autism Diagnostic Observation 
Schedule (ADOS) (Lord et al., 1989) or Autism Diagnostic Interview (ADI) (Lord, Rutter, & Le 
Couteur, 1994) in future research will improve comparison and replication with other studies. In 
addition, an important limitation of the study is the absence of a group with TD adolescents. Due to 
the lack of this TD control group, and the absence of normal values in short time measures of cardiac 
activity, it is not clear if the cardiac activation of the adolescents in current study is pathological or 
within normal limits. Future research comparing TD adolescents and adolescents with ADHD, ASD+, 
and ASD-only could offer more information about which physiological patterns are specific for ASD, 
ADHD or typical development during adolescence. A third limitation concerns the use of stimulant 
medication. If applicable, adolescents continued stimulant medication as described by their physician at 
study entry. Therefore, initial differences between stimulant-medicated and stimulant-free adolescents 
could not be controlled for. Ideally, psychophysiological measures should be taken at two moments in 
time: the first before starting stimulant medication or after a washout of stimulant medication and 
second after a controlled stimulant medication titration trial. At least, an improvement should entail a 
more equal division of age between the stimulant-medicated adolescents and the stimulant-free 
adolescents. In the current study, adolescents who used stimulant medication were younger than the 
adolescents who were not on stimulant medication. Consequently, it is difficult to distinguish between 
the effect of stimulant medication and age. A fourth limitation is that baseline parameters were 
measured for a relatively short period. Although the Task Force (1996) states that approximately two 
minutes of recording are sufficient to measure LF power, the same report advises a minimum of ten 
times the wavelength. A baseline of at least five minutes might therefore be preferable for more 
reliable baseline measures of LF power and LFHF ratio. Finally, future studies should include 
additional physiological measures, such as EEG, to see whether it can be related to more specific 
ADHD symptomatology, like attention processing.   
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 In conclusion, the present study showed a psychophysiological overlap in cardiac reactivity 
and in cognitive performance measures between adolescents with ASD+ and ADHD. Effects of 
stimulant medication did not appear to differ between the groups. As such, our study suggests that 
ADHD with or without ASD could be approached with similar treatment strategies. The current 
results support the idea of, for instance, Gadow et al. (2006), Goldstein and Schwebach (2004) and the 
DSM-V task force (American Psychiatric Association, 2012) for a comorbid diagnosis of ADHD in 
addition to ASD. A comorbid diagnosis of ADHD might thereby help prevent that ASD+ youngsters 
are excluded from potentially beneficial ADHD treatment.   
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ABSTRACT 
Attention problems are common in youngsters with attention deficit hyperactivity disorder (ADHD) as 
well as in adolescents with combined autism spectrum disorder (ASD) and ADHD. However, it is 
unknown whether there is psychophysiological overlap and/or a difference in electroencephalogram 
(EEG) power spectra between ADHD and comorbid ASD and ADHD (ASD+ADHD), on and off 
stimulant medication. In order to explore potential differences and overlap, measures of theta and beta 
power in adolescents diagnosed with ADHD (n=33) versus adolescents with combined ASD+ADHD 
(n=20), categorized by stimulant medication use (57% of the total sample), were compared. EEG 
measures were acquired in three conditions: (1) resting state, eyes closed, (2) resting state, eyes open and 
(3) during an oddball task. In addition performance on the d2 attention test was analyzed. Adolescents 
with ADHD displayed more absolute theta activity than adolescents with ASD+ADHD during the eyes 
open and task conditions, independent of stimulant medication use. In addition, only the adolescents with 
ADHD showed an association between diminished attention test performance and increased theta in the 
eyes open condition. Results of the current study suggest that although there is behavioral overlap 
between ADHD characteristics in adolescents with ADHD and adolescents with combined 
ASD+ADHD, the underlying psychophysiological mechanisms may be different. Adolescents with 
ASD+ADHD exhibited fewer of the EEG physiological signs usually associated with ADHD, although 
there was an overlap in attentional problems between the groups. This may indicate that treatments 




Attention deficit hyperactivity disorder (ADHD) co-occurs with autistic spectrum disorders (ASDs) in 
around 28 percent of youngsters with ASD (Simonoff et al., 2008). Stimulant medication, part of the gold 
standard treatment for ADHD, is also prescribed in cases of comorbid ASD and ADHD (ASD+ADHD). 
However, the reported stimulant medication response rate of 49% in ASD+ADHD (Research Units on 
Pediatric Psychopharmacology (RUPP) Autism Network, 2005) is lower than the 77% response rate in 
ADHD (Greenhill et al., 2001). This suggests that although there is behavioral overlap between ADHD 
with and without ASD, the psychophysiological mechanisms underlying attentional problems may be 
different in these groups. 
 Electro-encephalogram (EEG) power spectra have often been used to assess psychophysiological 
functioning in ADHD. The most robust finding in ADHD is increased theta power (Cortese, 2012; Loo 
& Makeig, 2012; Snyder & Hall, 2006) mainly in frontocentral areas (Loo & Makeig, 2012) and, to a lesser 
extent, decreased beta activity (Cortese, 2012; Snyder & Hall, 2006). The theta (4-7Hz) and beta (13-30Hz) 
bands of the power spectrum have been related to measures of vigilance and attention respectively, at the 
behavioral level (Banaschewski & Brandeis, 2007), and during childhood show maturational changes: 
decreasing slow wave activity (including theta) and increasing fast wave activity (including beta) (John et 
al., 1980). Specifically, theta power seems to be negatively associated with vigilance or alertness, with high 
theta corresponding to an underaroused (Banaschewski & Brandeis, 2007; Loo & Barkley, 2005; Loo & 
Makeig, 2012) and unfocused state (Loo & Barkley, 2005). In contrast, beta power seems to be positively 
associated with attention (Banaschewski & Brandeis, 2007; Loo & Barkley, 2005; Loo & Makeig, 2012), 
with decreased beta also associated with an unfocused state (Banaschewski & Brandeis, 2007). Lubar 
(1991) therefore proposed theta/beta ratio as an indicator of ADHD, and indeed, increased theta/beta 
ratio is found in some youngsters with ADHD (Arns, Conners, & Kraemer, 2013; Barry, Clarke, & 
Johnstone, 2003; Snyder & Hall, 2006). As a whole, the theta and beta data provide support for the 
hypothesized maturational lag (Clarke, Barry, McCarthy, & Selikowitz, 1998) and in the seventies 
generated underarousal theories of ADHD (Satterfield, Cantwell, & Satterfield, 1974).  
 The abnormal pattern of theta and beta activity in youngsters with ADHD can be partly 
normalized by stimulant medication use (Clarke, Barry, Bond, McCarthy, & Selikowitz, 2002; Clarke, 
Barry, McCarthy, Selikowitz, Brown, et al., 2003; Hermens, Williams, et al., 2005; Loo & Barkley, 2005), 
which typically decreases theta activity and increases beta activity. A subpopulation of youngsters with 
ADHD show excessive frontal beta instead of decreased beta (Clarke, Barry, McCarthy, & Selikowitz, 
2001b). These youngsters respond differently to stimulant medication, showing a reduction in beta and 
total power (Clarke, Barry, McCarthy, Selikowitz, Clarke, et al., 2003). Overall, it seems that stimulant 
medication in youngsters with ADHD results in power spectra that are more similar to those of typically 
developing (TD) youngsters. 
 Youngsters with ASD show increased relative theta compared to TD youngsters (Coben, Clarke, 
Hudspeth, & Barry, 2008; Murias, Webb, Greenson, & Dawson, 2007), similar to youngsters with ADHD 
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(Chabot & Serfontein, 1996; Clarke et al., 2002; Clarke et al., 1998; Clarke, Barry, McCarthy, & Selikowitz, 
2001a). In addition to increased relative theta, youngsters with ASD also show differences in absolute and 
relative beta; however, studies show mixed results. Adults with ASD show increased occipital relative beta 
(Murias et al., 2007) and young children with ASD have been shown to have increased absolute beta 
(Orekhova et al., 2007) relative to TD participants, but there is also a finding of decreased absolute beta, 
particularly in the right hemisphere, in children with ASD (Coben et al., 2008). EEG power spectra in 
children with a primary diagnosis of ADHD and ASD have been little studied. The clearest result of the 
only study that compared children with a primary diagnosis of ADHD with and without autistic 
characteristics (Clarke, Barry, Irving, McCarthy, & Selikowitz, 2011) was an increase in relative beta in 
children with ADHD with autistic characteristics compared to those with only ADHD. Although theta 
power did not differentiate the groups, this study also found a greater increase in theta from frontal to 
central regions in children with autistic characteristics (Clarke et al., 2011); it must be noted that in this 
study no formal DSM-IV (American Psychiatric Association, 2000) diagnosis of ASD was required. Taken 
together, these findings may point to a psychophysiological dissociation between ADHD with and 
without ASD, despite the behavioral overlap between the conditions. 
 Previous research on the psychophysiological effects of stimulant medication has focused mainly 
on adolescents with ADHD (Clarke et al., 2002; Clarke, Barry, McCarthy, Selikowitz, Brown, et al., 2003; 
Hermens, Williams, et al., 2005; Loo & Barkley, 2005). The relationship between attentional problems and 
EEG power spectra in ADHD and ASD+ADHD, both on and off medication remains unknown. A 
better understanding of potential underlying differences between the conditions could explain why 
adolescents with ASD+ADHD (RUPP, 2005) have a less favorable response to stimulant medication than 
adolescents with ADHD (Greenhill et al., 2001). If the underlying mechanisms of the conditions are 
similar, attentional problems in ASD+ADHD might be treated similarly to those in ADHD, for example 
with stimulant medication; however, differences in EEG power spectra between ADHD and 
ASD+ADHD would suggest that treatment options for the attentional problems should be specific to 
each subgroup. This study aimed to explore psychophysiological differences between these groups in 
terms of EEG power spectra, comparing stimulant-medicated and stimulant-free adolescents with a 
primary diagnosis ADHD with adolescents with a combined diagnosis of ASD and ADHD. We predicted 
an overlap in theta power and a specific increase in absolute and relative beta levels in adolescents with 
ASD+ADHD compared to adolescents with ADHD only. Furthermore, in line with previous studies 
(Clarke et al., 2002; Clarke, Barry, McCarthy, Selikowitz, Brown, et al., 2003; Hermens, Williams, et al., 
2005; Loo & Barkley, 2005), we predicted that stimulant-medicated adolescents would show less absolute 







This study used a sample of 53 adolescents recruited for an intervention study for adolescents with clinical 
ADHD symptoms. Prior to the start of the study, approval was obtained from the Medical Ethics 
Committee for Mental Health Institutions in the Netherlands (Ref. no: NL 24776.097.08 CCMO). The 
study took place in three centers of child and adolescent psychiatry (GGzE, GGz Breburg, Reinier van 
Arkel group) in the southern part of the Netherlands. Written informed consent was obtained from all 
participants. For participants aged less than 18 years, parents also provided written informed consent. The 
sample was the same as in Bink et al. (2013), with the exclusion of five adolescents because of poor quality 
of the EEG data and the addition of two patients: one who enrolled later in the study and one who had 
been excluded from the earlier study because of missing oddball task-performance data. This patient was 
included as the EEG data could be used. 
 Two diagnostic groups of male adolescents aged between 12 and 22 years old were included in 
the study. The first group consisted of 33 adolescents with a clinical DSM-IV(American Psychiatric 
Association, 2000) primary diagnosis of ADHD, including: combined subtype (n=16), inattentive subtype 
(n=16), and hyperactive/ impulsive subtype (n=1). The second group consisted of 20 adolescents with a 
primary diagnosis of ASD, including: Asperger’s syndrome (n=6) and pervasive developmental disorder – 
not otherwise specified (PDD-NOS; n=14). Adolescents with ASD also had a notification of clinical 
ADHD with symptoms sufficient for a full ADHD diagnosis. ADHD symptoms were verified by a DSM-
IV based Dutch semi-structured ADHD interview for adults (Kooij, 2002) and the Mini International 
Neuropsychiatric Interview (MINI; Sheehan et al., 1998; Sheehan et al., 1997). Exclusion criteria were 
IQ<80, neurological disorders, schizophrenia and other psychotic disorders, depression, attachment 
disorder or anxiety disorder, medication use other than stimulant medication and use of cannabis in the 24 
hours prior to physiological assessment. 
 Stimulant medication use was monitored through an intervention questionnaire based on the 
Dutch national basic ADHD program for children and adolescents (Vink & Van Wamel, 2007). 
Adherence to prescribed medication was verified by asking the adolescents whether they had been taking 
their medication as prescribed before the EEG measurement. In total, 30 (57%) of the adolescents used 
stimulant medication. In the ADHD group, 19 (58%) used stimulant medication: 6 used immediate release 
methylphenidate and 13 used sustained release methylphenidate. In the ASD+ADHD group, 11 (55%) 
used stimulant medication: 1 used immediate release methylphenidate and 10 used sustained release 
methylphenidate. Two adolescents in the ASD+ADHD group used low doses (0.5mg and 1.5mg per day) 
of antipsychotic medication (Risperdal®) in addition to their stimulant medication. Because the doses 
were low, in combination with stimulant medication use, potential impact on the outcome measures was 
considered minimal. 
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 Comorbid disorders were allowed: included in the ADHD group were participants with 
substance-related disorders (n=2), conduct disorders (n=3), and reading disorder (n=2). In the 




The group characteristics are listed in Table 1. The measures reported are Global Assessment of 
Functioning (GAF) score, the DSM-IV (American Psychiatric Association, 2000) based ADHD-rating 
scale (Kooij et al., 2008; Kooij et al., 2005) which is an adapted form of DuPaul et al. (1998), the MINI 
subscales for inattention and hyperactivity/impulsivity (HI), the Autism-Spectrum Quotient (AQ)-
adolescent version for individuals with normal intelligence (Baron-Cohen, Hoekstra, Knickmeyer, & 
Wheelwright, 2006; Baron-Cohen, Wheelwright, Skinner, Martin, & Clubley, 2001), the Child Behavior 
Checklist (CBCL) and the Youth Self Report (YSR) (Achenbach, 1991), and the WISC-III or the WAIS-
III full-scale total intelligence quotient (TIQ) (Wechsler, 1991, 1997). Further information about the 
reported group characteristics can be found elsewhere (Bink et al., 2013) 
 
Cognitive measures 
The d2 attention test (Brickenkamp, 2007) was administered and the raw scores of the total number of 
processed items (TN) and total correctly processed items (C) were analyzed. 
 
Physiological measures 
The EEGs were recorded between 10am and 11am. Where applicable, stimulant medication was taken 
with breakfast, before the measurement. No caffeine or nicotine intake was allowed during the two hours 
prior to physiological assessment. 
 The EEG recordings were performed in combination with a subset of the Brain Resource 
Company (BRC; Ultimo, Australia) test battery. This included a baseline condition in which participants 
had to sit quietly with their eyes open for two minutes and closed for two minutes. Subsequently, they 
performed an auditory oddball task lasting 6 minutes. EEGs were recorded using the 10-20 system using a 
Quick-Cap with 26 EEG electrodes and impedance <5kΩ. Horizontal electrooculograms (EOG) were 
recorded with two electrodes placed 1.5cm lateral to the lateral canthi of the eyes. Vertical EOGs were 
recorded with electrodes above and below the middle of the eye with the upper electrode placed 3mm 
above the eyebrow and the other electrode 1.5cm below the lower eye-lid. A Neuroscan NuAmps 
amplifier recorded the signals with a sampling frequency of 500Hz, 100Hz low-pass anti-aliasing filter, and 
32 bit, DC high-pass filter. 
EEG-recordings were analyzed with Brain Vision Analyzer v2.0 (Brain Products GmbH, 
Germany). Reference to linked mastoids was calculated off-line; a high-pass filter of 0.5Hz, 12dB/octave 
and a low-pass filter of 30Hz, 48dB/octave were applied. Ocular correction was applied as in Gratton, 
Coles, and Donchin (1983). Data were segmented in 2s epochs. Automatic raw data inspection was 
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applied with a maximum allowed voltage step between samples of 50µV/ms, maximum allowed 
difference of 120µV in each segment, and permitted amplitude range of -100µV-100µV. Data were 
marked as bad 200ms before and after a detected artifact, the lowest permitted activity in intervals was 
0.5µV with an interval length of 50ms. Fast Fourier Transformation (FFT) with a 20% Hamming window 
was applied for tapering, and averages over the artifact-free epochs per channel were calculated. At least 
30 artifact free epochs had to be available for a channel to be included. Mean included channels were for 
eyes closed condition: M=25.64, SD=.92; eyes open condition: M=25.89, SD=.32 and task condition: 
M=25.87, SD=.34, and did not differ between the diagnostic groups (eyes closed: F=.06, ηp2=.00, p>.05; 
eyes open: F=.42, ηp2=.01, p>.05; task: F=.09, ηp2=.00, p>.05) nor with stimulant medication use (eyes 
closed: F=.05, ηp2=.00, p>.05; eyes open: F=.12, ηp2=.00, p>.05; task: F=.00, ηp2=.00, p>.05). In 
addition, for each condition the number of epochs for the channel with the fewest epochs (minimum 
epochs) was considered. The mean minimum epochs were eyes closed: M=57.64, SD=8.04; eyes open: 
58.81, SD=4.35 and task: M=172.66, SD=21.72, and did not differ between the diagnostic groups (eyes 
closed: F=.32, ηp2=.01, p>.05; eyes open: F=.03, ηp2=.00, p>.05; task: F=.13, ηp2=.00, p>.05) nor 
according to stimulant medication use (eyes closed: F=.05, ηp2=.00, p>.05; eyes open: F=.30, ηp2=.01, 
p>.05; task: F=1.76, ηp2=.03, p>.05). Mean absolute power (µV2) was exported to SPSS for the 
following frequency bands: delta 1.5-3.5Hz, theta 3.5-7.5Hz, alpha 7.5-12.5Hz, beta 12.5-25Hz and total 
power 1.5-25Hz. To increase the comparability of the results the frequency bands used were similar to 
those used in previous studies in ADHD by Clarke et al. (Clarke et al., 2002; Clarke et al., 2011; Clarke et 
al., 2001b; Clarke, Barry, McCarthy, Selikowitz, Brown, et al., 2003; Clarke, Barry, McCarthy, Selikowitz, 
Clarke, et al., 2003). Relative power was calculated as the absolute power per frequency band divided by 
the total power (1.5-25 Hz). A log10 transformation was applied to all absolute and relative measures to 
give a Gaussian distribution.  
 Initial regions of interest (ROIs) were based on a principal components analysis (PCA) of the 
frequency bands for the electrodes with covariance matrix, varimax rotation and Kaiser normalization. 
Missing values were replaced by mean imputation. Two regions were defined for the different conditions 
and frequency bands: frontocentral (Fp1, Fp2, F7, F3, Fz, F4, F8, FC3, FCz, FC4, C3, Cz, C4, CP3, CPz, 
CP4, T3, T4) and parietal-occipital (P3, Pz, P4, O1, Oz, O2, T5, T6). To improve comparability with areas 
defined in other reports three ROIs were derived: anterior (Fp1, Fp2, F7, F3, Fz, F4, F8, FC3, FCz, FC4), 
central (C3, Cz, C4, Cp3, CPz, Cp4, T3, T4) and posterior (P3, Pz, P4, O1, Oz, O2, T5, T6). ROI values 




All analyses were performed using SPSS version 19.0. Differences in group characteristics were analyzed with 
a one-way ANOVA or a chi-square test (χ2) with Fisher exact correction. Generalized Linear Model 
(GLM) univariate ANCOVAs were conducted for the measures of the d2 test of attention, with age as 
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covariate and diagnostic group (ADHD or ASD+ADHD) and stimulant medication use (stimulant-
medicated and stimulant-free) as between-subjects factors. GLM repeated-measures (RM) ANCOVAs 
were conducted separately for the absolute and relative power measures, with age as covariate, ROI as 
within-subject factor, and diagnostic group and stimulant medication use as between-subjects factors. The 
full factorial models were tested. All ROI effects were evaluated using multivariate test criteria, a method 
known to be robust against violations of sphericity (Vasey & Thayer, 1987). In addition, where applicable, 
the least significant difference (LSD) adjusted difference (AD) and 95% confidence interval (95% CI) 
have been reported. Significant three-way between-groups interactions were investigated with separate 
post-hoc GLM RM ANCOVA for each stimulant medication condition (on and off stimulant 
medication), with age as covariate, ROI as within-subject factor and diagnostic group as between-subjects 
factor. Effect sizes are expressed as proportion of explained variance in partial η2 (ηp2). In this study, 
absolute theta, absolute beta, total power, relative theta, relative beta and the theta/beta ratio were 
considered. (For an overview of the total power spectrum including delta and alpha see eSupplement 1). 
 Post-hoc stepwise linear regressions were performed separately for diagnostic group (ADHD and 
ASD+ADHD) with the measures of the d2 attention test (TN and C) as dependent variables. Four sets of 
independent variables were analyzed in each behavioral condition (eyes closed, eyes open and task) for all 
ROIs: (1) absolute theta, (2) relative theta, (3) absolute beta, and (4) relative beta. Because of 
multicollinearity between the independent variables, only the variable with the strongest association to the 
d2 test attention measures was considered. Values of p<.05 were considered statistically significant. The 




Group characteristics are summarized in Table 1. The two diagnostic groups (ADHD and ASD+ADHD) 
did not differ in age (see Table 1). In total 30 (57%) adolescents used stimulant medication. Stimulant 
medication use was equally distributed over the diagnostic groups, with 19 (58%) adolescents with ADHD 
and 11 (55%) with combined ASD+ADHD using stimulant medication, χ2(1, 51)=.00, p>.05. In addition, 
the mean prescribed dose in mg for the stimulant-medicated adolescents was similar in the ADHD group 
(n=19, M=34.74, SD=13.02), and the ASD+ADHD group (n=11, M=35.27, SD=17.35; F(1, 28)=.01, 
p>.05, ηp2=.00). However, the average age of the stimulant-free adolescents (ADHD: M=16.21, SD=3.87; 
ASD+ADHD: M=16.78, SD=2.54) was somewhat older than that of the stimulant-medicated adolescents 
(ADHD: M=14.64, SD=2.38; ASD+ADHD: M=14.63, SD=2.19). This age difference was similar in the 
ADHD group and the ASD+ADHD group, (F(3,49)=.12, p>.05, ηp2 =.00. Stimulant-free and stimulant-
medicated adolescents did not differ significantly on other group characteristics. 
The AQ adolescent confirmed that the ASD+ADHD group exhibited more autism symptoms 
than the ADHD group. For the ASD+ADHD group, parents reported more total behavioral problems 
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Cognitive performance 
D2 attention test performance (TN and C) was similar for the two diagnostic groups, see Table 2. 
In addition, stimulant-free and stimulant-medicated adolescents did not differ in terms of d2 attention test 
performance. Older adolescents performed better than younger adolescents in terms of both TN and C. 
 
EEG 
EEG outcomes are summarized in Table 3 and absolute measures are shown in Figure 1. 
  
 
Diagnostic group and stimulant medication use 
Absolute theta power differed between the adolescents with ADHD and the adolescents with 
ASD+ADHD during the eyes open and task conditions. During the eyes open condition, adolescents 
with ADHD displayed more absolute theta than adolescents with ASD+ADHD, ADADHD-ASD+ADHD=.11, 
95%CI:.004-.21, p<.05. During the task condition adolescents with ADHD also showed more absolute 
theta than adolescents with ASD+ADHD, ADADHD-ASD+ADHD=.11, 95%CI:.01-.22, p<.05. There was no 
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Cognitive performance 
D2 attention test performance (TN and C) was similar for the two diagnostic groups, see Table 2. 
In addition, stimulant-free and stimulant-medicated adolescents did not differ in terms of d2 attention test 
performance. Older adolescents performed better than younger adolescents in terms of both TN and C. 
 
EEG 
EEG outcomes are summarized in Table 3 and absolute measures are shown in Figure 1. 
 
Figure  1 .  Absolute power as a function of region for the ADHD and ASD+ADHD groups, on and off stimulant 
medication 
Note: Estimated marginal means are shown for log transformed absolute power (µV2) with standard error bars for 
each ROI and the evaluated covariate age 15.42 years for each condition (eyes closed, eyes open and task), for 
stimulant-free and stimulant-medicated adolescents with ADHD and for stimulant-free and stimulant-medicated 
adolescents with ASD+ADHD; *a Absolute theta was higher during the eyes open and task conditions for 
adolescents with ADHD than adolescents with ASD+ADHD, irrespective of stimulant medication use; *b Total 
power increased from the anterior ROI to the central ROI in stimulant-medicated adolescents with ADHD during 
the eyes open condition. 
 
Diagnostic group and stimulant medication use 
Absolute theta power differed between the adolescents with ADHD and the adolescents with 
ASD+ADHD during the eyes open and task conditions. During the eyes open condition, adolescents 
with ADHD displayed more absolute theta than adolescents with ASD+ADHD, ADADHD-ASD+ADHD=.11, 















diagnostic group difference in absolute theta during the eyes closed condition. Differences in absolute 
theta are shown in Figure 1. There were no main effects of stimulant medication use on absolute theta and  
no interaction involving stimulant medication use. Absolute beta power and theta/beta ratio revealed no 
main effects of diagnostic group or stimulant medication use.   
There was an interaction between ROI, diagnostic group, and medication use on total power in 
the eyes open condition (see Table 3 and Figure 1). Post-hoc analyses showed an interaction between ROI 
and diagnostic group for stimulant-medicated adolescents, F(2,26)=4.40, p<.05, ηp2=.25, whereas in 
stimulant-free adolescents this interaction was not significant, F(2,19)=.72, p=.50, ηp2=.07. Figure 1 
shows that in the eyes open condition the interaction is more pronounced in the anterior region than the 
central region. Post-hoc analysis of the central and anterior ROIs confirmed this, showing an interaction 
between ROI and diagnostic group in stimulant-medicated adolescents, F(1,27)=8.81, p<.01, ηp2=.25, 
but not in stimulant-free adolescents, F(1,20)=1.51, p=.23, ηp2=.07. Stimulant-medicated adolescents 
with ADHD showed more total power in the central region than the anterior region, ADcentral-
anterior=.04, 95%CI:.01-.08, p<.01. For adolescents with combined ASD+ADHD there was no 
significant difference between central and anterior regions, ADcentral-anterior=-.03, 95%CI:-.06-.01, 
p>.05. In summary, stimulant-medicated adolescents with ADHD showed an increase in total power 
from the anterior region to central region. Relative theta and relative beta did not differ between 
stimulant-free and stimulant-medicated adolescents, nor was there an overall interaction between the two 
diagnostic groups on and off medication.  
 
Age effects 
Age by topography interactions are summarized in Table 3. For detailed information about the effects of 
age see eSupplement 1. Note: age was taken into consideration because the mean age of stimulant-
medicated adolescents was younger than that of stimulant-free adolescents. 
 There was an overall decrease in absolute power with age. Specifically, the reduction of absolute 
theta power in older adolescents during the eyes closed condition was greatest in the posterior region and 
smaller at more anterior scalp locations. During the eyes open and the task conditions a general decrease 
in absolute theta with age was seen. Absolute beta power decreased with age during the eyes open and the 
task conditions. There was a corresponding general decrease in theta/beta ratio with age during the eyes 
closed and task conditions. Reductions in theta/beta ratio in older adolescents during the eyes open 
condition were greatest in the posterior regions and smaller at more anterior scalp locations. In all three 
conditions there was a general decrease in total power with age. Relative theta did not change with age. In 
contrast, relative beta increased with age during the eyes closed and task conditions. During the eyes open 
condition the increase in relative beta was greatest in the posterior region and smaller at more anterior 
scalp locations. In summary, absolute power decreased with age for most frequency bands and only 
relative beta showed an increase in all three conditions. In general age effects were most pronounced in 
the posterior region.  
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Region 
During the eyes closed condition absolute beta and total power differed across ROIs (see also Figure 1). 
Absolute beta was greatest in the posterior region, ADposterior-anterior=.05, 95%CI:.02-.09, p<.01; ADposterior-
central=.06, 95%CI: .03-.08, p<.001. Similarly, total power was greatest in the posterior region, ADposterior-
anterior =.14, 95%CI:.10-.19, p<.01; ADposterior-central= .06, 95%CI:.03-.08, p<.001. Relative beta during the 
eyes open condition showed activity mainly at anterior sites, ADanterior-central=.03, 95%CI:.003-.05, p<.05; 
ADanterior-posterior=.04, 95%CI:.01-.08, p<.05. 
 
Post-hoc d2 attention test performance, theta and beta power  
In Table 4, the associations between d2 attention test performance and absolute and relative power are 
summarized separately for the two diagnostic groups. Low absolute theta the during eyes closed condition 
was associated with a higher TN than high absolute theta; in the ADHD group this applied to central 
theta and in the ASD+ADHD group it applied to posterior theta. During the eyes open condition, low 
posterior theta was associated with a higher TN in the ADHD group, but not in the ASD+ADHD group. 
During the task condition low posterior theta was associated with a higher TN than high posterior theta in 
both diagnostic groups. The ADHD group also showed an association between low theta and C in the 
central regions during the eyes closed condition and in the posterior region during the eyes open and task 
conditions. C was not related to theta in the ASD+ADHD group. Low relative theta in the central region 
during the eyes closed condition was associated with high TN in the ADHD group, but not in the 
ASD+ADHD group. In the other conditions there were no associations between relative theta and d2 
attention test performance.  
 Low absolute central beta during the eyes open and task conditions was associated with high TN 
in the ADHD group, but not in the ASD+ADHD group. High posterior relative beta during the eyes 
open and task conditions was associated with high TN in both diagnostic groups.  
 Overall, absolute theta was associated with attention test performance, in all three conditions in 
the ADHD group. There was an association between relative theta and TN in the eyes closed condition, 
but only in the ADHD group. In the ASD+ADHD group there was an association between posterior 
absolute theta and TN during the eyes closed and task conditions. High relative beta seems to be 
associated with better performance in both diagnostic groups. In general, the associations between 





The current study explored differences between adolescents with ADHD and ASD+ADHD, on and off 
stimulant medication, in attention test performance and EEG power spectra. The main results revealed 
that although behavioral and neuropsychological measures of attention were similar in adolescents with 
ADHD and ASD+ADHD, absolute theta was elevated in ADHD compared to ASD+ADHD during the 
eyes open and task conditions, irrespective of stimulant medication use.  
 In line with the only previous study comparing power spectra in adolescents with ADHD and 
ASD+ADHD (Clarke et al., 2011), no differences between these groups in terms of absolute theta were 
observed during an eyes closed condition. Extending the protocol used by Clarke et al. (2011), in which 
only an eyes closed condition was investigated, we recorded power spectra during an eyes open and a task 
condition, which revealed overall greater absolute theta in ADHD than in ASD+ADHD. It is notable that 
in ADHD increased theta power during resting state conditions (Cortese, 2012; Loo & Makeig, 2012; 
Snyder & Hall, 2006), mainly in frontocentral regions (Loo & Makeig, 2012), was the most robust finding. 
Theta is associated with an underaroused (Banaschewski & Brandeis, 2007; Loo & Barkley, 2005; Loo & 
Makeig, 2012) and unfocused state (Loo & Barkley, 2005). It could be suggested that with their eyes open 
and during the task condition, adolescents with ADHD in the present study were characterized by a more 
underactive and unfocused state than adolescents with ASD+ADHD. This may indicate that underarousal 
is a better explanation for attentional problems in adolescents with ADHD than in adolescents with 
ASD+ADHD; the attentional problems in ASD+ADHD may result from other brain dysfunctions, such 
as abnormal neuronal connectivity (Billeci et al., 2013; Coben et al., 2008) and top-down processing 
problems (Gomot & Wicker, 2012), rather than from frontocentral underarousal per se.  
 It is remarkable that the difference in absolute theta between the diagnostic groups during the 
eyes open and task conditions was present irrespective of stimulant medication use, because other studies 
have reported decreased theta and increased beta after stimulant medication use (Clarke et al., 2002; 
Clarke, Barry, McCarthy, Selikowitz, Brown, et al., 2003; Hermens, Williams, et al., 2005; Loo & Barkley, 
2005). However, although stimulant medication partly normalizes theta and beta power, children with 
ADHD do not reach similar theta and beta levels as TD children (Clarke et al., 2002; Clarke, Barry, 
McCarthy, Selikowitz, Brown, et al., 2003). Furthermore, the decrease in frontal theta in youngsters with 
ADHD associated with stimulant medication use has been related to parent-reported behavioral 
improvement (Loo, Hopfer, Teale, & Reite, 2004). As the adolescents with ASD+ADHD in our study did 
not show as much absolute theta as adolescents with ADHD, this suggests either that stimulant 
medication works differently in youngsters with ASD+ADHD or is less effective than in youngsters with 
ADHD only.  
 When controlling for overall power, relative theta was similar for both diagnostic groups. 
Increased relative but not absolute theta, was also seen in youngsters with ASD only (Coben et al., 2008; 
Murias et al., 2007). In contrast, in youngsters with ADHD both increased relative theta (Chabot & 
Serfontein, 1996; Clarke et al., 2002; Clarke et al., 1998, 2001a) and increased absolute theta (Cortese, 
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2012; Loo & Makeig, 2012; Snyder & Hall, 2006) have been reported. Subsequently, it has been suggested 
that elevated absolute theta is more specific to ADHD than relative theta, the latter being related to ASD 
as well.  
 The only difference related to stimulant medication use was that stimulus-medicated adolescents 
with ADHD showed an increase in total power from anterior to central regions in the eyes open 
condition, whereas stimulant-medicated adolescents with ASD+ADHD did not. This increase in total 
power specific to stimulant-medicated adolescents with ADHD during an eyes open condition has not 
been previously reported. Stimulant medication use is generally associated with decreased total power 
(Clarke, Barry, McCarthy, Selikowitz, Clarke, et al., 2003), decreased theta and increased beta (Clarke et al., 
2002; Clarke, Barry, McCarthy, Selikowitz, Brown, et al., 2003; Hermens, Williams, et al., 2005; Loo & 
Barkley, 2005). In the current study there were no overall differences in EEG power between stimulant-
medicated and stimulant-free adolescents. Baseline differences in age between adolescents on and off 
stimulant medication in our sample may have contributed to the lack of effects of stimulant medication: 
the stimulant-free adolescents were, on average, older than stimulant-medicated adolescents. Since aging 
(Segalowitz, Santesso, & Jetha, 2010) as well as using stimulant medication (Clarke et al., 2002; Clarke, 
Barry, McCarthy, Selikowitz, Brown, et al., 2003; Hermens, Williams, et al., 2005; Loo & Barkley, 2005) 
results in decreased theta power, the two effects may have cancelled each other out. In line with the 
review by Segalowitz et al. (2010) the current study found a clear maturation effect, with older adolescents 
displaying lower absolute power across all frequency bands, particularly in the posterior region, and 
increased relative beta. In addition, we observed a maturation effect on attention test performance, with 
better performance at older ages. 
 Although increased theta, particularly in the anterior region, is generally thought to be typical of 
ADHD, we observed an inverse association between posterior theta during the eyes closed condition and 
performance on the d2 attention test. This finding is similar to that of Hermens, Soei, et al. (2005) who 
found an inverse correlation between posterior theta during an eyes open condition and reaction time in 
TD adolescents but not adolescents with ADHD (Hermens, Soei, et al., 2005). It is striking that a lower 
posterior absolute theta during the eyes open condition was strongly associated with attentional 
performance in terms of total processed (TN) and total correct processed (C) items in adolescents with 
ADHD but not adolescents with ASD+ADHD. It should be noted that due to the smaller size of the 
ASD+ADHD group, associations had to be stronger to reach significance; but taking this difference in 
sample size into account, the association was so pronounced in the ADHD group that an association of 
similar strength in the combined ASD+ADHD would have proved significant, as was the association 
between TN and posterior theta during the eyes closed and task conditions. This finding provides support 
for the hypothesis that increased theta may be associated with attentional problems in ADHD more often 
than in ASD+ADHD. 
 In the current study, lower central absolute beta was associated with improved attention test 
performance in the adolescents with ADHD. In contrast, in TD young adults an increase in absolute beta 
during attention test performance has been associated with improved visual attention test performance 
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(Vazquez Marrufo, Vaquero, Cardoso, & Gomez, 2001). Similarly, strong positive correlations between 
absolute beta and attention test performance, as well as parent-reported measures of attention in children 
with ADHD have been reported previously (Loo et al., 2004). The reverse finding - a reduction in 
absolute beta and improved attention test performance - reflects maturation, which is generally 
accompanied by a decrease in power across all frequency bands and total power (Segalowitz et al., 2010). 
In terms of relative beta, the present results did reveal the expected positive association between attention 
test performance and relative beta in adolescents with ADHD and adolescents with ASD+ADHD. 
 The current results showed differences in absolute theta activity between adolescents with 
ADHD and adolescents with ASD+ADHD. Nevertheless, further systematic research on the 
psychophysiological aspects of ADHD and ASD+ADHD and their implications is warranted. First of all, 
replication of these psychophysiological results with a larger sample size is needed, ideally with a 
controlled stimulant medication titration trial including physiological baseline measures with stimulant-free 
adolescents with ADHD, ASD+ADHD, ASD and TD adolescents. Such a titration trial would control 
for the baseline differences in stimulant medication use and age that were observed in the current study. 
Although we controlled for age statistically, it is possible that stimulant medication use and maturation 
may affect EEG spectra similarly. The stimulant-medicated adolescents in this study were on average 
younger than the stimulant-free adolescents, this may have concealed potential effects of stimulant 
medication use. Secondly, the diagnostic group assignments in this study were based on clinician’s 
decisions using DSM-IV (American Psychiatric Association, 2000) criteria; whilst this increased the 
ecological validity of the study, information about specific diagnostic aspects of ASD were not available. 
Including diagnostic interviews such as the Autism Diagnostic Interview (Lord, Rutter, & Le Couteur, 
1994) or the Autism Diagnostic Observation Schedule (Lord et al., 1989) in future research, could give 
more detailed information about specific characteristics of ASD. Inclusion of a control group of TD 
adolescents would make it possible to determine whether physiological patterns in the diagnostic groups 
differ from those of TD adolescents. Future research should, if possible, include adolescents with ADHD 
only, ASD+ADHD, ASD only and TD adolescents in order to uncover the physiological patterns 
associated with ADHD, ASD, ASD+ADHD and typical development.  
 In conclusion, adolescents with ADHD displayed more absolute theta activity than adolescents 
with ASD+ADHD with their eyes open and during performance of a task. In addition, adolescents with 
ADHD but not adolescents with ASD+ADHD showed an association between diminished attention test 
performance and increased theta with their eyes open. The current study suggests that although there is an 
overlap in behavioral ADHD characteristics between adolescents with ADHD and adolescents with 
ASD+ADHD, the underlying psychophysiological mechanisms responsible may be different. This finding 
may help to explain why stimulant medication is less effective in ASD+ADHD than in ADHD. Further 
research into the psychophysiology of ASD+ADHD is therefore warranted. 
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ABSTRACT 
The current study explored event-related potentials for an auditory oddball task in adolescents 
diagnosed with Attention Hyperactivity Deficit Disorder (ADHD; n=33) or autism spectrum disorder 
with ADHD (ASD+ADHD; n=20) and categorized by stimulant medication use (57% of total sample) 
to investigate underlying brain functions. There was an interaction between diagnostic group and 
stimulant use for N1 latency and N2 amplitude, but not for the P3 component. Medication was 
associated with reduced N1 latencies in ADHD and with prolonged N1 peak latencies in 
ASD+ADHD. In ASD+ADHD, N2 amplitude was lower in stimulant-free adolescents; in ADHD 
there were no differences in N2 amplitude associated with stimulant medication. Results suggest that 




Features of attention deficit hyperactivity disorder (ADHD), such as hyperactivity/impulsivity 
symptoms and inattention symptoms, frequently occur in autism spectrum disorders (ASD) (American 
Psychiatric Association 2013). Estimates of the prevalence of ADHD in ASD range from 28 percent 
to over 50 percent (Simonoff et al. 2008; Lee and Ousley 2006; Gjevik et al. 2011). Stimulant 
medication and behavioral therapy are the treatments of choice for reducing ADHD symptoms. 
Stimulant medication is effective in reducing ADHD symptoms in youngsters with ADHD (Greenhill 
et al. 2001; Faraone and Buitelaar 2010). However, there are indications that stimulant medication is 
less effective in youngsters with co-occurring ASD and ADHD (ASD+ADHD) (Cortese et al. 2012; 
Research Units on Pediatric Psychopharmacology (RUPP) Autism Network 2005). Within the ADHD 
population, the number of hyperactivity/impulsivity symptoms declines with age (Hart et al. 1995; 
Kessler et al. 2005) and this is also true for the majority of youngsters with ASD+ADHD, whereas 
inattention symptoms seem to persist (Lee and Ousley 2006). This persistence makes attention 
processes in these groups of high clinical interest. It is not clear however, whether ADHD in ASD is 
similar to ADHD in the absence of ASD; in consequence it is not known whether stimulant 
medication that seems to treat ADHD effectively (Greenhill et al. 2001; Faraone and Buitelaar 2010) 
produces comparable effects in ASD+ADHD. Stimulant medication may be less effective in reducing 
ADHD symptoms in youngsters with ASD and it produces many adverse effects in youngsters with 
ASD (RUPP 2005; Cortese et al. 2012). Together, these finding indicate that despite the behavioral 
overlap in attention problems, there may be physiological differences between ADHD and 
ASD+ADHD. Better understanding of brain functioning related to attention in ADHD and ASD and 
the effects of stimulant medication may help to explain the different effects of stimulant medication in 
youngsters with ASD+ADHD and ADHD. Auditory event related potentials (ERPs) during 
performance of an oddball task are related to attentional processing and may offer insight into the 
attention deficits in ADHD and ASD+ADHD. 
 Abnormal ERPs are seen in adolescents with ADHD (Johnstone et al. 2013) and ASD 
(O'Connor 2012; Gomot and Wicker 2012). ERP components can be related to cognitive functions 
such as attention, response selection, inhibition, and response monitoring (Johnstone et al. 2013). With 
regard to attention, a recent review indicated that youngsters with ADHD have problems with 
stimulus discrimination (N2) and problem evaluation (P3) on oddball tasks, when compared to typical 
developing (TD) youngsters (Johnstone et al. 2013). Specifically, the N1 amplitude, which is associated 
with the processing of stimulus characteristics (Näätänen and Picton 1987); the N2, which is associated 
with stimulus orienting and discrimination (Näätänen et al. 1982); and the P3, which is associated with 
selective attention and working memory capacity (Polich and Herbst 2000), are abnormal during 
attentional task performance in youngsters with ADHD (Johnstone et al. 2013; Barry et al. 2003). In 
youngsters with ADHD, the N1 amplitude was reduced during some developmental stages: in pre-
adolescence (age 7 to 9 years) and from middle adolescence (16 years and older) (Barry et al. 2003). In 
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addition, reduced N1 peak enhancement from non-target to target stimuli has been seen in ADHD 
(Barry et al. 2003). Other studies have found enlarged N1 amplitude (Johnstone et al. 2013). The 
findings relating to N2 and P3 amplitudes are more reliable, these components are generally decreased 
in youngsters with ADHD (Johnstone et al. 2013; Barry et al. 2003). In addition to decreased P3 
activity, adolescents with ADHD or conduct disorder show prolonged N2 and P3 latencies (Du et al. 
2006). Stimulant medication appears to have some influence on ERPs, as increased P3 (Groom et al. 
2010; Hermens et al. 2005) and N2 (Pliszka et al. 2007) amplitudes have been seen in adolescents with 
ADHD following stimulant medication use.  
 Youngsters with ASD show abnormal patterns mainly in the earlier N1 and N2 ERP 
components (O'Connor 2012). Studies of ERP characteristics in ASD have produced mixed results for 
the early negative components. The N1 amplitude has been found to be attenuated in ASD children 
(O'Connor 2012). Shorter and longer N1 latencies have been reported (O'Connor 2012). N2 
amplitudes range from reduced to normal in ASD (O'Connor 2012). In most research, the later 
positive P3 amplitude has been reported to be smaller in ASD children than TD children and 
adolescents (O'Connor 2012; Gomot and Wicker 2012), indicating a deficit in sustained attention to 
detecting oddball stimuli. 
 There have been very few direct comparisons of children with ADHD, ASD, and 
ASD+ADHD, and the data are restricted to visual tasks (Tye et al. 2013a; Gomarus et al. 2009; 
Kemner et al. 1999; Tye et al. 2013b). In a visual continuous performance task, children with 
ASD+ADHD and ADHD showed reduced N2 amplitudes compared to TD children (Tye et al. 
2013a). In addition, the increase in N2 amplitude from target to no-target trials was smaller in children 
with ASD and ASD+ADHD compared to children with ADHD and TD children. Children with 
ADHD showed smaller frontal P3 amplitudes than children with ASD (Kemner et al. 1999) and 
attenuated P3 to attention orienting cues and inhibition of P3 related non-targets was found in children 
with ASD+ADHD or ADHD compared to children with ASD or TD children (Tye et al. 2013a). 
Moreover, children with ASD+ADHD showed a smaller increase in occipital P3 amplitude to target-
relevant features than children with ASD, ADHD, or TD children (Gomarus et al. 2009). Overall, 
these reductions in N2 and P3 may indicate that in children with ASD+ADHD, abnormal ERP 
patterns are the summation of abnormalities characteristic of ADHD and ASD. 
 In summary, the current literature suggests that youngsters with ASD show abnormal patterns 
in the earlier ERP components, whereas in youngsters with ADHD the main abnormality in ERPs is  
in the later P3 component. Stimulant medication seems to normalize ERPs in adolescents with 
ADHD, but it is less clear that it produces similar outcomes for adolescents with ASD+ADHD. The 
aim of the current study was therefore to explore ERP abnormalities in adolescents diagnosed with 
ADHD or ASD+ADHD. In addition, differences in ERP patterns associated with use of stimulant 
medication were also explored. It was predicted that (a) adolescents with ASD+ADHD would show 
similar or reduced N1, reduced N2, and similar P3 when compared with adolescents with ADHD; and 
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(b) stimulant-medicated adolescents in both groups would show larger ERP amplitudes and shorter 




This study used a subsample of 53 adolescents who had been recruited for an intervention study for 
adolescents with clinical ADHD symptoms. Prior to the start of the study, approval was obtained from 
the Medical Ethics Committee for Mental Health Institutions in the Netherlands (Ref. no: NL 
24776.097.08 CCMO). The study took place in three centers of child and adolescent psychiatry 
(GGzE, GGz Breburg, Reinier van Arkel group) in the southern part of the Netherlands. Written 
informed consent was obtained from each participant. Where the participant was younger than 18 
years the parents also provided written informed consent. The sample was similar to that used by (Bink 
et al. 2013), but 5 adolescents were excluded because of the quality of the EEG data and 2 additional 
patients were included: one who had enrolled later in the study and one for whom no response 
measures of the oddball task were available. 
 Two diagnostic groups of male adolescents between 12 and 24 years old were included in the 
study. The first group consisted of 33 adolescents with a clinical DSM-IV-TR (American Psychiatric 
Association 2000) primary diagnosis of ADHD: combined subtype (n=16), inattentive subtype (n=16), 
hyperactive /impulsive subtype (n=1). The second group consisted of 20 adolescents with a primary 
diagnosis of ASD: Asperger’s syndrome (n=6), pervasive developmental disorder – not otherwise 
specified (PDD-NOS; n=14). Adolescents with ASD also had a notification of clinical ADHD with 
symptoms sufficient for a clinical diagnosis of ADHD. ADHD symptoms were assessed using a Dutch 
DSM-IV-based semi-structured ADHD interview for adults (Kooij 2002) and the Mini International 
Neuropsychiatric Interview (MINI; Sheehan et al. 1997; Sheehan et al. 1998). Exclusion criteria were 
IQ<80, neurological disorders, schizophrenia and other psychotic disorders, depression, attachment 
disorder or anxiety disorder, use of cannabis in the 24 hours prior to physiological assessment, use of 
medication other than stimulant medication. 
 Stimulant medication use was monitored through an intervention questionnaire based on the 
Dutch national basic ADHD program for children and adolescents (Vink and Van Wamel 2007). 
Adherence to prescribed medication was determined by asking the adolescents whether they had been 
taking their medication as prescribed. In total, 30 (57%) adolescents used stimulant medication. In the 
ADHD group, 19 (58%) used stimulant medication: 6 used immediate release methylphenidate and 13 
used sustained release methylphenidate. In the ASD+ADHD group, 11 (55%) used stimulant 
medication: 1 used immediate release methylphenidate and 10 used sustained release methylphenidate. 
Two adolescents in the ASD+ADHD group used low doses (0.5 mg and 1.5 mg per day) of 
antipsychotic medication (Risperdal®) in addition to their stimulant medication; because the dosage 
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was low and combined with stimulant medication, we considered that the potential impact on the 
outcome measures would be minimal. 
 Comorbid disorders were allowed: included in the ADHD group were participants with 
substance-related disorders (n=2), conduct disorders (n=3), and reading disorder (n=2), and in the 




The group characteristics are listed in Table 1. We have reported Global Assessment of Functioning 
(GAF) score, the DSM-IV based ADHD-rating scale (Kooij et al. 2005; Kooij et al. 2008), the MINI 
subscales for inattention and hyperactivity/impulsivity (HI), the Autism-Spectrum Quotient (AQ)-
adolescent version for individuals with normal intelligence (Baron-Cohen et al. 2006; Baron-Cohen et 
al. 2001), the Child Behavior Checklist (CBCL) and the Youth Self Report (YSR;(Achenbach 1991), 
and the WISC-III or the WAIS-III (Wechsler 1991, 1997) full-scale total intelligence quotient (TIQ). 
Further information about the reported group characteristics can be found elsewhere (Bink et al. 
2013). 
 
Auditory oddball task 
The auditory oddball task is an attention test in which relevant target stimuli need to be processed and 
irrelevant standard stimuli need to be ignored. In this task a 75dB tone lasting 50 ms was presented 
binaurally by headphones every second. Low frequency standard tones (500Hz) were presented 280 
times and intermixed with infrequent (60 presentations in 6 minutes) high target tones (1000Hz); the 
tones were presented in quasi-random order. The duration of both standard and target tones was 5ms. 
Adolescents were asked to press the answer box with both index fingers as fast as they could on 
hearing the high frequency 1000Hz target tone. Hearing ability for the different tones was checked in a 
short practice trial before the start of the oddball task. Response measures included mean reaction 
time, reaction time variability and total number of errors. 
 
Psychophysiological recording 
Electroencephalograms (EEGs) were recorded between 10am and 11am. When applicable, stimulant 
medication was taken during breakfast, before the measurement. No caffeine or nicotine intake was 
allowed in the two hours prior to physiological assessment. 
 The EEG-recording was performed in combination with a subset of the brain resource 
company (BRC, Ultimo, Australia) test battery. This included a baseline condition in which adolescents 
had to sit quietly with their eyes closed for two minutes. Subsequently they performed the task 
condition, which consisted of a six-minute auditory oddball task. EEGs were recorded according to 
the 10-20 system using a Quick-Cap with 26 EEG channels. Horizontal electrooculograms (EOGs) 
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were recorded with two electrodes placed 1.5cm lateral to the canthi of the eyes. Vertical EOGs were 
recorded with electrodes placed above and below the middle of the eye with the upper electrode placed 
3mm above the eyebrow and the other electrode 1.5cm below the lower eyelid. A Neuroscan NuAmps 
amplifier recorded the signals with a sampling rate of 500Hz, a 100Hz low pass anti-aliasing filter and 
32-bit DC high-pass filter,. 
 EEG recordings were analyzed with a Brain Vision Analyzer v2.0 (Brain Products GmbH, 
Germany). References were set offline to linked mastoid; a 0.5Hz 12dB/oct high pass filter, and a 
30Hz, 48dB/oct low pass filter were applied. Ocular correction was applied according to the 
procedure of Gratton et al. (1983). Automatic raw data inspection was applied with a maximum 
allowed voltage step of 50µV/ms, maximum allowed interval difference of 200µV, and minimum and 
maximum allowed amplitudes of -200µV and 200 µV respectively. Data was marked as bad 200ms 
before and after the event; the lowest permitted level of activity in intervals was 0.5µV with an interval 
length of 100ms. Data was segmented from 100ms pre-stimulus to 500ms post-stimulus, and the 
100ms pre-stimulus interval was used for baseline correction. We used automatic artifact rejection 
inspection in each segment with a maximum voltage step of 50µV/ms, maximum allowed difference in 
intervals of 100µV, minimum allowed amplitude of -100µV, maximum allowed amplitude of 100µV, 
and the lowest permitted level of activity in the 100ms intervals was 0.5µV. Averages over all the 
segments were calculated separately for standard and target tones and for each channel. Semi-
automatic peak picking was based on the target, with the N1 at 50-150ms, the N2 at 150-250ms and 
the P3 at 250–500ms. Peaks were inspected visually by the first author (MB), who was blind to 
diagnostic group and stimulant medication use, and were manually adjusted if necessary. Peak picking 
was not done separately for the standard wave, because it was not feasible to score the N2 and P3 
components reliably due to the shape of the standard wave. To address the standard wave, difference 
waves were calculated as the difference between the target and standard stimuli at the moment of the 
observed target peak. Peak amplitudes were assessed as the mean value in µV of a 10ms interval 
around the peak, and for each channel peak latencies in ms were exported to SPSS.  
 Initial regions of interest (ROIs) were based on a principal component analysis (PCA) of the 
target N1, N2 and P3 peak amplitudes (V) with covariance matrix, varimax rotation, and Kaiser 
normalization. Missing values (1.23%) were replaced using mean imputation. Three ROIs were 
distinguished: anterior, central and posterior. For an electrode to be included, the electrode had to be 
part of the same ROI for all three components: N1, N2 and P3. Three congruent ROIs were 
distinguished for 16 electrodes: anterior [Fp1, Pp2, F7, F3, Fz, F4, F8,], central [C3, Cz, C4,], and 
posterior [P3, Pz, P4, O1, Oz, O2]. Accordingly, ROI values were calculated for the N1, N2, and P3 
components as the means of values at the relevant electrodes.  
 Data quality did not differ between the diagnostic groups or with stimulant medication use. 
Total included electrodes, M=15.85, SD=.60, did not differ between the diagnostic groups, 
F(1,51)=2.01, ηp2=.04, p>.05, or with stimulant medication use, F(1,51)=1.37, ηp2=.03, p>.05. For 
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standard and target stimuli the number of artifact free segments of the electrode with the fewest 
included segments (minimum segments) was considered. The mean number of minimum segments for 
standard stimuli, M=271.55 SD=14.36, and target stimuli, M=57.00, SD=5.27, did not vary across the 
diagnostic groups (standard: F(1,51)=.09, ηp2=.00, p>.05; target: F(1,51)=.03, ηp2=.00, p>.05) or with 
stimulant medication use (standard: F(1,51)=.01, ηp2=.00, p>.05; target: F(1,51)=.02, ηp2=.00, p>.05). 
 
Data analysis 
All analyses were performed using SPSS version 19.0. Differences in group characteristics were analyzed 
with a one-way ANOVA or a chi-square test (χ2) with Fisher’s exact correction. Generalized Linear 
Model (GLM) repeated-measures (RM) ANCOVAs were conducted separately for the peak amplitudes 
and latencies, with age as covariate, ROI as within-subjects factor and diagnostic group (ASD+ADHD 
or ADHD) and stimulant use (stimulant-medicated and stimulant-free) as between-subjects factors. 
The full factorial models were tested. All ROI effects were evaluated using multivariate test criteria, a 
method known to be robust against violations of sphericity (Vasey and Thayer 1987). Effect sizes have 
been expressed as percentage of explained variance in partial η2 (ηp2). In addition, the adjusted 
difference between ROIs (AD) and 95% confidence interval [95% CI] have been reported where 
applicable. Significant two-way between-groups interactions were explored with post hoc GLM RM 
ANCOVA for diagnostic group, with age as covariate, ROI as within-subjects factor and stimulant 
medication use as between-subjects factor. Pearson correlations for all latency and amplitude measures 
were calculated for all ERP components. In addition, where there was a main effect of diagnostic 
group or stimulant medication on an ERP component, Pearson’s correlation coefficients for reaction 
time and reaction time variability were considered separately for each diagnostic group and stimulant 
medication use group as well as for the whole sample. 
Values of p<.05 were considered statistically significant; p<.10 was considered a trend. Only 
significant results and trends have been reported. Because of the exploratory nature of the study, no 
alpha correction for multiple testing was applied. Effect sizes have been expressed as percentage of 




There were no differences between the diagnostic groups (ADHD, ASD+ADHD) in terms of age, 
M=15.42 years, SD=2.88, or stimulant medication use, χ2(1, 51)=.00, p>.05. In addition, the mean 
prescribed dose for stimulant-medicated adolescents was similar in the ADHD group, N=19, 
M=34.74, SD=13.02, and the ASD+ADHD group, N=11, M=35.27, SD=17.35; F(1,28)=.01, p>.05, 
ηp2=.00. However, the average age of the stimulant-free adolescents (ADHD: M=16.21 years, 
SD=3.87; ASD+ADHD: M=16.78 years, SD=2.54) was somewhat older than stimulant-medicated 
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This age difference was similar for the ADHD group and the ASD+ADHD group, F(3,49)=.12, 
p>.05, ηp2 =.00. Stimulant-free and stimulant-medicated adolescents did not differ significantly on 
other group characteristics. 
 The AQ-adolescent version confirmed that the ASD+ADHD group exhibited more 
symptoms of autism than the ADHD group. The parents of the ASD+ADHD group reported more 
behavioral problems on the CBCL. The diagnostic groups did not differ on other group characteristics. 
 
ERPs 
The peak amplitude, difference wave and latency measures of the ERP components are summarized in 
Table 2. Figure 1 depicts the topographical distribution of the grand averages of the standard, target 
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Figure  1 .  Topographical distribution of ERP activity 
 
Note: Grand averages for the whole sample are depicted. The black line represents the standard wave, the red 
line the target wave. For graphical presentation of the ERPs, electrode positions are slightly adapted from the 
original electrode position. Original electrode positions are according to the 10-20 system 
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Diagnostic group and stimulant medication use 
The N1 peak latencies showed an interaction between diagnostic group and stimulant medication use. 
Post hoc separate analysis of the diagnostic groups revealed that stimulant-medicated adolescents with 
ASD+ADHD had longer N1 peak latencies than stimulant-free adolescents with ASD+ADHD, 
ADASD+ADHD (stimulant-medicated)-(stimulant-free) [95%CI]=17.47[5.65-29.29], F(1,17)=9.73, p<..01, ηp2=.36. In 
contrast, N1 peak latencies were shorter in stimulant-medicated adolescents with ADHD than 
stimulant-free adolescents ADADHD (stimulant-medicated)-(stimulant-free) [95%CI]= 9.78[-19.07--.50], F(1,30)=4.63, 
p<.05, ηp2=.13. Representative grand averages are depicted in Figure 2. 
 There was an interaction between diagnostic group and stimulant use for the N2 peak 
amplitude and N2 difference wave. Post hoc separate analysis of the diagnostic groups confirmed that 
stimulant-free adolescents with ASD+ADHD had lower N2 peak amplitudes than stimulant-
medicated adolescents with ASD+ADHD for the target peak: ADASD+ADHD (stimulant-medicated)-(stimulant-free) 
[95%CI]=-4.37 [-8.09--.65], F(1,17)=6.16, p<.05, ηp2=.27 and for the difference wave: 
ADASD+ADHD(stimulant-medicated)-(stimulant-free) [95%CI]=-4.02 [-7.90--.15], F(1,17)=4.80, p<.05, ηp2=.22. In the 
ADHD group there was no significant difference in N2 peak amplitude between stimulant-free and 
stimulant-medicated adolescents for the target peak: ADADHD (stimulant-medicated)-(stimulant-free) [95%CI]=1.06 [-
1.55-3.67], F(1,30)=.69, p>.05, ηp2=.02 or the difference wave: ADADHD (stimulant-medicated)-(stimulant-free) 
[95%CI]=.99 [-1.63-3.62], F(1,30)=.60, p>.05, ηp2=.02. Representative grand averages are depicted in 
Figure 3. 
 There were no significant interactions for the P3 peak amplitude or difference wave. For the 
P3 latency there was a trend towards an interaction between diagnostic group and stimulant 
medication use. Post hoc separate analyses of the P3 latency for each diagnostic group did not confirm 
a trend for stimulant-free and stimulant-medicated adolescents to differ in P3 in either group.  
 
Age effects 
Effects of age and interactions between age and scalp distributions of the ERP components are 
summarized in Table 2. Age was taken into consideration because the stimulant-medicated adolescents 
were on average younger than stimulant-free adolescents.  
 Overall, the N1 peak latencies were shorter for older adolescents than younger adolescents, 
F(1,48)=4.31, p<.05, ηp2=.08. 
Scalp distribution of the N2 interacted with age. The older adolescents showed less negative 
N2 peak amplitudes than the younger adolescents at anterior, B=.68, p<.005, but not central, B=.10, 
p>.05, or posterior, B=-.04, p>.05 regions. Accordingly, the difference wave of the N2 was also less 
negative at anterior, B=.68, p<.005 but not central, B=.05, p>.05, or posterior, B=-.08, p>.05 regions. 
In addition, there was a trend for scalp distributions of the N2 latency to interact with age, with a trend 
for shorter N2 latencies at posterior, B=-2.40, p=.06, but not central, B=-.20, p>.10 or anterior, B=-
.67, p>.10 locations. 
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There was a trend for scalp distributions of the P3 peak amplitude to interact with age. The P3 
peak amplitude was less positive in older than younger adolescents at posterior sites, B=-.63, p<.05, 
there was a trend towards this pattern centrally, B=-.46, p=.09, but no age difference at anterior sites, 
B=.06, p>.05.  
 
Topographical distribution 
The N2 and P3 peak amplitudes and difference waves exhibited characteristic scalp distributions (see 
Table 2).  
 The N2 peak amplitude was more negative at anterior than central sites, ADanterior-central 
[95%CI]=-3.25 [-4.39--2.11]; more negative at central than posterior sites, ADcentral-posterior [95%CI]=- 
3.35 [-4.44--2.27] and also more negative at anterior than posterior sites, ADanterior-posterior [95%CI]=-
6.60 [-7.91--5.29]. The N2 difference wave was not significantly more negative at anterior sites than 
central sites, ADanterior-central [95%CI]=-.91 [-2.10, .28]; but was more negative at central than posterior 
sites, ADcentral-posterior [95%CI]=- 3.54 [-4.56--2.51] and more negative at anterior than posterior sites, 
ADanterior-posterior [95%CI]=-4.44 [-5.77--3.12].   
 The P3 peak amplitude was more positive at posterior sites than central sites, ADposterior-central 
[95%CI]=2.32 [1.14-3.50]; more positive at central than anterior sites, ADcentral-anterior [95%CI]=6.56 
[5.27-7.84] and more positive at posterior than anterior sites, ADposterior -anterior 
[95%CI]=8.88[7.27-10.49]. The P3 difference wave was more positive at posterior sites than central 
sites, ADposterior-central [95%CI]=1.89 [.72-3.05]; more positive at central than anterior sites, ADcentral-anterior 
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Figure  3 .  Interaction between diagnostic group and stimulant medication use for N2 peak amplitude 
Note: The left panel depicts grand average ERPs at Fz for the stimulant-free adolescents with combined ASD+ADHD (n=9), stimulant-medicated adolescents with ASD+ADHD 
(n=11) stimulant–free adolecents with ADHD (n=14) and stimulant-medicated adolescents with ADHD (n=19). ERP activity is displayed on the y-axis in µV; negative up and 
positive down as a function of time in ms on the x-axis. The right panel depicts the topographical distributions of grand averages in the N2 time interval for each group from 
196- 220ms. There was an interaction between diagnostic group and stimulant medication use for the N2 peak amplitude. Stimulant-free adolescents with ASD+ADHD showed 
diminished N2 peak amplitude compared to stimulant-medicated adolescents with ASD+ADHD, whereas there was no difference between stimulant-free and stimulant-medicated 
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Amplitude and latency correlations 
Correlations between latencies and amplitude for the three components are summarized in Table 3. 
There was a negative correlation between N1 latency and peak amplitude at anterior and posterior 
sites: longer latencies correlated with more negative (i.e. larger) N1 peak amplitudes. Similar, N1 
latencies correlated negatively with N1 difference waves at anterior, central and posterior sites. 
Latencies and peak amplitudes or difference waves were not correlated for the N2 and the P3 




ERP activity related to task performance 
There were no significant correlations between reaction time or reaction time variability and N2 peak amplitude 
or N2 difference wave. Reaction time was not correlated with N1 latencies. Variability in reaction time was 
negatively correlated with N1 latency at anterior and central sites (Table 4). Over the whole sample, long latencies 
were related to low reaction time variability. Considering the diagnostic groups separately, long anterior and 
central N1 latencies were related to low reaction time variability for adolescents with ASD+ADHD, but there 
was no significant relationship in adolescents with ADHD. In addition, for stimulant-medicated adolescents long 
central N1 latencies were associated with low reaction time variability. In stimulant-free adolescents long 




Chapter 4 – ERP components in ADHD and ASD+ADHD 26 
sites: longer latencies correlated with more negative (i.e. larger) N1 peak amplitudes. Similar, N1 
latencies correlated negatively with N1 difference waves at anterior, central and posterior sites. 
Latencies and peak amplitudes or difference waves were not correlated for the N2 and the P3 
components of the ERP. 
 
Table 3. Correlation Between Latency and Amplitude Measures. 
  Latency   
  Anterior Central Posterior 
Peak Amplitude Target N1 -.390** -.209 -.302* 
 N2 -.068 0.038 -.060 
 P3 -.033 -.178 -.124 
Peak Amplitude Difference Wave N1 -.437* -.306* -.557** 
 N2 -.035 0.026 -.056 
 P3 -.034 -.158 -.105 
Note: *p<.05, **p<.01; Pearson’s correlations between latency and amplitude  
(peak amplitude and difference waves) of the same ROI (Anterior, Central or Posterior)  
for each of the three ERP components (N1, N2 and P3) 
 
ERP activity related to task performance 
There were no significant correlations between reaction time or reaction time variability and N2 peak amplitude 
or N2 difference wave. Reaction time was not correlated with N1 latencies. Variability in reaction time was 
negatively correlated with N1 latency at anterior and central sites (Table 4). Over the whole sample, long latencies 
w re related to low reaction time variability. Considering th  diagnostic groups separat ly, long anterior and 
central N1 latencies were related to low react on time variability for adolescents with ASD+ADHD, but there 
was no significant relationship in adolescents with ADHD. In addition, for stimulant-medicated adolescents long 
central N1 latencies were associated with low reaction time variability. In stimulant-free adolescents long 
posterior N1 latencies were associated with low reaction time variability.  
 













N1 peak latency      
  Anterior -.315* -.463* -.211 -.328 -.302 
  Central -.347* -.523* -.239 -.403* -.318 
  Posterior -.140 -.332 -.014 .129 -.442* 
Note: *p<.05, **p<.01; Pearson correlations between N1 latency and reaction time variability.  
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DISCUSSION 
The current study explored ERPs in stimulant-medicated and stimulant-free adolescents diagnosed 
with ADHD or ASD+ADHD. To our knowledge, there are no other published ERP studies that 
included stimulant-medicated adolescents with a diagnosis of ASD+ADHD. The results of this study 
showed that stimulus processing, reflected in N1 latencies and N2 peak amplitudes, is different in 
adolescents with ADHD and adolescents with ASD+ADHD, both on and off stimulant medication.  
The current study did not reveal overall ERP differences between ADHD and ASD+ADHD. 
These results are in line with the study of Gomarus et al. (2009), which also failed to differentiate 
between stimulant-free children with ADHD, ASD or ASD+ADHD in terms of early visual ERPs – 
up to 300 s – or behavioral measures related to selective attention. However, Tye et al. (2013a) did find 
that the reduction in N2 amplitude enhancement for non-target stimuli was different in ADHD and 
ADHD+ASD. On the basis of earlier studies we predicted overall differences for the N1 and N2 
components between the two diagnostic groups. Stimulant-medication may modulate these overall 
effects. In the current study these early negative components were differently affected by stimulant 
medication in adolescents with ADHD and ASD+ADHD.  
For adolescents with ASD+ADHD N1 peak latencies were longer under stimulant medication 
than stimulant-free. The opposite pattern was observed for the adolescents with ADHD; N1 peak 
latencies -were shorter in stimulant-medicated than in stimulant-free adolescents. Shorter latencies are 
generally seen as an indication of more efficient information processing. Nonetheless, the results of the 
current study also showed that prolonged central N1 latencies were associated with more negative 
(larger) N1 amplitudes. In addition, long N1 latency was related with less reaction time variability, 
mainly in adolescents with ASD+ADHD. These results suggest that the later N1 peak is associated 
with a more consistent reaction to target stimuli. 
In adolescents with ASD+ADHD, the N2 peak amplitudes and difference waves were smaller 
stimulant-free than under stimulant medication, but no such difference was found for adolescents 
diagnosed with ADHD. The smaller N2 difference wave suggests that stimulant-free adolescents with 
ASD+ADHD might have more problems discriminating between standard and target stimuli than 
stimulant-medicated adolescents with ASD+ADHD. Tye et al. (2013a) found diminished N2 
enhancement in target trials in stimulant-free children with ASD or ASD+ADHD than in stimulant-
free ADHD or TD children. Both this study and our results indicate that ASD is associated with 
problems in shifting attention from one stimulus to another. The N2 difference wave in adolescents 
with ASD+ADHD was larger in stimulant-medicated than stimulant-free adolescents, which may 
imply that stimulant medication helps to improve stimulus discrimination.  
The results of Tye et al. (2013a) indicated that children with ADHD and ASD+ADHD 
showed more reaction time variability and attenuated P3 amplitudes compared with TD children or 
children with ASD (Tye et al. 2013a). Previous studies found a normalization of P3 activity in young 
adolescents with ADHD who were taking stimulant medication (Groom et al. 2010; Hermens et al. 
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2005). Although a previous investigation with this sample did find improved task performance and less 
reaction time variability in stimulant-medicated than stimulant-free adolescents (Bink et al. 2013), in 
line with Groen et al. (2008), we did not find that use of stimulant medication enhanced P3 activity. 
Older adolescents showed a shorter N1 latency and smaller anterior N2 peak amplitude and 
difference wave than younger adolescents. In addition, there was a trend towards shorter posterior N2 
latencies and attenuated posterior P3 peak amplitudes in older adolescents. In a healthy population, 
increasing age is associated with reduced N1 and N2 amplitudes and latencies (Johnstone et al. 1996), 
although P3 peak amplitudes increase and P3 latencies decrease with age, from childhood to adulthood 
(Segalowitz et al. 2010; Johnstone et al. 1996). The reduction of N1 peak latencies and anterior N2 
amplitudes seen in older adolescents  in the current study is in line with the normal developmental 
trajectory. In contrast, the trend towards age effects on P3 peak amplitudes suggests a variation from 
typical development. 
The current outcomes suggest that use of stimulant medication has different outcomes in 
ADHD and ASD+ADHD; however, additional research is necessary. Firstly, replication of these 
results in a larger sample is needed, preferably in the form of a controlled trial titrating dosage of 
stimulant medication and including EEG measures taken pre-intervention without any form of 
medication, and at the end of the stimulant medication titration trial. In the current study, adolescents 
took stimulant medication as prescribed by their physician on the day of assessment, in consequence 
we were not able to control for initial differences between stimulant-medicated and stimulant-free 
adolescents such as the ages difference we observed (stimulant-medicated adolescents were somewhat 
younger than stimulant-free adolescents). Although we controlled for age effects statistically, it is 
possible that stimulant medication use and maturation produce similar physiological changes; this 
might have masked potential effects of stimulant medication use in our study. Secondly, the 
constitution of the diagnostic groups could be improved. Inclusion criteria for the current study were 
based on the presence of severe ADHD symptomatology and clinical, DSM-IV-based diagnoses made 
by experts in the participating institutions. Although this increased the ecological validity of the study, 
more detailed information about the features of ASD is lacking. Future research should therefore 
entail completion of either the Autism Diagnostic Interview (Lord et al. 1994) or the Autism 
Diagnostic Observation Schedule (Lord et al. 1989). In addition, because the current study did not 
include a group of TD adolescents it was not possible to determine whether any of the physiological 
patterns we observed deviated from those expected in typical development. To determine whether 
specific physiological patterns are characteristic of ADHD, ASD, ASD+ADHD, and typical 
development, future research should include TD and ASD-only adolescents as well as adolescents with 
ADHD and ASD+ADHD. 
 In conclusion, the present study found smaller N2 amplitudes for stimulant-free adolescents 
with ASD+ADHD than stimulant-medicated adolescents with ASD+ADHD. This finding suggests 
that in adolescents with ASD+ADHD stimulus discrimination is better when taking stimulant 
medication than when stimulant-free. In addition, in adolescents with ASD+ADHD, use of stimulant 
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medication was associated with longer N1 latencies. In contrast, in ADHD use of stimulant medication 
was associated with shorter N1 latencies. The current study has shown differences in ERP activity in 
stimulant-medicated and stimulant-free adolescents with ASD+ADHD compared to adolescents with 
ADHD. Overall, the results indicate that stimulant medication may affect adolescents with 
ASD+ADHD differently from adolescents with ADHD. The clinical implications of these 
physiological differences in response to stimulant medication use should be further investigated to 
optimize treatment of ADHD in ASD patients. 
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ABSTRACT 
Objective:  Neurofeedback has been proposed as a potentially effective intervention for reducing 
Attention Deficit Hyperactivity Disorder (ADHD) symptoms. However, it remains unclear whether 
neurofeedback is of additional value to treatment as usual (TAU) for adolescents with clinical ADHD 
symptoms. Method: Using a multicenter parallel-randomized controlled trial design, adolescents with 
ADHD symptoms were randomized to receive either a combination of TAU and neurofeedback 
(NFB+TAU, n=45) or TAU-only (n=26). Randomization was computer-generated and stratified for 
age group (ages 12 through 16, 16 through 20, 20 through 24). Neurofeedback treatment consisted of 
approximately 37 sessions of theta/sensorimotor rhythm (SMR)-training on the vertex (Cz). Primary 
behavioral outcome measures included the ADHD-rating scale, Youth Self Report, and Child Behavior 
Checklist all assessed pre- and post-intervention. Results: Behavioral problems decreased equally for 
both groups with medium to large effect sizes, range partial η2= .08 to .31, p<.05. Hence, the 
combination of NFB+TAU was not more effective than TAU-only on the behavioral outcome 
measures. In addition, reported adverse effects were similar for both groups. Conclusions: On 
behavioral outcome measures, the combination of neurofeedback and TAU was as effective as TAU-
only for adolescents with ADHD symptoms. Considering the absence of additional behavioral effects 
in the current study, in combination with the limited knowledge of specific treatment effects, it is 
questionable whether theta/SMR neurofeedback for adolescents with ADHD and comorbid disorders 
in clinical practice should be used. Further research is warranted to investigate possible working 




Adolescents who show a persistent pattern of frequent inattention and/or hyperactivity-impulsivity 
symptoms - and for whom these symptoms are interfering with developmentally appropriate social, 
academic, or occupational functioning - are diagnosed with Attention Deficit/Hyperactivity Disorders 
(ADHD) (American Psychiatric Association, 2000). This is the most common neurodevelopment 
disorder with a prevalence of around 5,9% to 7,1% (Willcutt, 2012). Comorbid disorders like conduct 
disorders, mood and anxiety disorders are common (Barkley, 2006; Larson, Russ, Kahn, & Halfon, 
2011). Additionally, in youngsters with autism spectrum disorders (ASD) estimations indicate high 
rates (ranging from 28% up to 78%) of ADHD comorbidity (Gjevik, Eldevik, Fjaeran-Granum, & 
Sponheim, 2011; Lee & Ousley, 2006; Simonoff et al., 2008).  
 Currently, best practice in ADHD treatment for adolescents consists of stimulant-medication, 
preferably in combination with behavior therapy (Wolraich et al., 2011). Stimulant-medication is 
effective in reducing ADHD symptoms (Faraone & Buitelaar, 2010) in 70% to 80% of the children 
suffering from ADHD (Greenhill et al., 2001), and in almost half of the children with ASD and 
comorbid ADHD (Research Units on Pediatric Psychopharmacology (RUPP) Autism Network, 2005). 
Thus, about a quarter of adolescents with ADHD and half of the adolescents with ASD and comorbid 
ADHD do not benefit (enough) from standard treatment with stimulant-medication. Moreover, mild 
adverse effects of stimulant-medication, such as decreased appetite, difficulty falling asleep and 
headaches are reported relatively often (Graham & Coghill, 2008; RUPP, 2005). Therefore, additional 
ADHD interventions that further increase effectiveness and reduce adverse effects to the standard 
ADHD treatment are warranted. In this respect, neurofeedback has been suggested as an intervention 
that is potentially effective in reducing ADHD symptoms by modifying brain activity in youngsters 
with ADHD (Gevensleben, Rothenberger, Moll, & Heinrich, 2012; Lofthouse, Arnold, Hersch, Hurt, 
& DeBeus, 2012; Moriyama et al., 2012) and ASD with comorbid ADHD (Holtmann et al., 2011). 
 Neurofeedback intends to alter brain activity by giving feedback of electroencephalogram 
(EEG) activity to patients. Notably, alterations in EEG activity patterns have been related to 
behavioral problems as seen in ADHD (Banaschewski & Brandeis, 2007; Snyder & Hall, 2006). 
Increased electroencephalogram (EEG) theta (4-7Hz) and decreased beta (13-30Hz) activity in 
ADHD-children compared to typically developing (TD) children, has been observed across studies 
(Snyder & Hall, 2006). Theta and beta activity can be related to vigilance and attention respectively 
(Banaschewski & Brandeis, 2007). Hence, adaptation of the theta- and beta-activity in children with 
ADHD, may lead to improved behavior. Likewise, sensorimotor rhythm (SMR)-activity (13-15Hz) 
measured above the central sulcus, is positively related to motor inhibition (Sterman & Wyrwicka, 
1967; Sterman, Wyrwicka, & Roth, 1969). Correspondingly, it was reasoned by Lubar and Shouse 
(1976) that training aimed at increasing SMR-activity would improve inhibition in children with 
ADHD. As a result, the most frequently applied neurofeedback training protocols for ADHD aim to 
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decrease theta (4-7Hz) activity and increase SMR (12-15Hz) or beta (12-20Hz) activity, with electrode 
placement on the vertex (Cz) (Lofthouse et al., 2012; Loo & Makeig, 2012; Moriyama et al., 2012). 
 Based on previous reviews, claims on the effectiveness of neurofeedback for ADHD 
symptoms range from possibly effective (Gevensleben et al., 2012; Lofthouse et al., 2012; Moriyama et 
al., 2012) to ‘efficacious and specific’ (Arns, de Ridder, Strehl, Breteler, & Coenen, 2009). The 
estimated effect sizes varied between medium and large for the ADHD symptoms hyperactivity, 
impulsivity and attention (Arns et al., 2009). However, several methodological shortcomings have 
hampered many of the included studies: the majority of the studies were not randomized, sample sizes 
were small, and/or non-specific treatment effects were not controlled for. The more recently 
published reviews, using more rigorous inclusion criteria, report more conservative estimations of 
effects (Gevensleben et al., 2012; Lofthouse et al., 2012; Loo & Makeig, 2012; Moriyama et al., 2012) 
and results even dropped to non-significant levels when only studies were included with probably 
blinded assessments (Sonuga-Barke et al., 2013). In addition, a review pertaining to neurofeedback 
training in children with ASD concluded that neurofeedback was not effective for autism symptoms 
but possibly effective for comorbid ADHD symptoms (Holtmann et al., 2011). All in all, 
neurofeedback seems potentially effective though previous shortcomings in study design and unknown 
(negative) side effects preclude strong conclusions. To address these shortcomings, more controlled 
research is necessary to see which specific patients will profit from which specific neurofeedback 
training protocol (Gevensleben et al., 2012; Lofthouse et al., 2012). Furthermore, research is needed to 
see whether neurofeedback can be of additional value to multimodal treatment protocols 
(Gevensleben et al., 2012). 
 Therefore, the aim of the current study was to investigate the additional value of 
neurofeedback on behavior over treatment as usual (TAU) for adolescents diagnosed with ADHD and 
comorbid disorders, with a multicenter parallel randomized controlled trial design. It was expected that 
behavioral measures of attention would improve more in the group that received neurofeedback (in 
addition to TAU) than the group that received TAU-only. In addition, to address non-specific 
treatment effects and side effects of neurofeedback, indices of experienced improvement on non-
standardized behavioral measures, headaches and sleep problems, as well as effects on autism 





Eligible participants were male adolescents with Dutch as their native language, between 12 and 24 
years old, with a clinical DSM-IV-TR primary diagnosis of ADHD and a full-scale total intelligence 
quotient (TIQ)>80 on the Wechsler Intelligence Scale for Children (WISC-III) or the Wechsler Adult 
Intelligence Scale (WAIS-III) (Wechsler, 1991, 1997). Adolescents diagnosed with ASD (including: 
Autism, Asperger disorder and PDD-NOS) with notification of clinical ADHD symptoms equal to a 
full ADHD diagnosis were also included. ADHD symptoms were verified by a DSM-IV based Dutch 
semi-structured ADHD interview for adults (Kooij, 2002) and the Mini International Neuropsychiatric 
Interview (MINI; Sheehan et al., 1998; Sheehan et al., 1997). Exclusion criteria were neurological 
disorders, schizophrenia and other psychotic disorders. 
Initially, a total of 90 adolescents were randomized over the interventions: combined 
neurofeedback and TAU (NFB+TAU; n=59) or TAU (n=31). The drop-out and exclusion rate did 
not differ for NFB+TAU, n=14 (23.7%) and TAU, n=5 (16.1%), p=.778 two-tailed Fisher exact test. 
At direct post-intervention analysis, NFB+TAU and TAU comprised n=45 and n=26 adolescents, 
respectively. Drop-out reasons included motivational and/or organizational reasons NFB+TAU=9; 
TAU=5) and transfer to another region (NFB+TAU=2). Three adolescents were excluded from 
analyses because of occurrence of psychotic symptoms (NFB+TAU=2) and borderline disorder 
(NFB+TAU=1) and hence these data were considered not reliable. A participant flow diagram is 
presented in Figure 1.  
 Medication use and presence of comorbid disorders were allowed. Comorbid disorders 
included: Depressive disorders (4), Anxiety disorders (2), Substance related disorders (4), Conduct 
disorders (4), Learning disorders (6), Communication disorders (1), Tic disorders (1) Elimination 
Disorders (1), Adjustment disorders (1), Reactive attachment disorder (1). The final group 
characteristics are listed in Table 1. 
 
Trial Design 
This was a multicenter parallel-group study, stratified for age (12 through 16, 16 through 20, 20 
through 24 years of age) and with imbalanced randomization [2:1] for NFB+TAU versus TAU-only. 
Randomization was generated using an online automatic random number generator (Dallal, 2007). The 
block lengths were 3, 6, 9, and 12 and varied randomly. An independent administrative employee was 
responsible for the assignment of participants to their groups. The investigators were blind for block-
lengths and for the number of participants in each stratification group. After pre-intervention 
assessments the investigator e-mailed the administrative employee to apply randomization. The same 
day, the participant (and if applicable, his parents) was notified whether he would receive 
neurofeedback intervention or not. Participants, parents, neurofeedback trainers and clinical 
professionals were aware of the allocated arm randomization. The outcome assessor and 
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neurofeedback trainer were not the same person. All data entry was performed blind to the allocated 
arm and was checked twice by different research interns or assistants. 
 Previous estimated effect sizes for decreased ADHD symptoms by neurofeedback range from 
medium to large. Sample size estimation was done by G*power version 3.1.5.1 (Faul, Erdefelder, Lang, 
& Buchner, 2007). For an ANOVA repeated measures, within-between interaction a total sample size 
of 46 (or 23 per intervention arm) was calculated to be sufficient to detect a medium effect size (f=.25) 
with an alpha .05 and a power of 90%.  
 This trial is registered in the Dutch trial register (Ref. no: added in non-blinded manuscript) 
and is funded by: (Government grant added in non-blinded manuscript). In this article, the 
CONSORT 2010 guidelines for reporting parallel group randomized trials were followed (Schulz, 
Altman, & Moher, 2010). 
 
Interventions 
Treatment as usual (TAU). In the TAU-group, the participants received treatment as prescribed by 
the main therapist of the participating center for child and adolescent psychiatry (GGzE, GGz 
Breburg, Reinier van Arkel group). TAU was monitored through an intervention questionnaire based 
on the ‘Dutch national basic program ADHD for children and adolescents’ (Vink & Van Wamel, 
2007). Behavioral interventions included cognitive behavioral therapy, systemic therapy, and/or 
supportive counseling, either directed at the adolescent and/or at the parent(s). Stimulant medication 
use included immediate release methylphenidate, sustained release methylphenidate and 
dexamphetamine. Atomoxetine was used by two participants at study entry. Because of the suggested 
similar clinical effects of stimulant medication and atomoxetine, in the analyses these two participants 
were categorized within the group of stimulant-medicated adolescents. Adherence to prescribed 
medication was verified by questioning the participants whether they took the prescribed medication. 
Stimulant medication use and received behavioral therapy did not differ between the group receiving 
TAU-only and the group who received neurofeedback in addition to TAU (see Table 1). 
 
Neurofeedback in addition to TAU. Neurofeedback training was carried out over a period of 
around five months (25 weeks), with two to three training sessions every week. Each participant was 
offered 40 training sessions of 30 minutes in total. The mean number who followed the training 
sessions was 37 (36.98± 4.94) with a minimum of 19 sessions. A neuropsychologist, EEG Biofeedback 
EEG Spectrum International Inc. certified, accredited by the Biofeedback Certification International 
Alliance (BCIA) (MB), trained the psychologists who gave the neurofeedback training. The treatment 
protocol was based on rationales of J. F. Lubar (2003), J. O. Lubar and Lubar (1984), and Fuchs, 
Birbaumer, Lutzenberger, Gruzelier, and Kaiser (2003). The aim of the treatment was to increase 
SMR-activity, while simultaneously decreasing theta, alpha and electromyographic (EMG) activity due 
to muscle tension to ensure an attentive and relaxed state of engagement with an altered EEG state for 
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longer periods of time (J. F. Lubar, 2003). The treatment protocol therefore consisted of decreasing 
low frequency bands (4-11Hz), increasing SMR-activity (12-15Hz) and decreasing high beta/gamma 
(22-36Hz) at Cz. Inhibition of higher beta/gamma frequency band was conducted in this study to 
minimize the increase of SMR-activity by increased muscle-tension, and to decrease potential high beta 
that seems to occur in an estimated 10-20% of children with ADHD (Snyder & Hall, 2006). 
Training was conducted on Cz, referred to linked mastoids. The EEG-signal was transmitted 
to the computer by the Brainquiry PET EEG 2 channel bipolar system (Braininquiry): a DC amplifier 
with active electrodes, a low-pass anti-aliasing filter of 40 Hz, a sample rate of 200 Hz and a 29 bit AD 
resolution. Neurofeedback training was conducted with ‘EEGer’ neurofeedback software version 4.2.1 
(EEGer Spectrum Systems). The EEG-signal was accordingly band pass-filtered in the different 
frequency bands with an exponentially weighted moving average filter over 0.5 second to produce a 
short-term average. Each frequency band involved a 0.25Hz increment step size reward filter. Each 
training session was divided into ten 3-minute epochs. Artifact rejection thresholds for the raw EEG-
signal were set to 60µV, to prevent the effect of gross movements from the participants. Relative 
thresholds for each frequency band were set to accept the signal 80%and to reject the signal 20% of 
the time. Thresholds were calculated to correspond to the mean amplitude in µV of each frequency 
band over the last 30 seconds of input and were calculated after 30 seconds from the beginning of 
each 3-minute session. For the first 30 seconds, thresholds of former 3-minute session were preserved.  
The signal was visually presented to the participant on a screen by simple graphics, which 
represented the different frequency bands by three colored boxes. The colors of the boxes were 
moving: sometimes a color did not totally fill the box and sometimes the color exceeded the borders of 
the box. The participant was instructed that the left, purple-colored box represented slow wave activity 
(4-11Hz) and the right, yellow-colored box represented fast wave activity and muscle tension (22-
36Hz). For both these boxes the colors were to be kept in the drawn box (inhibit). The middle, blue-
colored box represented the ‘good’ waves (SMR 12-15Hz) and the participant was instructed that this 
color should exceed the borders of the box and get as wide as possible (reward). At the moment the 
signal for all frequency bands fulfilled all threshold criteria, audible feedback was given by a short .25-
second beep. Subsequently, the participants obtained a point that increased the score on the bottom of 
the screen.  
 
Outcome Measures 
Primary outcome measures included three behavioral questionnaires. Secondary outcome measures 
consisted of non-standardized behavioral measures, side effects on reported sleeping problems and 
headaches, and autism symptoms. Neuropsychological and electro-physiological outcome measures 
assessed during the study will be reported elsewhere.  
 Primary behavioral outcome measures. The ADHD-rating scale is a DSM-IV-based self-
report for adults (Kooij et al., 2008; Kooij et al., 2005). This is an adapted form of DuPaul et al. (1998) 
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which contains 23 items rated on a 4-point scale ranging from ‘rarely or never’ to ‘very often’. Items 
were filled out for occurrence of current symptoms (in the past 6 months) at pre- and post-
intervention. Two nine-item subscales were used: inattention and hyperactivity/ impulsivity (Kooij et 
al., 2008; Kooij et al., 2005).  
The Child Behavior Checklist (CBCL) and the Youth Self Report (YSR) (Achenbach, 1991) 
are questionnaires that cover respectively parent-reported and self-reported behavioral and emotional 
problems for children and adolescents up to 18 years old. In this study, the subscale attention 
problems, the broadband scale externalizing problems and the global scale total problems were used. 
For participants over 18 years also the CBCL and YSR were used, since most of them were still 
attending school and living with their parents. 
 Secondary outcome measures. Behavioral changes on non-standardized measures, autism 
symptoms and side effects were included as secondary outcome measures. Experienced behavioral 
changes on non-standardized measures at post-intervention (‘Did you notice any behavioral changes 
during the last period (6-months)?’) were scored as no improvement (0) or improvement (1) for overall 
behavior, attention, and hyperactivity/impulsivity. 
Autism symptoms were screened with the Autism-Spectrum Quotient (AQ)-adolescent 
version for individuals with normal intelligence (Baron-Cohen, Hoekstra, Knickmeyer, & Wheelwright, 
2006). Parents or other relevant adults filled out the AQ-adolescent. AQ-questionnaires were excluded 
from analyses when three or more answers were missing.  
 Headache frequency (‘Did you experience headaches during the last 6-months and what was 
the frequency of the headaches?’) were scored as never (0), sometimes (1), 1-2/month (2), 3-8/month 
(3) and >3/week (4). Sleep pattern (‘Do you have difficulties with: (I) falling asleep / (II) sleeping 
through / (III) getting up in the morning? and (IV) are you feeling sleepy during the day?’), was scored 
dichotomously per question (I-IV) as not problematic (0) and problematic (1) and summarized. 
 
Procedure  
Prior to the start of the study, approval was obtained from the medical ethics committee for mental 
health institutions in the Netherlands (Ref.no: NL 24776.097.08 CCMO). The study took place in 
three centers for child and adolescent psychiatry (GGzE, GGz Breburg, Reinier van Arkel group) in 
the South of the Netherlands. After the study was explained (verbally and in writing), written informed 
consent was obtained from each participant. For those younger than 18, parents also provided written 
informed consent. 
 At pre-intervention, participants were seen on three occasions for the administration of 
behavioral questionnaires, neuropsychological tests, an assessment of intellectual functioning using the 
WAIS- or WISC-intelligence test and EEG measurements. In cases where participants were on 
medication, medication intake was also continued on the day of assessment. 
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 Interventions took place between December 2009 and July 2012. The duration of the 
intervention period was approximately five months (25 weeks).  
At post-intervention assessment, behavioral questionnaires and neuropsychological tests were 
assessed for all 71 participants. One participant refused to complete the YSR. For two participants, 
reported headache frequency was missing.  
Parents or relevant adults received the parent-report questionnaires (CBCL and AQ-
adolescent) by mail, requesting their return pre- and post-intervention. CBCL-data were incomplete or 
missing for 13 participants. The AQ-questionnaire was missing or incomplete for 19 participants.  
 
Statistical Analysis 
 All analyses were performed using SPSS version 19.0. Effects were considered significant if 
p<.05. Differences on group characteristics were analyzed with a one-way ANOVA or a chi-square test 
(χ2) with Fisher exact correction. Attrition analyses, for behavioral data with smaller sample size than 
the total sample size due to missing or incomplete data, were performed by comparing the analyzed 
subsample for a particular measure to the total sample on group characteristics and other pre-
intervention primary behavioral outcome measures with a one-way ANOVA.  
 A completion analysis was applied involving the participants who finished all assessments up 
to post-intervention (including neurofeedback training, if applicable), in order to determine whether 
neurofeedback had additional value after completion of the training. The effect of neurofeedback 
training was investigated using a Generalized Linear Model (GLM) with between- and within-subjects 
factors. The analysis was applied for all the primary behavioral outcome measures separately with 
intervention group as between-subject factors and time [e.g. between pre-intervention (t1) and post-
intervention (t2)] as within-subjects factor. The full factorial models were tested. All behavioral effects 
were evaluated using multivariate test criteria. Effect sizes are expressed in percentage of explained 
variance in partial η2 (ηp2). In addition, the adjusted difference at post-intervention (ADt2-t1) and 95% 
confidence interval [95% CI] were noted. Post hoc analyses were performed with the addition of 
stimulant medication use at pre-intervention and diagnostic group (ADHD or ASD with comorbid 
ADHD) as between-subject factor to the GLM. To control for potential outcome bias of the drop-
outs (n=16) after randomization post-hoc analyses were performed based on imputation with Last 
Observation Carried Forward (LOCF) for the total group as randomized with the exception of the 
three excluded participants.  
 Non-standardized secondary behavioral measures were examined by calculation of the relative 
risk (RR). Change is considered significant when the RR and 95% CI do not include [1.0]. Frequency 
of headaches, total sleeping problems and autism symptoms were analyzed using a GLM with 
between- and within-subjects factors as described in the primary outcome measures.   
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Figure  1 :  Participant Flow Diagram 
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Figure  1 .  Participant Flow Diagram 
Assessed for eligibility (n=106) 
Excluded (n =16) 
♦  Not meeting inclusion criteria (n =8) 
♦  Declined to participate (n =8) 
Analysed (n= 45) 
♦ Excluded from analysis (n=2) 
• Borderline disorder (n=1) 
• Expression of psychotic symptoms 
(n=1)  
Lost to follow-up (n= 12) 
♦ Discontinued intervention due to 
motivational and/or organizational 
reasons (n=9) 
♦ Transfer to other region for clinical 
admission (n=2) 
♦ Expression of bipolar disorder with 
severe psychotic symptoms (n=1) 
 
 
Allocated to neurofeedback +treatment 
as usual (n=59) 
Lost to follow-up (n = 5) 
♦ Discontinued intervention due to 
motivational and/or organizational 
reasons (n =5) 
 
Allocated to treatment as usual (n =31) 
 























Applied for admission (n=141) 
♦  Declined to participate (n=35) 
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RESULTS 
Group Characteristics  
 There were no baseline differences for group characteristics between the NFB+TAU group 
and the TAU-group (Table 1). In both groups, most participants who used stimulant medication 
started taking stimulant medication more than 6 months before pre-intervention. The mean (standard 
deviation) doses of stimulant medication in mg was 37.19 (16.41), 95% CI= [31.64, 42.75], range [10, 
72] and did not differ between the groups, F(1, 34)=.21, p=.65 ηp2=.01. The TAU-group seemed to 
have a somewhat higher total intelligence quotient (TIQ) than the NFB+TAU group. Performance 
intelligence quotient (PIQ) was similar for both groups. There were no group differences at pre-




Table 1: Group characteristics1 
 TOTAL NFB+TAU TAU GROUP 
 N=71 n=45 n=26 F p 
Age in Years  16.14(3.32) 16.09(3.33) 16.2(3.37) .03 .86 
Primary DSM diagnoses      
 ADHD 47(66%) 29(64%)  18(69%)   .79 
 ASD+ADHD  24(34%) 16(36%) 8(31%)  .79 
GAF-scores  54.66(6.74) 53.80(7.07) 56.15(5.95) 2.04 .16 
Stimulant Medication t1 36(51%) 20(44%) 16(62%)  .22 
 Months of intake before t1    3.74 .46 
  Up to 3 months  6 (8%) 4(9%) 2(8%)   
  3 to 6 months  3(4%) 2(4%) 1(4%)   
  6 to 12 months 4(6%) 3(7%) 1(4%)   
  12 months or more 23(32%) 11(24%) 12(46%)   
  Stimulant-free 35(49%) 25(56%) 10(39%)   
 Started after t1 6(8%) 3(7%) 3(12%)  .66 
 Stopped after t1 9(13%) 5(11%) 4(15%)  .72 
Behavioral interventions2       
 Adolescent 26(37%) 14(31%) 12(46%)  .32 
 Parent 20(28%) 12(27%) 8(30%)  .79 
MINI ADHD Inattention 5.63(2.61) 5.38(2,56) 6.08(2.68) 1.18 .28 
MINI ADHD H/I 4.00(2.46) 4.16(2.58) 3.73(2.29) .49 .49 
ADHD-rating Childhood Inattention3 6.07(2.66) 5.67(2.92) 6.77(2.01) 2.90 .09 
ADHD-rating Childhood H/I3 4.94(2.87) 4.58(2.99) 5.58(2.60) 2.02 .16 
IQ Discrepancy profile4  24(34%) 14(31%) 10(38%)  .61 
 Total IQ  100.66(11.30) 98.62 (10.38) 104.19 (12.15) 4.18 .05 
 VIQ 102.37(12.89) 100.16(11.43) 106.19(14.54) 3.76 .06 
 PIQ 99.51(11.93) 98.44(11.20) 101.35(13.12) .97 .33 
Note: t1 is pre-intervention; 1Data are means (SD) or numbers (%); 2Behavrioural interventions followed between 
pre- and post-intervention (t1-t2). 3ADHD-rating scale retrospective self-reported childhood symptoms for 
Inattention and Hyperactivity/Impulsivity (HI). Group characteristics did not differ between groups. 4Intelligence 
Quotient (IQ) Discrepancy profile is considered as a profile with a difference score between verbal IQ (VIQ) and 
performance IQ (PIQ) of 15 points or more. Because of the discrepancy profiles VIQ and PIQ are noted separately. 
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Attrition Analysis 
Attrition analysis showed that the drop-out group (N=16) did not differ from the completers (N=71) 
on group characteristics or primary behavioral outcome measures. Attrition analyses for the 
subsamples with respect to the YSR (N=70), CBCL (N=58), reported headaches frequency (N=69) or 
AQ-adolescent (N=52) showed no difference from the completers (N=71) on group characteristics or 
primary behavioral outcome measures at pre-intervention. 
 
Behavioral Measures 
Behavioral primary outcome measures are summarized in Table 2. The ADHD-rating scale showed 
that both inattention and hyperactivity/impulsivity (HI) decreased over time, for the NFB+TAU 
group and TAU-group alike. The YSR and the CBCL revealed the same pattern for attention, 
externalizing and total problems, again, irrespective of the groups. 
 
Stimulant medication use and diagnostic group 
Post hoc analysis for stimulant medication use or diagnostic group showed no difference between 




Post hoc analysis, to control for potential outcome bias due to drop-out, showed similar outcomes on 
all measures with a decrease of behavioral problems over time for all adolescents (N=87), irrespective 
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Secondary Outcome Measures 
A larger percentage of NFB+TAU participants reported improvement in attention, compared to TAU 
on the non-standardized behavioral question. Overall improvement was reported by 29 of the 45 
(64%) in the NFB+TAU group and by 10 of the 26 (38%) in the TAU-group, RR=1.68, 95%CI=[0.98, 
2.85]. More specifically, improvement in attention was reported by 17 (38%) of the NFB+TAU group 
and in 3 (12%) of the TAU-group. Participants in the NFB+TAU group were 3.27 times more likely to 
report attention improvement than the TAU-group, RR=3.27, 95%CI=[1.06, 10.12]. Improvement in 
hyperactivity/impulsivity did not differ between the groups and was reported in the NFB+TAU group 
by 16 (36%) participants and by 6 (23%) in the TAU-group, RR=.84; 95%CI=[0.62, 1.13]. 
 Parent-reported autism symptoms showed no decline over time (Table 3). No differences in 
autism symptoms between the NFB+TAU group and TAU-group were found or interactions for time 
and group.  
 There were no changes over time or interactions between time and group for headache 
frequency and sleeping problems. The frequency of headaches and amount of reported sleeping 
problems stayed the same over time for both groups (Table 3). There was however an interaction for 
stimulant medication use over time with post-hoc analyses showing that stimulant-free adolescents 
report fewer headaches over time (n=33, pre-intervention (t1) M=1.67, SD=1,05, post-intervention 
(t2) M=1.06, SD=1.27, ADt2-t1=-.61, 95%CI=[-0.99, -0.22], ηp2 =.24, whereas for stimulant-medicated 
adolescents the amount of headaches stayed the same over time (n=36, pre-intervention (t1) M=1.58 
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DISCUSSION 
The present study examined the additional value of neurofeedback on behavior over TAU with a 
multicenter parallel-randomized controlled trial design. A decline in behavioral problems of ADHD in 
adolescents in both treatment groups was found. Hence, an additional effect of neurofeedback over 
TAU on the primary behavioral outcome measures was not observed. However, when asked for 
changes, adolescents who received neurofeedback in addition to TAU more often reported 
improvement in attention than adolescents who received only TAU.  
 As for the large decrease in behavioral problems of ADHD between pre- and post-
intervention assessment on behavioral outcome measures, a recently published randomized controlled 
trial showed similar behavioral improvements in children with ADHD receiving neurofeedback alone, 
stimulant medication, or combined stimulant medication and neurofeedback (Duric, Assmus, 
Gundersen, & Elgen, 2012). In line with the results in the present, improvement was observed 
regardless of type of treatment. In addition, double blinded RCT's also were not able to show 
superiority for neurofeedback over sham-neurofeedback to improve behavior (Arnold et al., 2013; 
Perreau-Linck, Lessard, Levesque, & Beauregard, 2010; van Dongen-Boomsma, Vollebregt, Slaats-
Willemse, & Buitelaar, 2013) or neurocognitive functioning (Vollebregt, van Dongen-Boomsma, 
Buitelaar, & Slaats-Willemse, 2013) in children with ADHD. The results of the current RCT are in line 
with the neurocognitive outcomes (Bink et al., In Press). In contrast, a previous large non-randomized 
study found additional effects on behavior with more improvement in attention for children who 
received neurofeedback in addition to a combined intervention of medication and behavioral therapy 
than children who received only medication and behavioral therapy one year post-intervention 
(Monastra, Monastra, & George, 2002). Possibly, the non-randomized nature of this study may have 
caused selection biases such as differences between parents with a preference for neurofeedback and 
parents who choose conventional treatment that may account for this discrepancy. Parents with a 
preference for neurofeedback might be more inclined to motivate their child to change and thereby 
make an environment that enables the child to improve more on behavioral attention measures.  
 In this study, improvement in attention was reported more often by adolescents who received 
neurofeedback in addition to TAU than adolescents who received TAU-only. This is remarkable when 
compared to the outcome on the other standardized self- and parent-reported questionnaires, which 
show similar behavioral improvements over time for both groups. It might be that the adolescents in 
the NFB+TAU group were more aware of the improvement, or more prone to point out the 
improvement, because of the investment they put in the neurofeedback intervention. 
 Results show that autism symptoms were not influenced by treatment (NFB+TAU or TAU). 
Parents did not report significant changes in autism symptoms over time. This is in line with a recent 
review, which concluded that neurofeedback treatment does not seem to improve core autistic 
symptoms (Holtmann et al., 2011). On the other behavioral measures used in the current study, it 
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seems that behavioral problems diminished over time for the adolescents with ADHD as well as for 
the adolescents with ASD and comorbid ADHD. 
 Side effects as a result of neurofeedback were not found: no differences in negative adverse 
effects with respect to sleep pattern or headaches were found between the intervention groups. This is 
in accordance with two double-blinded studies that showed no adverse effects for neurofeedback or 
placebo-neurofeedback training (Arnold et al., 2013; van Dongen-Boomsma et al., 2013). The other 
randomized trials did not address adverse effects. Positive effects of SMR-neurofeedback in relation to 
quality of sleep, have been hypothesized (Arns & Kenemans, 2012). Sleep spindle activity is activity in 
the SMR frequency-band (12-15Hz). Neurofeedback aimed at an increase of SMR-activity has been 
positively related to the increase of sleep spindle density during sleep and thereby the quality of sleep 
(Arns & Kenemans, 2012). However, the present study did not find improvements in sleep patterns. 
There was a decrease in the frequency of headaches over time for stimulant-free adolescents. 
Headache is a common adverse effect of stimulant medication use (Graham & Coghill, 2008), as a 
result, this might be the reason that stimulant-medicated adolescents did not experience a reduction in 
headache frequency over time. 
 The present study is the first to investigate effects of neurofeedback as an additional treatment 
to TAU in a naturalistic multimodal treatment setting applying a randomized controlled trial design. 
The implementation of neurofeedback in addition to TAU increases the ecological validity of the 
study. Although there was no selective dropout, this design also includes several limitations. For 
example, the target population consists of a heterogeneous group of male adolescents with complex 
problems. It might be that neurofeedback is only effective for a specific part of the population with 
ADHD symptoms. Furthermore, it could be that the used theta/SMR-training is not the optimal 
neurofeedback protocol for ADHD. Loo and Makeig (2012) have already stated that, based on the 
current literature, theta/beta training results are not indicative to applying this training as an additional 
treatment to standard practice. Other neurofeedback protocols, like the training of slow cortical 
potentials (SCP <0.1Hz) or training of other frequency bands, might lead to better results. Another 
limitation is the intensity of the training: adolescents who received neurofeedback were trained 
approximately twice a week over a total period of 5 months. Perhaps a shorter and more intensive 
training period, with three or more training sessions a week, is needed for inducing clinical relevant 
behavioral changes. Another limitation is the use of self- and parent reported behavioral measures in 
combination with the non-blinded nature of the study. Because of the investment of parents and 
participants in the neurofeedback intervention, this might have increased the risk of a bias. It could be 
expected that the outcomes for the NFB+TAU condition were positively biased compared to TAU. A 
recent meta-analysis (Sonuga-Barke et al., 2013) pointed out that the neurofeedback treatment showed 
significant effects when non-blinded assessments were considered, but not when only probably 
blinded assessments were considered. In the current study, however, results showed no additional 
effects of neurofeedback on behavioral measures and as a consequence the effects were not likely 
influenced by such a positive bias. In addition, ceiling effects in improvement on the behavioral 
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measures by the TAU or as a result of developmental related improvement and multiple testing could 
be the cause for not finding additional effects for neurofeedback. Given the sample size of the study, 
effects of neurofeedback should be medium to large to be reliably detected; as a result small effects 
might be missed. Nevertheless, neurofeedback is a costly intervention in time investment for patients, 
parents, therapists, and health care resources. The important question therefore is what effect size 
would make neurofeedback cost-effective and clinically relevant.  
 In conclusion, the present study showed that on behavioral outcome measures, the 
combination of neurofeedback and TAU was as effective as TAU-only for adolescents with ADHD 
symptoms. Neurofeedback in combination with TAU and TAU-only both showed significantly 
improved behavior, mainly in attention, at post-intervention. Considering the absence of additional 
behavioral effects in the current study, in combination with the limited knowledge of specific 
treatment effects of neurofeedback, it is questionable whether theta/SMR neurofeedback for 
adolescents with ADHD and comorbid disorders should be used in clinical practice. Further research 
is warranted to investigate possible working mechanisms and (long-term) specific treatment effects of 
neurofeedback.   
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ABSTRACT 
Objective: Neurofeedback aims to reduce Attention Deficit/Hyperactivity Disorder (ADHD) symptoms, 
mainly attention problems. However, the additional influence of neurofeedback over treatment as 
usual (TAU) on neurocognitive functioning for adolescents with ADHD remains unclear. Method: 
Using a multicenter parallel-randomized controlled trial (RCT) design, male adolescents with a DSM-
IV-TR diagnosis ADHD (mean age 16.1, range 12-24) were randomized to receive either a 
combination of TAU and neurofeedback (NFB+TAU, n=45) or TAU (n=26). Randomization was 
computer-generated and stratified for age group (ages 12 through 15, 16 through 20, and 21 through 
24 years). The neurofeedback intervention consisted of approximately 37 sessions over a period of 25 
weeks of theta/sensorimotor rhythm (SMR) training on the vertex (Cz). Primary neurocognitive 
outcomes included performance parameters derived from the D2 test of attention, the digit span 
backwards, the Stroop color-word test and the Tower of London, all assessed pre- and post-
intervention. Data were collected between December 2009 and July 2012. Results: At post-intervention, 
outcomes of attention and/or motor speed were improved with faster processing times for both 
intervention conditions with medium to large effect sizes (range ηp2= .08-.54, p values <.023). In both 
groups, no improvements for higher executive functions were observed. Results might partly resemble 
practice effects. Conclusion: Although neurocognitive outcomes improved in all adolescents receiving 
treatment for ADHD, no additional value for neurofeedback over TAU was observed. Hence, this 
study does not provide evidence for using theta/SMR neurofeedback to enhance neurocognitive 




Attention Deficit/Hyperactivity Disorder (ADHD) is the most common neurodevelopmental disorder 
with a worldwide prevalence of around 5% (Polanczyk, de Lima, Horta, Biederman, & Rohde, 2007; 
Willcutt, 2012). In addition, estimations of ADHD comorbidity in autism spectrum disorders (ASD) 
range between 30% and 78% (Gjevik, Eldevik, Fjaeran-Granum, & Sponheim, 2011; Holtmann, Bolte, 
& Poustka, 2007; Lee & Ousley, 2006; Simonoff et al., 2008). Best practice for reducing ADHD 
symptoms consists of stimulant-medication, and/or behavioral therapy. Stimulant-medication is 
effective in reducing ADHD symptoms in youngsters with ADHD (Faraone & Buitelaar, 2010; 
Greenhill et al., 2001) and effective, although possible to a lesser extend, for treatment of ADHD in 
youngsters with combined ASD and ADHD (Cortese, Castelnau, Morcillo, Roux, & Bonnet-Brilhault, 
2012; RUPP, 2005). Similarly, neurocognitive dysfunction as associated in ADHD, generally seems to 
improve with the use of stimulant medication (Coghill et al.). A recent review indicates that generally 
remittance of ADHD symptoms is not associated with improved neurocognitive functions: 
adolescents with remitted ADHD still experience decreased neurocognitive performance (van 
Lieshout, Luman, Buitelaar, Rommelse, & Oosterlaan, 2013). This indicates that ADHD-
symptomatology and neurocognitive functioning should be considered as separate treatment outcome 
measures (Coghill et al.). Moreover, although stimulant-medication seems effective in reducing ADHD 
symptoms (Cortese et al., 2012; Faraone & Buitelaar, 2010; Greenhill et al., 2001; RUPP, 2005) and 
improving neurocognitive functioning (Coghill et al.), the majority of adolescents above the age of 15 
discontinue stimulant-medication use despite the persistent course of the disorder (Zetterqvist, 
Asherson, Halldner, Langstrom, & Larsson, 2012). Therefore, additional interventions to the current 
treatment as usual (TAU) to further reduce ADHD symptoms enduringly and simultaneously improve 
neurocognitive functioning are warranted. In this respect, neurofeedback, which is seen as a potential 
effective intervention for reducing ADHD symptoms in ADHD(Lofthouse, Arnold, Hersch, Hurt, & 
DeBeus, 2012; Moriyama et al., 2012) and ASD,(Holtmann et al., 2011) might as well be able to 
improve neurocognitive functioning.  
 Neurofeedback is based on the principle of operant conditioning and aims to alter brain 
functioning by giving real-time feedback of electroencephalogram (EEG) activity to the patient. 
Children with ADHD show an increased theta activity and decreased beta activity compared with 
typically developing children (Snyder & Hall, 2006). Accordingly, the most frequently used 
neurofeedback protocol is the theta/beta training, which aims to decrease theta (4-7Hz) and increase 
SMR (12-15Hz) or beta (12-20Hz) (Lofthouse et al., 2012; Loo & Makeig, 2012; Moriyama et al., 
2012). Following theta/beta training, one study found changes in brain functioning as reflected in a 
decrease of posterior-midline theta activity (Gevensleben, Holl, Albrecht, Schlamp, et al., 2009). In 
addition, the decrease in theta activity was related to the decrease in ADHD symptoms as reported by 
parents (Gevensleben, Holl, Albrecht, Schlamp, et al., 2009). Two other studies showed similar 
improvement in attention on behavioral questionnaires over time for children with ADHD who were 
treated with neurofeedback and/or with stimulant medication (Duric, Assmus, Gundersen, & Elgen, 
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2012; Meisel, Servera, Garcia-Banda, Cardo, & Moreno, 2013). Thus, some randomized controlled 
trials (RCT) (Duric et al., 2012; Gevensleben, Holl, Albrecht, Schlamp, et al., 2009; Meisel et al., 2013) 
have shown improvements in ADHD symptomatology, as reported by parents. However, these studies 
(Duric et al., 2012; Gevensleben, Holl, Albrecht, Schlamp, et al., 2009; Meisel et al., 2013) did not 
report on intervention effects in relation to neurocognitive functioning.  
 To date, the findings of four blinded RCT studies (Arnold et al., 2012; Bakhshayesh, Hansch, 
Wyschkon, Rezai, & Esser, 2011; Logemann, Lansbergen, Van Os, Bocker, & Kenemans, 2010; 
Vollebregt, van Dongen-Boomsma, Buitelaar, & Slaats-Willemse, 2013) on neurofeedback for ADHD 
in which neurocognitive measures were reported, are inconsistent. In one single-blinded study, 
children with ADHD who received neurofeedback improved more in reaction time (RT) and accuracy 
than those receiving electromyography (EMG) biofeedback (Bakhshayesh et al., 2011). In contrast, 
three double-blind studies failed to find additional improvement on neurocognitive measures for 
neurofeedback over sham-neurofeedback in children with ADHD (Arnold et al., 2012; Vollebregt et 
al., 2013) and healthy students with ADHD features (Logemann et al., 2010). These neurocognitive 
outcomes (Arnold et al., 2012; Logemann et al., 2010; Vollebregt et al., 2013) are in line with the 
behavioral outcomes of blinded studies that fail to find additional value of neurofeedback over sham-
neurofeedback (Arnold et al., 2012; Logemann et al., 2010; Sonuga-Barke et al., 2013; van Dongen-
Boomsma, Vollebregt, Slaats-Willemse, & Buitelaar, 2013). 
 To summarize, although neurofeedback is seen as a potentially effective intervention for 
reduction of ADHD symptoms in children (Lofthouse et al., 2012; Moriyama et al., 2012), knowledge 
about the neurocognitive effects of neurofeedback is limited. Therefore, the aim of this study was to 
investigate the additional effect of neurofeedback to TAU on neurocognitive functioning in 




Eligible participants were male adolescents with Dutch as their native language, between 12 and 24 
years old, with a clinical DSM-IV-TR primary diagnosis of ADHD and a full-scale total intelligence 
quotient (TIQ) > 80 on the Wechsler Intelligence Scale for Children (WISC-III)(Wechsler, 1991) or 
the Wechsler Adult Intelligence Scale (WAIS-III).(Wechsler, 1997) Adolescents diagnosed with ASD 
(including: Autism, Asperger disorder and PDD-NOS) with confirmed symptoms of clinical ADHD - 
equal to a full ADHD diagnosis - were also included. Diagnosed ADHD symptoms were verified by a 
DSM-IV based Dutch semi-structured ADHD interview for adults (Kooij, 2002) and the Mini 
International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998; Sheehan et al., 1997). Trained 
psychologists administered the semi-structured interviews. Exclusion criteria were neurological 
disorders, schizophrenia and other psychotic disorders.  
Initially, a total of 90 adolescents were randomized over the interventions: combined 
neurofeedback and TAU (NFB+TAU; n=59) or TAU (n=31). The dropout rate did not differ for 
NFB+TAU, n=14 (23.7%) and TAU, n=5(16.1%), p=.778 two-tailed Fisher exact test. At direct post-
intervention analysis, NFB+TAU and TAU comprised n=45 and n=26 adolescents, respectively. The 
participant flow diagram is presented in Figure 1.  
 Medication use and presence of comorbid disorders were allowed. Comorbid disorders 
included: depressive disorders (4), anxiety disorders (2), substance related disorders (4), conduct 
disorders (4), learning disorders (6), communication disorders (1), tic disorders (1) elimination 
disorders (1), adjustment disorders (1), reactive attachment disorder (1). The final group characteristics 
are listed in Table 1. 
 
Trial design 
A multicenter parallel-group study was conducted, with stratification for age group (ages 12 through 
15, 16 through 20, and 21 through 24 years) and imbalanced randomization (2:1) for NFB+TAU 
versus TAU. Randomization was computer-generated,(Dallal, 2007) with block lengths of 3, 6, 9 and 
12 that varied randomly. An independent administrative employee was responsible for the assignment 
of participants to their groups immediately after pre-intervention assessment. The participant (and if 
applicable, his parents) was notified the same day whether he would receive neurofeedback 
intervention or not. Participants, parents, neurofeedback trainers, outcome assessor and clinical 
professionals were aware of the allocated group. The outcome assessor and neurofeedback trainer 
were not the same person. All data entry was performed blind to allocated intervention (NFB+TAU or 
TAU) and was checked twice by different research assistants.  
 Beforehand, a total sample size of 46 was calculated with G*power version 3.1.5.1(Faul, 
Erdefelder, Lang, & Buchner, 2007) to be sufficient to detect a medium effect size (f=.25) in a 
repeated measures ANOVA with an alpha .05 and a power of 90%. In this article, the CONSORT 
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2010 guidelines for reporting parallel group randomized trials were followed.(Schulz, Altman, & 




Treatment as usual (TAU).  
In the TAU group, the participants received treatment as prescribed by the main therapist of the 
participating center for child and adolescent psychiatry (GGzE, GGz Breburg, Reinier van Arkel 
group). TAU was monitored through an intervention questionnaire based on the “Dutch national basic 
program ADHD for children and adolescents”(Vink & Van Wamel, 2007). Behavioral interventions 
included cognitive behavioral therapy, systemic therapy and/or supportive counseling on a regular 
basis -at least once every two weeks, general session duration is 45 minutes-, either directed at the 
adolescent, n=26 (36.6%), and/or at the parent(s), n=20 (28.2%) (see Table 1). Stimulant medication 
use, n=35 (49.3%), included immediate release methylphenidate, sustained release methylphenidate or 
dexamphetamine. Atomoxetine was used by two participants at study entry. Because of the suggested 
similar clinical effects of stimulant medication and atomoxetine, in the analyses these two participants 
were categorized within the group of stimulant-medicated adolescents. Adherence to prescribed 
medication was verified by questioning the participants whether they took the prescribed medication. 
Stimulant medication use and received behavioral therapy did not differ between the group receiving 
TAU-only and the group who received neurofeedback in addition to TAU (see Table 1).  
 
Neurofeedback in addition to TAU.  
Neurofeedback training was carried out over a period of around 25 weeks, with two to three training 
sessions every week. Each participant was offered 40 training sessions of 30 minutes in total. The 
mean number of training sessions was 37 (36.98±4.94) with a minimum of 19 sessions. A 
neuropsychologist, EEG Biofeedback EEG Spectrum International Inc. certified, accredited by the 
Biofeedback Certification International Alliance (BCIA) (MB), trained the psychologists who gave the 
neurofeedback training.  
Theta/SMR training (Lubar, 2003; Palsson, Pope, Ball, Turner, & Nevin, 2001, March) – a 
form of theta/beta training – was applied, with thresholds to inhibit theta/alpha frequency bands (4-
7Hz and 8-11Hz), to reward SMR activity (13-15Hz) and inhibit beta/gamma (22-36Hz). Inhibition of 
the higher beta/gamma frequency band was conducted in this study to minimize the increase in SMR 
activity by increased muscle tension, and to decrease potential high beta that seems to occur in an 
estimated 10-20% of children with ADHD (Snyder & Hall, 2006). Training was conducted on Cz, 
referred to linked mastoids. The EEG signal was transmitted to the computer by the Brainquiry PET 
EEG 2 channel bipolar system:(Braininquiry) a DC amplifier with active electrodes, a low-pass anti-
aliasing filter of 40Hz, a sample rate of 200Hz, and a 29-bit AD resolution. Neurofeedback training 
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was conducted with “EEGer” neurofeedback software version 4.2.1.(EEGer Spectrum Systems) The 
EEG signal was accordingly bandpass-filtered in the different frequency bands with an exponentially 
weighted moving average filter over 0.5 seconds to produce a short-term average. Each frequency 
band involved a 0.25Hz increment step size reward filter. Each training session was divided into ten 3-
minute epochs. Artefact rejection thresholds for the raw EEG signal were set to 60µV. Relative 
thresholds for each frequency band were set to accept the signal 80 percent and to reject the signal 20 
percent of the time. Thresholds were calculated to correspond to the mean amplitude in µV of each 
frequency band over the last 30 seconds of input and were calculated after 30 seconds from the 
beginning of each 3-minute part session. For the first 30 seconds, thresholds of former 3-minute 
session were preserved.  
The trained frequency bands were represented in visual information to the participant on a 
screen by simple graphics. At the moment the signal for all frequency bands fulfilled all threshold 
criteria, auditory feedback was given by a short 0.25-second beep and the participants obtained a credit 
that increased the total session score. 
 
Outcome measures 
Primary outcome measures consisted of behavioral, neurocognitive, and electro-physiological 
measures. Behavioral measures included the DSM-IV based ADHD rating scale (Kooij et al., 2005), 
the Child Behavior Checklist (CBCL), and the Youth Self Report (YSR) (Achenbach, 1991).  
Neurocognitive measures of sustained and selective attention, interference, concentration, 
working memory, and executive planning were applied. The d2 test of attention(Brickenkamp, 2007) 
was administered and the raw scores of the total number of processed items (TN) and total number of 
correctly processed items (C) were analyzed. Three digit spans backward (DSB) (Lezak, 2004; 
Wechsler, 1997) versions were constructed for the current study (see eAppendix 1) and applied 
alternately across the participants and the pre- and post-intervention assessments. Raw scores were 
computed for the total score – the amount correct recalled rows – and the amount of numbers of the 
longest recalled row. The Stroop color-word test (Hammes, 1978; Stroop, 1935) was applied; for 
analysis, raw scores of total execution time for the color-word card and the interference time – the 
difference in time between the color-word card and color card – were used. The Tower of London 
(TOL) (Culbertson & Zilmer, 2001, 2005) was applied according to the age of the participant: either 
the 7-15 years form or the 16+ years form. Raw scores used were the total correct score (tasks 
performed in the fewest number of moves possible), the total move score (number of moves, above 
the minimal required steps per task), initiation time (time before the first move), executive time (time 
from the first move to task completion), and total time (initiation time + executive time). TOL scores 
were summed scores over all ten tasks. 
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Procedure 
Prior to the start of the study, approval was obtained from the medical ethics committee for mental 
health institutions in the Netherlands (Ref.no: NL 24776.097.08 CCMO). The study took place in 
three centers for child and adolescent psychiatry (GGzE, GGz Breburg, Reinier van Arkel group) in 
the South of the Netherlands. After the study was explained (verbally and in writing), written informed 
consent was obtained from each participant. For those younger than 18, parents also provided written 
informed consent.  
 At pre-intervention, participants were seen on three occasions for the administration of 
behavioral questionnaires, neurocognitive tests, the WAIS or WISC intelligence test, and 
electroencephalogram (EEG) measurements. In cases where participants were on medication, 
medication intake was also continued on the day of assessment. 
 Interventions took place between December 2009 and July 2012. Duration of the intervention 
period was approximately 25 weeks. 
Post-intervention assessment included behavioral questionnaires and neurocognitive tests for all 
71 participants.  
Because of test administration problems, five participants were excluded for analysis of either 
the d2 test of attention, Stroop or TOL. One participant was excluded from analysis for the d2 test of 
attention, because of misinterpretation of the instructions at the second measurement. Two 
participants were excluded from analysis for the Stroop: one because he refused to cooperate with the 
test and the other because of a broken timer. For one participant, a version of the TOL, which was not 
age appropriate, was mistakenly administered and he was therefore excluded from further analysis. 
 
Statistical analysis 
All analyses were performed using SPSS version 21. Effects were considered significant if p<.05. 
Differences on group characteristics were analyzed with a one-way ANOVA or a chi-square test (χ2) 
with Fisher exact correction. Attrition analyses compared the analyzed subsample to the total sample 
on group characteristics, behavioral and neurocognitive measures with a one-way ANOVA.  
 A Generalized Linear Model (GLM) ANOVA was applied for all the primary neurocognitive 
outcome measures with intervention group as between-subjects factor and time (e.g. between pre-
intervention[t1] and post-intervention[t2]) as within-subjects factor. The full factorial models were 
tested. All neurocognitive effects were evaluated using multivariate test criteria. Effect sizes are 
expressed in percentage of explained variance in partial η2(ηp2). In addition, the adjusted difference at 
post-intervention (ADt2-t1) and 95% confidence interval (95% CI) were reported. Post hoc analyses 
were performed with separate addition of stimulant medication use at pre-intervention and diagnostic 




Figure  1 :  Participant Flow Diagram 
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Figure  1 .  Participant Flow Diagram 
Assessed for eligibility (n=106) 
Excluded (n =16) 
♦  Not meeting inclusion criteria (n =8) 
♦  Declined to participate (n =8) 
Analysed (n= 45) 
♦ Excluded from analysis (n=2) 
• Borderline disorder (n=1) 
• Expression of psychotic symptoms 
(n=1)  
Lost to follow-up (n= 12) 
♦ Discontinued intervention due to 
motivational and/or organizational 
reasons (n=9) 
♦ Transfer to other region for clinical 
admission (n=2) 
♦ Expression of bipolar disorder with 
severe psychotic symptoms (n=1) 
 
 
Allocated to neurofeedback +treatment 
as usual (n=59) 
Lost to follow-up (n = 5) 
♦ Discontinued intervention due to 
motivational and/or organizational 
reasons (n =5) 
 
Allocated to treatment as usual (n =31) 
 























Applied for admission (n=141) 
♦  Declined to participate (n=35) 
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Table 1. Group characteristics and treatment as usuala 
 TOTAL NFB+TAU TAU   
 N=71 n=45 n=26 F p 
Age in Years (SD) 16.1(3.3) 16.1(3.3) 16.2(3.4) .0 .864 
DSM-IV-TR      
 Diagnosis ADHD (%) 47(66.2) 29(64.4)  18(69.2)   .797 
 Diagnoses ASD+ ADHD (%) 24(33.8) 16(35.6) 8(30.7)  .797 
 GAF-scores (SD) 54.7(6.7) 53.8(7.1) 56.2(5.95) 2.0 .157 
Treatment as usual      
 Stimulant Med Pre-Intervention t1 (%) 35(49.3) 20(44.4) 16(61.5)  .220 
  Mean doses in mg (SD)b 37.2(16.4) 36.1(17.1) 38.6(15.9) .2 .647 
  Months of intake before t1    3.7 .457 
   Up to 3 months (%) 6(8.5) 4(8.9) 2(7.7)   
   3 to 6 months (%) 3(4.2) 2(4.4) 1(3.8)   
   6 to 12 months (%) 4(5.6) 3(6.7) 1(3.8)   
   12 months or longer (%) 23(32.4) 11(24.4) 12(46.2)   
   Stimulant free (%) 35(49.3) 25(55.6) 10(38.5)   
 Stimulant Med Started after t1 (%) 6(8.5) 3(6.7) 3(11.5)  .662 
 Stimulant Med Stopped after t1 (%) 9(12.7) 5(11.1) 4(15.4)  .716 
 Behavioral Interventions Adolescentc (%) 26(36.6) 14(31.1) 12(46.2)  .318 
 Behavioral Interventions Parentc (%) 20(28.2) 12(26.6) 8(30.7)  .787 
Behavioral measures      
 MINI ADHD Inattention (SD) 5.6(2.6) 5.4(2,6) 6.1(2.7) 1.2 .280 
 MINI ADHD H/I (SD) 4.0(2.5) 4.2(2.6) 3.7(2.3) .5 .489 
 ADHD rating scale      
  Inattention Childhood Symptomsd (SD) 6.1(2.7) 5.7(2.9) 6.8(2.0) 2.9 .093 
  H/I Childhood Symptomsd  (SD) 4.9(2.9) 4.6(3.0) 5.6(2.6) 2.0 .160 
  Inattention Current Symptoms (SD) 4.7(2.4) 4.4(2.5) 5.3(2.2) 2.2 .142 
  H/I Current Symptoms (SD) 3.4(2.1) 3.4(2.1) 3.3(2.5) .1 .734 
 YSR Total problem score (SD) 49.7(20.9) 48.0(22.0) 52.6(18.9) .8 .382 
 YSR Attention problems (SD) 9.6(3.3) 9.4(3.32) 9.9(3.2) .5 .487 
 CBCL Total problem scoree(SD) 62.3(27.6) 61.1(28.0) 64.1(27.3) .2 .662 
 CBCL Attention problemse (SD) 11.5(3.4) 11.2(3.7) 12.0(3.1) .9 .359 
Intelligence        
 IQ Discrepancy profilef (%) 24(33.8) 14(31.1) 10(38.5)  .606 
 Total IQ (SD) 100.7(11.3) 98.6(10.4) 104.2(12.2) 4.2 .045 
  Verbal IQ (SD) 102.4(12.9) 100.2(11.4) 106.2(14.5) 3.8 .057 
  Performance IQ (SD) 99.5(11.9) 98.4(11.2) 101.3(13.1) 1.0 .327 
Note: aData are means (SD) or numbers (%), t1 is pre-intervention, df(1,69); bmean doses in mg calculated for the 
adolescents on stimulant medication (n=35); cBehavioral interventions followed between pre- and post-intervention 
(t1-t2) as followed by the adolescents or one of the parents respectively; dRetrospective self-reported childhood 
symptoms (primary school period) and current symptoms (in the past 6 months); eCBCL data; total N=66 
participants, NFB+ (n=40) and TAU (n=26), df(1,64); fIQ Discrepancy profile is considered as a profile with a 
difference score between VIQ and PIQ of 15 points or more. Because of the discrepancy profiles VIQ and PIQ are 
noted separately. 
Abbreviations: NFB= neurofeedback, TAU= treatment as usual, DSM= Diagnostic and Statistical Manual, ADHD= 
attention deficit/hyperactivity disorder, ASD= autism spectrum disorder, GAF= Global Assessment of Functioning, 
Med: medication, MINI= Mini International Neuropsychiatric Interview, H/I = hyperactivity/impulsivity, YSR= 




Group Characteristics  
At pre-intervention there were no differences for group characteristics, behavioral and neurocognitive 
primary outcome measures between the NFB+TAU group and the TAU group (Table 1). The only 
exception was TIQ: although TIQ for both groups was within the average range [95-105], TIQ was 
higher for the TAU group than for the NFB+TAU group. 
 
Attrition Analysis 
Attrition analysis showed that the dropout group (n=16), due to transfer, motivational and/or 
organizational reasons, did not differ from the total analyzed group (N=71) on group characteristics, 
behavioral and neurocognitive measures at pre-intervention. In addition, the subsamples of the d2 test 
of attention (n=70), Stroop (n=69) and TOL (n=70) did not differ from the total analyzed sample 
(N=71) on group characteristics, behavioral and neurocognitive measures at pre-intervention. 
 
Neurocognitive measures 
Neurocognitive outcome measures are summarized in Table 2. On the d2 test of attention, there was a 
large improvement over time for the adolescents on attention and/or motor speed, with more 
processed items and more correct processed items over the whole test. The DSB showed a medium 
improvement in attention for the adolescents with an increased total score over time. On the other 
hand, working memory, as estimated with the longest recalled row, did not change over time. Medium 
improvements were found on the Stroop, with shorter executive and interference times at post-
intervention. Similarly, the TOL revealed a medium improvement with shorter executive and total 
times. However, planning as estimated with the total move score, total correct score and initiation time 
revealed no improvement over time. Neurocognitive measures were similar for the NFB+TAU and 
the TAU group and did not differ between the groups over time.  
 
Post hoc analyses for stimulant medication use and ASD.  
Stimulant-medicated adolescents did not differ over time from stimulant-free adolescents on the 
neurocognitive measures. Likewise, there were no differences over time on neurocognitive measures 
between adolescents with ADHD or combined ASD with ADHD. 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The present study examined the additional value of neurofeedback to TAU on neurocognitive 
functioning in adolescents with ADHD, using a multicenter parallel-randomized controlled trial 
design. Results showed an improvement in neurocognitive measures of attention and/or motor skills 
at post-intervention for all adolescents with ADHD. Adolescents needed less time to process 
information and performed tasks with the same accuracy. Working memory and planning estimations 
remained stable over time.  
 Neurocognitive functioning improved as much for the adolescents who received 
neurofeedback in addition to the TAU as for the adolescents who received only TAU. The 
neurocognitive outcomes are in agreement with the behavioral outcomes of the current study that 
showed large improvements on parent as well as on self-reported behavior irrespective of treatment 
allocation. This is in line with results from two double-blind studies with children with ADHD that 
also failed to find more improvement on behavioral questionnaires (Arnold et al., 2012; van Dongen-
Boomsma et al., 2013) and neurocognitive measures (Arnold et al., 2012; Vollebregt et al., 2013) for 
neurofeedback over sham-neurofeedback. Furthermore, a study in healthy students who scored 
relatively high on ADHD symptoms found similar results for neurofeedback and sham-neurofeedback 
on self-reported attention problems as well as RT and accuracy (Logemann et al., 2010). In contrast, 
positive results were shown in a study with better performance for neurofeedback compared to EMG 
biofeedback on RT and accuracy in children with ADHD (Bakhshayesh et al., 2011).  
 The differences in outcomes of the studies might be a result of the applied training protocol. 
The RCT studies that failed to find significant effects for neurofeedback in the treatment of ADHD 
(Arnold et al., 2012; Logemann et al., 2010; van Dongen-Boomsma et al., 2013), like the current study, 
combined inhibition of theta with reward of SMR (12-15Hz) activity in the majority of the applied 
(sometimes individualized) training protocols. In contrast, the neurofeedback versus EMG 
biofeedback study of Bakhshayesh et al. (2011) applied a somewhat different protocol with also 
inhibition of theta, but reward of beta (16-20Hz) instead of SMR activity. Similarly, reward of the 
higher beta (16-20Hz) range in the training protocol was also applied in the study of Gevensleben, 
Holl, Albrecht, Vogel, et al. (2009) that showed neurofeedback to be more effective in reducing 
ADHD symptoms than computerized attention training, and in the studies that compared 
neurofeedback to stimulant medication (Duric et al., 2012; Meisel et al., 2013). It might be that training 
protocols aimed at (also) rewarding beta (16-20Hz) are more favorable in the training of attention. 
However, at this moment training protocols are used alternately in clinical practice as well as in 
research. There is no consensus on the exact kind of protocol to apply for the treatment of ADHD. 
Therefore, additional knowledge about specific working mechanisms of neurofeedback on the brain is 
necessary before neurofeedback protocols can be adapted appropriately for the treatment of 
psychiatric disorders. 
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 Stimulant-medication use by the participants was allowed in the current study as a part of 
TAU. Therefore, it could be hypothesized that medication could have mediated the effect of 
neurofeedback. Overall, stimulant-medication improves neurocognitive functioning (Coghill et al.). It 
could be that the magnitude of the improvement depends on the cognitive domain. Task 
improvements by stimulant medication were seen especially in less cognitive demanding repetitive 
tasks that need sustained attention as RT variability and less in more complex cognitive tasks 
(Swanson, Baler, & Volkow, 2011). Comparably, the current study shows improvement over time in 
measures of attention and processing speed and not in more complex cognitive tasks. However, we did 
not find the expected better performance in stimulant-medicated adolescents compared to stimulant-
free adolescents. The long-term effects of stimulant-treatment on neurocognitive functioning are less 
well known (Swanson et al., 2011). Three-quart of the adolescents who used stimulant medication 
started intake 6-months or longer before study entrance. Consequently, this long-term intake of 
stimulant medication might contribute to the absence of differentiation by stimulant medication use.  
 Although neurofeedback does not seem effective for autism symptoms, a review indicated it 
could be effective for comorbid ADHD symptoms in ASD (Holtmann et al., 2011). Therefore, 
adolescents with clinical ADHD symptoms and ASD were also included in the current study. None of 
the outcomes differentiated between adolescents with ADHD versus combined ASD and ADHD; 
both diagnostic groups showed similar improvements over time. This suggests that the co-occurrence 
of ASD did not influence the outcomes.  
 The present study contributes to the literature by applying an RCT design in a naturalistic 
multimodal treatment setting, thereby increasing the ecological validity of the study. However, as a 
consequence, the target population consisted of a heterogeneous group of male adolescents with 
complex problems. Previous research that showed positive results on measures of attention 
(Gevensleben, Holl, Albrecht, Vogel, et al., 2009) was based on more homogeneous populations with 
ADHD.  Another point of consideration is that the current study included adolescents who were older 
than the children in previous research. Studies that revealed positive results all aimed at children with a 
mean age of around ten years, whereas the mean age of the participants was sixteen years in the current 
study. Developmental related large increases in attention and/or (motor) speed during adolescence 
(Gur et al., 2012) might have induced ceiling effects on the neurocognitive tests. Furthermore, practice 
effects by multiple testing are known to have a considerable impact on test outcomes (Calamia, 
Markon, & Tranel, 2012). Consequently, outcomes might reflect practice effects rather than improved 
neurocognitive functioning. In addition, TIQ was somewhat higher for the TAU group than the 
NFB+TAU group. As a result, it could be assumed that with a higher TIQ, practice effects could be 
larger (Calamia et al., 2012) and could conceal potential treatment effects in the NFB+TAU group. 
Diminished and improved learning curves have indeed been found in low and high average TIQ 
respectively (Rapport, Axelrod, et al., 1997; Rapport, Brines, Theisen, & Axelrod, 1997). Note, that 
both intervention groups had a mean TIQ within the average range [95-105] and did not differ 
significant on any of the other measures, including PIQ. Therefore, we consider the impact of the 
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difference is likely to be minimal. Overall, the large improvement over time might reflect practice 
effects, developmental changes, learning effects, as well as effects of TAU. 
 In conclusion, NFB+TAU and TAU both showed significantly improved neurocognitive 
outcomes – mainly processing speed – at post-intervention. No additional value of neurofeedback over 
TAU was found. Hence, this study does not provide evidence for using theta/SMR neurofeedback to 
enhance neurocognitive performance as additional intervention to TAU for adolescents with ADHD 
and comorbid disorders in clinical practice. 
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ABSTRACT 
Background: Neurofeedback is proposed as an effective treatment for reduction of Attention Deficit 
Hyperactivity Disorder (ADHD) symptoms. Therefore, long-term additional effects of neurofeedback 
compared to treatment as usual (TAU) for adolescents with ADHD were investigated. Methods: 
Using a multicenter parallel-randomized controlled trial design, 90 adolescents with a DSM-IV-TR 
diagnosis of ADHD, were randomized and stratified for age group (ages 12 through 15 years, 16 
through 20 years, and 21 through 24 years) to receive either a combination of neurofeedback and TAU 
(NFB+TAU) or TAU. Neurofeedback treatment consisted of approximately 37 sessions of 
theta/SMR-training on Cz. Sixty adolescents receiving NFB+TAU (n=41) or TAU (n=19), (age 
M=15.95 years, SD=3.33), were followed for one year after the treatment period. Outcome measures 
at follow-up included behavioral self-reports (MINI, ADHD rating scale, YSR) and neurocognitive 
measures (d2 attention test, digit span backward, Stroop test, Tower of London test). Data were 
collected between December 2009 and August 2013. Results: Behavioral problems decreased from 
pre-intervention to one-year follow-up for both groups. Adjusted differences [95% confidence 
intervals] for attention problems were MINI: -1.38[-2.04 to -.72], ADHD rating scale: -1.64[-2.24 to -
1.03] and YSR: -2.23 [-3.09 to-1.37]. At follow-up adolescents’ performance of the neurocognitive 
tasks was faster irrespective of treatment group. Conclusions: Overall, TAU was as effective as 
NFB+TAU for adolescents with ADHD symptoms. Given the absence of robust additional long-term 
effects in the current study, it is questionable whether theta/SMR neurofeedback should be used to 
treat adolescents with ADHD and comorbid disorders. Clinical Trials Registration: This trial is 





Attention Deficit/Hyperactivity Disorder (ADHD) is characterized by re-occurring patterns of 
inattention and/or hyperactivity-impulsivity (HI) symptoms that interfere with developmentally 
appropriate social, academic, or occupational functioning (American Psychiatric Association, 2000). 
Neurodevelopmental conditions like learning disabilities, conduct disorder, depression and anxiety are 
seen more often in youngsters with ADHD than in youngsters without ADHD (Larson, Russ, Kahn, 
& Halfon, 2011). In addition, it is estimated that around one third to half of youngsters with autism 
spectrum disorders (ASD) display ADHD comorbidity (Gjevik, Eldevik, Fjaeran-Granum, & 
Sponheim, 2011; Simonoff et al., 2008). Stimulant medication and behavioral therapy are considered 
the treatments of choice for ADHD. Stimulant medication is effective in reducing ADHD symptoms 
in youngsters with ADHD (Faraone & Buitelaar, 2010; Greenhill et al., 2001) and - although possibly 
to a lesser extent - in youngsters with combined ADHD and ASD (Cortese, Castelnau, Morcillo, Roux, 
& Bonnet-Brilhault, 2012; Research Units on Pediatric Psychopharmacology (RUPP) Autism Network, 
2005). Although medication seems to be effective, there are some noteworthy limitations, namely that 
knowledge of the long-term and side-effects of stimulant medication is limited (van de Loo-Neus, 
Rommelse, & Buitelaar, 2011). Moreover, despite the persistent nature of ADHD, the majority of 
adolescents with ADHD discontinues stimulant medication before adulthood (McCarthy et al., 2012; 
Zetterqvist, Asherson, Halldner, Langstrom, & Larsson, 2013). Additions or alternatives to the current 
treatment as usual (TAU) to reduce ADHD symptoms further, and on a long-term basis, are therefore 
desirable. Neurofeedback has been suggested as a potentially effective intervention for reducing 
ADHD symptoms (Lofthouse, Arnold, Hersch, Hurt, & DeBeus, 2012; Moriyama et al., 2012) and 
ASD (Holtmann et al., 2011).  
 Neurofeedback is intended to alter brain activity by providing feedback from 
electroencephalogram (EEG) activity to patients; this is expected to lead to improvements in behavior. 
Overall, youngsters with ADHD show increased theta (Cortese, 2012; Loo & Makeig, 2012; Snyder & 
Hall, 2006), and decreased beta (Cortese, 2012; Snyder & Hall, 2006) activity compared to typical 
developing (TD) youngsters. Increased theta (4-7Hz) is associated with lower vigilance and decreased 
beta (13-30Hz) is associated with reduced attention (Banaschewski & Brandeis, 2007). In addition, beta 
activity (12-20Hz) has been related to behavioral inhibition (Sterman & Wyrwicka, 1967), specifically, 
low beta activity measured above the central sulcus - also referred to as the sensorimotor rhythm 
(SMR; 12-16Hz) (Roth, Sterman, & Clemente, 1967; Sterman & Wyrwicka, 1967; Sterman, Wyrwicka, 
& Roth, 1969). As neurofeedback aims to reduce ADHD symptoms such as diminished vigilance, 
attention and inhibition, most neurofeedback protocols include training to suppress theta activity and 
reinforce beta (12-20Hz) or SMR (12-15Hz) with electrode placement on Cz (Lofthouse et al., 2012; 
Loo & Makeig, 2012; Moriyama et al., 2012). A complete neurofeedback intervention typically 
comprises 20 to 40 training sessions (Loo & Makeig, 2012).  
Estimates of the effectiveness of neurofeedback for the treatment of ADHD depend on the 
study design. The most stringent double-blind studies have failed to find that neurofeedback is 
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superior to placebo neurofeedback for the reduction of ADHD symptoms assessed by behavioral 
(Arnold et al., 2013; van Dongen-Boomsma, Vollebregt, Slaats-Willemse, & Buitelaar, 2013) or 
neurocognitive measures (Vollebregt, van Dongen-Boomsma, Buitelaar, & Slaats-Willemse, 2013). A 
single-blind study did find that children who received neurofeedback showed a greater improvement in 
attention on the basis of parental report, and reaction time and accuracy on neurocognitive tests than 
children who received electromyography (EMG) biofeedback (Bakhshayesh, Hansch, Wyschkon, 
Rezai, & Esser, 2011). However, none of the blind studies looked at the long-term effects of 
neurofeedback. Long-term effects of neurofeedback were found in two randomized controlled trials 
(RCT): neurofeedback was more effective in reducing ADHD symptoms as reported by parents than 
computerized attention training up to six months post-treatment (Gevensleben et al., 2010; Steiner, 
Frenette, Rene, Brennan, & Perrin, 2014). Two further RCT studies found that neurofeedback was as 
effective as stimulant medication (Duric, Assmus, Gundersen, & Elgen, 2012; Meisel, Servera, Garcia-
Banda, Cardo, & Moreno, 2013). Conversely, another RCT found that stimulant medication but not 
neurofeedback decreased ADHD symptoms (Ogrim & Hestad, 2013). To date there has been only one 
study comparing the long-term effects of stimulant medication and neurofeedback (Meisel et al., 2013). 
This study used a naturalistic follow-up at 6 months, and at follow-up the level of ADHD symptoms 
was similar for children who had received neurofeedback (n=12) and children treated with stimulant 
medication (n=11).  
In summary, neurofeedback is viewed as a possible treatment for ADHD symptoms. 
Comparative studies of effectiveness have shown that neurofeedback training can be as effective as 
stimulant medication or a combination of stimulant medication and neurofeedback (Duric et al., 2012), 
but evidence on the long-term effects of neurofeedback is limited. Since the aim of neurofeedback is 
to induce enduring changes in brain regulation in order to improve behavior, one would predict long-
term effects as a consequence of improved brain functioning. The aim of the current study was 
therefore to investigate the value of neurofeedback as a supplement to TAU for adolescents with 






Eligible participants were male adolescents with Dutch as their native language, between 12 and 24 
years old, with a primary clinical DSM-IV-TR (American Psychiatric Association, 2000) diagnosis of 
ADHD and a full-scale total intelligence quotient (TIQ) >80 on the Wechsler Intelligence Scale for 
Children (WISC-III) or the Wechsler Adult Intelligence Scale (WAIS-III) (Wechsler, 1991, 1997). 
Adolescents diagnosed with ASD (autism, Asperger’s syndrome or pervasive developmental 
disorder - not otherwise specified; PDD-NOS) with confirmed clinical ADHD symptoms sufficient 
for a clinical diagnosis were also included. ADHD symptoms were verified by a Dutch semi-structured 
DSM-IV-based ADHD interview for adults (Kooij, 2002) and the Mini International Neuropsychiatric 
Interview (MINI) (Sheehan et al., 1998; Sheehan et al., 1997). Exclusion criteria were neurological 
disorders, schizophrenia and other psychotic disorders. 
In total 90 adolescents were randomly assigned to the treatment groups: combined 
neurofeedback and TAU (NFB+TAU; n=59) or TAU only (TAU; n=31). The total dropout and 
exclusion rate after randomization did not differ for NFB+TAU, n=18 (30.5%) or TAU, n=12 
(38.7%), p=.485 two-tailed Fisher exact test. For the one-year follow-up analysis the group sizes were 
NFB+TAU: n=41 and TAU: n=19. The participant flow diagram is presented in Figure 1.  
Medication use and comorbid disorders were allowed. Comorbid disorders present in the final 
group at one-year follow-up: depressive disorders (1), anxiety disorders (3), substance-related disorders 
(3), conduct disorders (3), learning disorders (5), tic disorders (1), reactive attachment disorder (1). The 
final group characteristics are listed in Table 1. 
 
Trial design 
A multicenter parallel group study was conducted, with stratification for age group (12 through 15 
years, 16 through 20 years, and 21 through 24 years) and unbalanced randomization to treatment (2 
NFB+TAU: 1 TAU). The randomization process was computer-controlled (Dallal, 2007), using 
randomly varying block lengths of 3, 6, 9 and 12. An independent administrative employee was 
responsible for the assignment of participants to the treatment groups immediately after pre-
intervention assessment. The participant (and if applicable, his parents) was notified the same day 
whether he would receive neurofeedback treatment. Participants, parents, neurofeedback trainers, the 
outcome assessor and clinical professionals were aware of group allocations. The roles of outcome 
assessor and neurofeedback trainer were fulfilled by different individuals. All data entry was blind to 
group allocation (NFB+TAU or TAU) and was checked twice by different research assistants.  
Prior to the study we used G*power version 3.1.5.1 (Faul, Erdefelder, Lang, & Buchner, 2007) 
to calculate that a total sample size of 46 would be sufficient to detect a medium effect size (f=.25) in a 
repeated measures ANOVA with two measurements, with an alpha of .05 and a power of 90%. Where 
three measurements (pre-intervention, post-intervention and one-year follow-up) were available a total  
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sample size of 36 was predicted to be adequate to detect a similar effect size. We have followed the 
CONSORT 2010 guidelines (Schulz, Altman, & Moher, 2010) for reporting parallel group randomized 




Treatment as usual (TAU) 
In the TAU group, the participants received treatment as prescribed by the main therapist in the 
participating centers for child and adolescent psychiatry (GGzE, GGz Breburg, Reinier van Arkel 
group). The TAU group was monitored using an intervention questionnaire based on the Dutch national 
basic program ADHD for children and adolescents (Vink & Van Wamel, 2007). Behavioral interventions 
included regular (at least once every two weeks, typical session duration: 45 minutes) cognitive 
behavioral therapy, systemic therapy and/or supportive counseling for the adolescent and/or his 
parent(s) (see Table 1). Stimulants prescribed included immediate release methylphenidate, sustained 
release methylphenidate and dexamphetamine. Two participants were taking atomoxetine at study 
entry; one participant had changed to sustained released methylphenidate by the time of the one-year 
follow-up, the other participant continued to use atomoxetine through one-year follow-up. Because 
the clinical effects of stimulant medication and atomoxetine are suggested to be similar this participant 
was categorized as stimulant-medicated for the purposes of analysis at one-year follow-up. Adherence 
to prescribed medication was verified by asking participants whether they took their prescribed 
medication. There were no group differences (TAU vs. NFB+TAU) in the use of stimulant medication 
or the type of behavioral therapy received (see Table 1).  
 
Neurofeedback in addition to TAU 
Neurofeedback training was carried out over a period of around 5 months (25 weeks), with 2 to 3 
training sessions every week. Each participant was offered a total of 40 thirty-minute training sessions. 
The mean number of training sessions undertaken was 38 (37.73 ± 4.43) with a minimum of 19 
sessions for the adolescents in the NFB+TAU group at one-year follow-up, n=41. A 
neuropsychologist (MB) who was certified by EEG Biofeedback EEG Spectrum International Inc. 
certified, accredited by the Biofeedback Certification International Alliance (BCIA) trained the 
psychologists who administered the neurofeedback training. Theta/SMR training (Lubar, 2003) – a 
form of theta/beta training – was used, with thresholds to inhibit theta/alpha frequency bands (4-7Hz 
and 8-11Hz), reward SMR activity (13-15Hz) and inhibit beta/gamma (22-36Hz). Inhibition of the 
higher beta/gamma was used to minimize the increase in SMR activity resulting from increased muscle 
tension and to decrease the high beta activity that occurs in an estimated 10-20% of children with 
ADHD (Snyder & Hall, 2006). Training was conducted on Cz, referenced to linked mastoids. The 
EEG signal was transmitted to computer by the Brainquiry PET EEG 2 channel bipolar system 
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(Braininquiry): a DC amplifier with active electrodes, a 40Hz low-pass anti-aliasing filter, a sample rate 
of 200Hz, and 29-bit AD resolution. Neurofeedback training was conducted with ‘EEGer’ 
neurofeedback software version 4.2.1 (EEGer Spectrum Systems). The EEG signal was bandpass-
filtered in the different frequency bands and an exponentially weighted moving average (0.5 seconds) 
filter was used to produce short-term averages. Each frequency band had a 0.25Hz increment reward 
filter. Each training session was divided into 10 three-minute epochs. Artifact rejection thresholds for 
the raw EEG signal were set at 60µV. Relative thresholds for each frequency band were set to accept 
the signal of the particular frequency band 80% of the time and reject the signal 20% of the time. 
Thresholds corresponded to the mean amplitude in µV of each frequency band over the previous 30 
seconds of input and were calculated 30 seconds after the start of each three-minute part session. For 
the first 30 seconds of a three-minute session, the thresholds from the previous three-minute session 
were used. The trained frequency bands were represented to the participant using simple graphics on a 
screen. Reinforcement was given when all frequency bands were within thresholds at the same 
moment, by auditory feedback -a 0.25s beep-, and an increase of the participant’s session score.  
 
Outcome Measures 
Outcome measures included three behavioral self-reports and four neurocognitive measures.  
Behavioral measures: 1) The MINI (Sheehan et al., 1998; Sheehan et al., 1997) ADHD subscales 
for children and adolescents covering inattention and HI symptoms over the last six months (scale 
range: 0 to 9). 2) The ADHD rating scale, a DSM-IV-based self-report for adults (Kooij et al., 2008; 
Kooij et al., 2005), with subscales for inattention and HI (scale range: 0 to 9) (46,47). 3) The Youth Self 
Report (YSR) (Achenbach, 1991): the attention problems subscale, the externalizing problems scale 
and total problems scale were used. Participants aged over 18 years also completed the YSR, as most 
of them were still attending school and living with their parents. 
Neurocognitive measures: 1) The d2 attention test (Brickenkamp, 2007) was administered and the 
raw scores for total processed items (TN) and total correctly processed items (C) were analyzed. 2) 
Three versions of the digit span backwards (DSB) (Lezak, 2004; Wechsler, 1997) were constructed for 
the current study and applied in turn across participants and assessments (pre-intervention, post-
intervention and one-year-follow-up); total score (number of rows recalled correctly) and the 
maximum correctly recalled row length were used. 3) The Stroop color-word test (Hammes, 1978; 
Stroop, 1935), was administered; raw scores for color-word card total execution time and interference 
time (difference between execution times for color-word card and color card) were used. 4) The age 
appropriate form (7-15 years or 16+ years) of the Tower of London (TOL) test (Culbertson & Zilmer, 
2001, 2005) was administered. The total correct (tasks performed in the minimum number of moves), 
total moves (number of moves in excess of the minimum required), initiation time (time to first move), 
execution time (time between first move and task completion), and total time (initiation time plus 
execution time) were calculated. TOL scores were the summed across all ten tasks.  
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Assessed for eligibility (n=106) 
Excluded (n =16) 
♦  Not meeting inclusion criteria (n =8) 
♦  Declined to participate (n =8) 
Analyzed (n= 45) 
♦ Excluded from analysis (n=2) 
• Excluded: Borderline disorder (n=1) 
• Excluded: Expression of psychotic 
symptoms (n=1)  
Lost to follow-up (n= 12) 
♦ Discontinued intervention due to 
motivational and/or organizational 
reasons (n=9) 
♦ Transfer to other region for clinical 
admission (n=2) 
♦ Excluded: Expression of bipolar disorder 
with severe psychotic symptoms (n=1) 
 
Allocated to neurofeedback +treatment as 
usual (n=59) 
Lost to follow-up (n = 5) 
♦ Discontinued intervention due to 
motivational and/or organizational 
reasons (n =5) 
 
Allocated to treatment as usual (n =31) 
 


























Applied for admission (n=141) 
♦ Declined to participate (n=35) 
Analyzed (n= 41) 
♦ Lost to follow-up due to motivational 
and/or organizational reasons (n= 4) 
 
Analyzed (n =19) 
♦ Lost to follow-up due to motivational 










Prior to the start of the study, approval was obtained from the Medical Ethics Committee for Mental 
Health Institutions in the Netherlands (Ref. no: NL 24776.097.08 CCMO). The study took place in 
three centers for child and adolescent psychiatry (GGzE, GGz Breburg, Reinier van Arkel group) in 
the south of the Netherlands. After the study was explained (verbally and in writing), written informed 
consent was obtained from each participant. For those younger than 18 years, parents also provided 
written informed consent.  
At pre-intervention, participants were seen on three occasions for the administration of 
behavioral questionnaires, neurocognitive tests, the WAIS or WISC intelligence test, and 
electroencephalogram (EEG) measurements, where applicable medication was taken as normal on the 
day of assessment. Interventions took place between December 2009 and July 2012. The duration of 
the intervention period was approximately 25 weeks. Data collection continued until August 2013. 
Post-intervention and one-year follow-up assessments included behavioral questionnaires and 
neurocognitive tests for all 60 participants. There was missing data for the d2 attention test (2 
participants), Stroop test (2 participants), TOL (1 participant) either because of administrative 
problems or because the participant refused to complete the task. Parent reports (CBCL and autism 
questionnaire (AQ)) were not included because of the low response rate (48%) of the total randomized 
sample at the follow-up measurements. 
 
Statistical Analysis 
All analyses were performed using SPSS version 19.0. Effects were considered significant at p<.05. 
Differences in group characteristics were analyzed with a one-way ANOVA or a chi-square test (χ2) 
with Fisher’s exact correction. Attrition analyses for behavioral data with smaller sample size than the 
total sample size due to missing or incomplete data were performed by comparing group 
characteristics and other pre-intervention primary behavioral measures for the analyzed subsample and 
the total sample using a one-way ANOVA.  
A completion analysis was applied involving the participants who finished all assessments up 
to one-year after the intervention (including neurofeedback training, if applicable), in order to 
determine whether neurofeedback had additional value after completion of the training. The effect of 
neurofeedback training was investigated using a Generalized Linear Model (GLM) with between- and 
within-subjects factors. This analysis was used separately for all primary behavioral measures with 
treatment group as between-subjects factor and time (i.e. pre-intervention (T1), post-intervention (T2) 
and one-year follow-up (T3)) as within-subjects factor. The full factorial models were tested. All 
behavioral effects were evaluated using multivariate test criteria. The adjusted difference (AD) and 
95% confidence interval [95% CI] for the total sample (NFB+TAU and TAU) were noted and if 
applicable, separate post-hoc analyses of NFB+TAU and TAU effects were performed. Significant 
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two-way between-group interactions were investigated with separate post-hoc GLM ANOVAs for the 
NFB+TAU and TAU groups with time as within-subjects factor.  
 To control for potential outcome bias of the drop-outs (n=27) after randomization post-hoc 
analyses were performed based on imputation with Last Observation Carried Forward (LOCF) for the 
total group as randomized with the exception of the three excluded participants (see also flowchart: 
Figure 1).  
To determine whether changes over time were associated with stimulant medication use, post-
hoc analyses were performed to look for three-way interactions involving stimulant medication use 
(stimulant-medicated and stimulant-free) at one-year follow-up as an additional between-subjects 
factor. To determine whether co-occurrence of ASD influenced the outcomes, possible three-way 
interactions were also explored with post-hoc analyses with diagnostic group (ADHD or ASD with 
comorbid ADHD) as an additional between-subjects factor. Significant three-way between-groups 
interactions were investigated with separate post-hoc GLM RM ANOVAs for both stimulant 
medication conditions (stimulant-medicated and stimulant-free). 
 
RESULTS 
Group Characteristics  
There were no baseline differences for the participants who completed the study up to one-year post-
treatment in group characteristics between the NFB+TAU group and the TAU group (Table 1). There 
were also no pre-intervention group differences on behavioral or neurocognitive measures.  
There were no significant differences between the treatment groups in terms of stimulant 
medication use at pre-intervention or one-year follow-up. Mean doses of stimulant medication in mg 
did not change for the total group (n=60) between pre-intervention, M=19.45, SD=22.43 and one-year 
follow-up, M=18.88, SD=22.98. For those who used stimulant medication at one-year follow-up 
(n=30) a general increase in dose was observed from pre-intervention M=30.30, SD=23.16 to one-year 
follow-up M=37.75, SD=18.37, ADT3-T1=8.81, 95%CI=[.69 to 16.93]. There were no significant 
interactions between time and treatment group for dosage. In addition, those who used stimulant 
medication at one-year follow-up (n=30) started stimulant medication M=32,97, SD=32.39, 




Attrition analysis showed that the participants who dropped out for motivational or organizational 
reasons (n=27), did not differ from the completers group (n=60) in terms of group characteristics or 
behavioral measures at pre-intervention. In addition, the subsamples for the d2 attention test (n=58) 
and the Stroop test (n=57) did not differ from the completers sample (n=60) in terms of group 





Behavioral outcome measures are summarized in Table 2. All measures showed a reduction in reported 
problems over time: MINI inattention subscale (p<.001) and HI subscale (p=.009), ADHD inattention 
scale (p<.001) and HI scale (p=.006), and the YSR total problems scale (p<.001)  and externalizing 
problems scale (p=.013). The reduction over time in attention problems measured by the YSR 
attention problems subscale (p<.001), followed a different time course in the NFB+TAU and TAU 
groups (p=.041). The NFB+TAU group showed a decrease in YSR attention problems from pre-
intervention to one-year follow-up, ADT3-T1=-2.20, 95%CI=[-3.14 to -1.25], as did the TAU group, 
ADT3-T1=-2.26, 95%CI=[-3.85 to -.67]. The NFB+TAU group showed a decrease from pre-
intervention to post-intervention, ADT2-T1=-2.02, 95%CI=[-2.99 to-1.06]; but not between post-
intervention and one-year follow-up, ADT3-T2=-.17, 95%CI=[-.97 to .62]. However, the TAU group did 
not show a decrease between pre-intervention and post-intervention, ADT2-T1=-.37, 95%CI=[-2.11 to 
1.37]; but there was a decrease from post-intervention to one-year follow-up, ADT3-T2 =-1.89, 
95%CI=[-3.07 to .72].  
 
Table 1: Group characteristics and treatment as usualA 
 TOTAL NFB+TAU TAU 
 N=60 n=41 n=19 
Age in Years T1  15.95(3.33) 15.85(3.34) 16.16(3.40) 
DSM-IV-TR    
 Diagnosis ADHD 38(63%) 26(63%) 12(63%) 
 Diagnosis ASD+ADHD  22(37%) 15(37%) 7(37%) 
 GAF-scores  54.85(6.58) 53.93(6.46) 56.84(6.58) 
Treatment as usual    
 Stimulant Medication T1 31 (52%) 19 (46%) 12(63%) 
 Stimulant Medication T2 29(48%) 17(41%) 12(63%) 
 Stimulant Medication T3 30(49%) 19(46%) 11(58%) 
 Behavioral interventionsB     
  Adolescent T1-T2 22(37%) 13(32%) 9(47%) 
  Adolescent T2-T3 13(22%) 9(22%) 5(26%) 
  Adolescent T1-T3 26(43%) 16(39%) 10(53%) 
  Parent T1-T2 16(27%) 11(27%) 5(26%) 
  Parent T2-T3 6(10%) 5(12%) 1(5%) 
  Parent T1-T3 18(30%) 12(29%) 6(32%) 
Childhood behavior    
 ADHD-rating InattentionC 6.10(2.46) 5.85(2.74) 6.63(1.67) 
 ADHD-rating H/IC 4.83(2.80) 4.71(2.87) 5.11(2.69) 
Intelligence    
 Total IQ  101.12(11.51) 99.22(10.61) 105.21(12.57) 
Note:A Data are means (SD) or numbers (%);T1= pre-intervention; T2= direct post-intervention;  
T3=one-year follow-up; BBehavioural interventions followed between pre- and post-intervention 
(T1-T2), between post-intervention and the one-year follow-up (T2-T3) and between pre-intervention  
and one-year follow-up (T1-T3). CADHD-rating scale retrospective self-reported childhood symptoms  
for Inattention and Hyperactivity/Impulsivity (HI). Group characteristics did not differ between groups.  
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Neurocognitive measures 
Neurocognitive measures are summarized in Table 3. There were no significant interactions between 
treatment group and time on the neurocognitive measures. Time interacted with the d2 attention test 
measures: TN  (p<.001), and C (p<.001), reflecting an increase in both scores from pre-intervention to 
one-year follow-up (see Table 3). There were also interactions with time for some TOL measures: 
initiation time (p=.040), execution time (p=.002) and total time (p=.014). At the one-year follow-up 
adolescents took longer to make their first move, but needed less time to execute the task and less time 
overall to complete the task than pre-intervention (see Table 3).  
 
Post-hoc analyses for stimulant medication use and diagnostic group 
LOCF: Post hoc analysis based on LOCF, to control for potential outcome bias due to drop-out, 
showed behavioral and neurocognitive outcomes comparable to the completion analyses with a 
decrease of behavioral problems and faster performance of neurocognitive task over time for all 
adolescents (N=87), irrespective of treatment group (NFB+TAU or TAU). There are four exceptions: 
1) in contrast to the completion analyses, the decrease for the YSR attention problem scale did not 
follow a significant different time course in the NFB+TAU and TAU groups (p=.080). 2) There was 
no longer a significant effect over time for the TOL initiation time (p=.105). Conversely, time effects 
became significant for 3) the DSB with an increase in total score (p=.020) and 4) the Stroop 
color/word card with a decrease in execution time (p=.013).  
 
Stimulant medication use: The ADHD HI scale, MINI, YSR and neurocognitive measures showed 
no interactions with time for either treatment group or stimulant medication use. There was an 
interaction between time, treatment group and stimulant medication use for the ADHD inattention 
scale (p=.011). There was a reduction in inattention problems from pre-intervention, M=4.23, 
SD=2.42 to follow-up, M=2.83, SD=2.31, ADT3-T1=-1.55, 95%CI=[-2.25 to -.85], for stimulant-
medicated adolescents irrespective of whether they received neurofeedback. Separate analyses for each 
treatment group showed that stimulant-free adolescents in the NFB+TAU group showed a reduction 
in inattention from pre-intervention, M=5.36, SD=2.08 to one-year follow-up, M=2.68, SD=2.38, 
ADT3-T1=-2.68, 95%CI=[-.3.73 to -1.64]; however stimulant-free adolescents in the TAU group 
reported similar levels of inattention at pre-intervention, M=6.00, SD=1.93, and one-year follow-up, 
M=5.63, SD=2.77, ADT3-T1=-.38, 95%CI=[-2.04 to 1.29].  
 
ADHD or ASD+ADHD: Post-hoc analysis showed no interactions between time, treatment group 




Long-term effects on behavioral and neurocognitive functioning from supplementing TAU with 
neurofeedback were investigated in the present study, using a multicenter parallel RCT design. This is 
the first study to investigate the long-term additional value of using neurofeedback to supplement 
TAU up to one year after the end of the intervention. Overall, the adolescents reported reductions in 
ADHD-symptoms, irrespective of whether they had received neurofeedback. Neurocognitive 
measures of attention or processing speed showed improvements between pre-intervention and 
follow-up indexed by decreased execution time on the TOL task and an increase in total processed 
items on the d2 attention test. There was no additional benefit from supplementing TAU with 
neurofeedback one year after treatment. This is consistent with a naturalistic six-month follow-up 
study in which similar improvements were found in stimulant-medicated children and children who 
had received neurofeedback (Meisel et al., 2013). However, it should be noted that by the time of the 
follow-up, eight of the twelve children who had received neurofeedback had started stimulant 
medication treatment (Meisel et al., 2013). Our findings are also consistent with the randomized 
studies, which showed that directly after the treatment period neurofeedback was as effective as 
stimulant medication (Duric et al., 2012; Meisel et al., 2013), or a combination of stimulant medication 
and neurofeedback (Duric et al., 2012).  
One RCT study found long-term positive results for neurofeedback (n=38) compared with 
computerized attention training (n=23), six months post-treatment in stimulant-free children with 
ADHD (Gevensleben et al., 2010). In this study children for whom stimulant medication was indicated 
were excluded from the trial or excluded from the follow-up analysis; this probably excluded children 
with more severe ADHD symptoms. In consequence the effectiveness of neurofeedback as a 
treatment for ADHD in this study cannot be generalized to children with more severe ADHD 
symptoms. A recent published RCT did overcome this generalization problem by including children 
while standard community care continued: a larger decrease of ADHD problems was found from pre-
intervention to six month follow-up for children receiving neurofeedback (n=34) than children 
receiving only standard community care (n=36) (Steiner et al., 2014). However, significant results were 
only found on parent-reports and as such bias of the parents for the intervention might have 
influenced the outcomes of the non-blinded study. By investigating the effects of neurofeedback as an 
additional treatment for adolescents with ADHD with a combination of behavioral and neurocognitive 
measures, we aimed to ensure the ecological validity of the current study. Nevertheless, this also 
resulted in several limitations. For example, the target population consists of a heterogeneous group of 
male adolescents with complex problems and there was variety in the prescription of stimulant 
medication.   
 Dropout during the course of the study did not seem to have influenced the outcomes. The 
effects of stimulant medication use and comorbid ASD and possible interactions with the effects of 
the treatment over time were also explored in the current study. Adolescents with comorbid ASD did 
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not respond to the interventions differently from adolescents with ADHD only. Stimulant-medication 
use at one-year follow-up interacted with treatment group on inattention assessed by the ADHD 
inattention subscale: inattention did not decrease in stimulant-free adolescents who received TAU 
without neurofeedback; however stimulant-free adolescents receiving TAU did report reduced 
attention problems on the MINI inattention scale and the YSR attention problems scale. The small 
TAU sample (n=19; stimulant-free n=8, stimulant-medicated n=11) was a limitation in this subgroup 
analysis and precludes strong conclusions.  
 In conclusion, one year after treatment the reduction in ADHD symptoms and improvements 
in neurocognitive performance were similar in adolescents who received neurofeedback in addition to 
TAU and adolescents receiving TAU; these results do not support the use of theta/SMR 
neurofeedback as a supplement to TAU to produce enduring improvements in behavior or 
neurocognitive functioning in adolescents with ADHD. The absence in the current study of long-term 
effects of neurofeedback additional to those of stimulant medication, combined with the absence of 
specific effects of neurofeedback over sham neurofeedback (24-27) and the requirement for lengthy 
training (20 to 40 sessions) (18), do not support use of theta/SMR neurofeedback as a treatment for 
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Summary and Discussion 
 
The morbid alterations to which attention is subject, may all be 
reduced under the two following heads: 
 
First. The incapacity of attending with a necessary degree  
of constancy to any one object. 
Second. A total suspension of its effects on the brain. 
 
“The incapacity with a necessary degree of constancy to  
any one object, almost always arises from an unnatural or  
morbid sensibility of the nerves, by which means this  
faculty is incessantly withdrawn from one impression to 
another.” (….) ”When born within a person it becomes  
evident at a very early period of life, and has a very bad  
effect, inasmuch as it renders him incapable of 
attending with constancy to any one object of education” 
A. Crichton (2008) 
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INTRODUCTION 
The first aim of this thesis was to explore psychophysiology in adolescents with ADHD and combined 
ASD+ADHD as well as possible clinical implications (Part 1). The second aim of this thesis was to 
investigate whether neurofeedback has additional value to treatment as usual in improving behavior 
and neurocognitive functioning in adolescents with ADHD (Part 2). The current chapter summarizes 
the main findings and discusses limitations, future research and clinical implications.  
 
SUMMARY 
Part 1: Psychophysiology in adolescents with ADHD and comorbid ASD+ADHD 
Attention deficit/hyperactivity disorder has a worldwide prevalence of around 5% (Polanczyk, de 
Lima, Horta, Biederman, & Rohde, 2007; Willcutt, 2012) and as such constitutes the most common 
neurodevelopmental disorder. In addition, a large number of youngsters with autism spectrum 
disorders (ASD) display comorbid attention deficit/hyperactivity disorder (ADHD) symptoms. 
Physiological measures, such as cardiac reactivity, electroencephalogram (EEG) power spectra and 
event related potentials (ERPs) have been related to ADHD symptomatology. The first part of the 
thesis explored overlap and differences in psychophysiological correlates of ADHD between 
adolescents with ADHD and adolescents with comorbid ASD and ADHD (ASD+ADHD), on and 
off stimulant medication.  
In Chapter 2, overlap and differences in cardiac activity between adolescents with ADHD and 
adolescents with combined ASD+ADHD were explored. Atypical cardiac activity such as increased 
parasympathetic activation with lower heart rate (Negrao, Bipath, van der Westhuizen, & Viljoen, 
2011) and increased heart rate variability (Borger & van der Meere, 2000; Borger et al., 1999; Negrao et 
al., 2011) have been related to ADHD. In contrast, ASD has been associated with increased 
sympathetic activation (Bal et al., 2010; Daluwatte et al., 2012; Van Hecke et al., 2009). Accordingly, it 
was expected that the adolescents with ASD+ADHD would show signs of more sympathetic and less 
parasympathetic activation than ADHD adolescents. However, when comparing cardiac measures in a 
clinical sample, adolescents diagnosed with ADHD (n=36) and ASD+ADHD (n=20) showed similar 
cardiac reactivity. Stimulant-medicated adolescents (n=31) showed decreased adaptation of LF/HF 
ratio and faster reaction times than stimulant-free adolescents (n=25), irrespective of diagnosis. In 
conclusion, this study underlines overlap in cardiac activity between adolescents with ADHD and 
combined ASD+ADHD.  
Chapter 3 aimed to explore overlap and differences in theta and beta power spectra between 
adolescents with ADHD versus combined ASD+ADHD. In contrast to the overlap in cardiac activity 
demonstrated in chapter 2, EEG power spectra differed in adolescents with ADHD (n=33) versus 
adolescents with combined ASD+ADHD (n=20). Adolescents with ADHD displayed more absolute 
theta activity than adolescents with combined ASD+ADHD during the eyes open and task conditions, 
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irrespective of stimulant medication use. During eyes closed absolute theta was similar for both 
diagnoses. In addition, adolescents with ADHD but not adolescents with ASD+ADHD showed an 
association between diminished attention test performance and increased theta in the eyes open 
condition. Indeed, increased theta power during resting state conditions (Cortese, 2012; Loo & Makeig, 
2012; Snyder & Hall, 2006), mainly in frontocentral regions (Loo & Makeig, 2012), is one of the most 
robust findings in ADHD. Consequently, the results of Chapter 3 indicate that adolescents with 
ASD+ADHD exhibited fewer of the physiological signs in the EEG usually associated with ADHD, 
although there was an overlap in attention problems between the adolescents with ADHD en 
ASD+ADHD.  
Chapter 4 explored event related potentials during an auditory oddball task. 
Psychophysiological measures of brain functioning, such as ERP indices, are related to cognitive 
functions such as attention, response selection, inhibition, and response monitoring (Johnstone, Barry, 
& Clarke, 2013). ERP components differed dependent on diagnoses and stimulant medication use. In 
combined ASD+ADHD (n=20), the N2 peak amplitude and difference wave was smaller in stimulant-
free (n=9) than in stimulant-medicated adolescents (n=11), but in adolescents diagnosed with ADHD  
there was no such difference between  stimulant-free (n=14) and stimulant-medicated (n=19) 
participants. The smaller N2 difference wave suggests that stimulant-free adolescents with 
ASD+ADHD might have more problems to discriminate between standard and target stimuli than 
stimulant-medicated adolescents with combined ASD+ADHD. In addition, medication use was 
associated with reduced N1 peak latencies in ADHD adolescents and with prolonged N1 peak 
latencies in ASD+ADHD. Chapter 4 indicates distinctive ERP activity in stimulant-medicated and 
stimulant-free adolescents that dependents on diagnostic group. 
In sum, results from the first part of this thesis show that whereas there is behavioral overlap 
and overlap in cardiac activity between adolescents with ADHD and adolescents with combined 
ASD+ADHD, there are differences in brain activity between these diagnostic subgroups. Such 
differences are of importance, because this may indicate that treatments developed for ADHD work 
out in a different manner in adolescents with ASD+ADHD compared to adolescents with ADHD. 
 
Part 2: The additional value of neurofeedback over treatment as usual 
Neurofeedback is seen as a potentially effective treatment to reduce Attention Deficit Hyperactivity 
Disorder (ADHD)-symptomatology, mainly attention problems. Neurofeedback intends to alter brain 
activity by giving feedback of electroencephalogram (EEG) activity to patients and subsequently 
improve behavior using operant conditioning principles. Overall, youngsters with ADHD show 
increased theta (Cortese, 2012; Loo & Makeig, 2012; Snyder & Hall, 2006), and decreased beta 
(Cortese, 2012; Snyder & Hall, 2006) activity compared to typical developing youngsters. Accordingly, 
the most frequently used neurofeedback protocol is the theta/beta training, which aims to decrease 
theta (4-7Hz) and increase SMR (12-15Hz) or beta (12-20Hz) activity (Lofthouse, Arnold, Hersch, 
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Hurt, & DeBeus, 2012; Loo & Makeig, 2012; Moriyama et al., 2012). Typically, the complete 
neurofeedback intervention comprises 20 to 40 training sessions (Loo & Makeig, 2012). In the second 
part of the thesis additional effects of neurofeedback over treatment as usual on behavioral and 
neurocognitive functioning were investigated.  
 Using a multicenter parallel-randomized controlled trial design, 90 male adolescents with a 
DSM-IV-TR diagnosis of ADHD were randomized to receive either a combination of neurofeedback 
and treatment as usual or only treatment as usual. Neurofeedback treatment consisted of 
approximately 37 sessions of theta/SMR-training on the vertex (Cz). The duration of the intervention 
period was around 25 weeks. In total, 71 adolescents (mean age 16.1 years, standard deviation 3.3 
years) were compared on behavioral and neurocognitive measures pre-intervention and immediately 
post-intervention. One-year after the intervention period, 60 adolescents were compared again on 
behavioral and neurocognitive measures.  
 In Chapter 5 the additional effects of neurofeedback over treatment as usual on behavior 
were investigated direct after the intervention period. For all adolescents with ADHD, self-reported 
and parent reported behavioral problems such as inattention and hyperactivity/impulsivity decreased 
from pre-intervention to post-intervention. There was no difference in this decrease between the 45 
adolescents who had received neurofeedback in addition to treatment as usual and the 26 adolescents 
who had received only treatment as usual. Furthermore, stimulant-medication use or the presence of 
comorbid ASD had no effect on the reported decrease in behavioral problems over time. Similarly, 
reported side-effects were comparable regardless of received treatment. However, the stimulant-free 
adolescents reported a decrease in headache frequency after the intervention period, whereas the 
stimulant-medicated adolescents did not report such a decrease. In conclusion, on behavioral 
outcomes, neurofeedback in combination with treatment as usual was equally effective compared to 
only treatment as usual. There were no additional behavioral effects of neurofeedback as such.  
 After investigation of the behavioral effects, in Chapter 6 potential additional effects of 
neurofeedback on neurocognitive functioning were examined. Before and immediately after the 
intervention period, all participants were compared on several neurocognitive measures: the d2 test of 
attention, the digit span backwards, the Stroop test and the Tower of London. Results showed an 
improvement in neurocognitive measures of attention at post-intervention for all participants. They 
needed less time to process information, while accuracy remained unchanged. Working memory and 
planning indices remained stable over time. The 45 adolescents who received neurofeedback in 
addition to treatment as usual did not outperform the 26 adolescents who did not receive 
neurofeedback. Similar to chapter 5, no additional value of neurofeedback over treatment as usual was 
found. Accordingly, this study did not provide evidence for using theta/SMR neurofeedback to 
enhance neurocognitive performance as additional intervention to TAU for adolescents with ADHD 
symptoms. 
 A year after the intervention period, 60 adolescents were assessed again. In Chapter 7, long-
term additional value of neurofeedback to treatment as usual on ADHD symptom reduction was 
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investigated. For this purpose, behavioral self-reports, neurocognitive measures and side effects were 
compared between 41 adolescents who had received neurofeedback as additional treatment and 19 
adolescents who had received only treatment as usual. The adolescents reported a decrease in 
behavioral problems from pre-intervention through one-year follow-up. Furthermore, the adolescents 
became faster in performing the neurocognitive tasks, irrespective of received treatment. Headaches 
decreased over time and reported sleep problems stayed the same over time. Similar to chapter 5 and 
chapter 6, neurofeedback in combination with treatment as usual was equally effective compared to 
only treatment as usual for adolescents with ADHD.  
 To conclude, the second part of this thesis investigated the additional effects of neurofeedback 
to treatment as usual. No additional direct or long-term effects of neurofeedback over treatment as 
usual were found with respect to behavior or neurocognitive functioning in adolescents with ADHD. 
Considering the absence of robust additional direct or long-term effects, the results do not support the 
use of theta/SMR neurofeedback as additional treatment to enduringly improve behavior or enhance 
neurocognitive functioning in adolescents with ADHD and comorbid disorders in clinical practice.   
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DISCUSSION 
In the 18th century Sir Alexander Crichton was the first to describe a disorder similar to ADHD with 
“morbid alternations of which attention is subject” in his second book: An inquiry into the nature and 
origin of mental derangement: comprehending a concise system of the physiology and pathology of 
the human mind (Crichton, 1798). Sir Crichton already combined physiology and pathology by stating 
that these morbid alternations can be seen as “The incapacity of attending with a necessary degree of 
constancy to any one object” and “A total suspension of its effects on the brain.” Ironically, the first 
published edition of his chapter underlines that alternations in attention are not always morbid, being 
even present during his own study, by stating that: “The morbid alterations to which attention is 
subject, may all be reduced under the three following heads” (see Chapter 1). Only two heads followed 
after this description. Over time, this possible alternation in attention was corrected: in later published 
versions the “three heads” (Crichton, 1798) became “two heads” (Crichton, 2008). Correction of 
alternations in attention, however, is not that simple in ADHD. By combining physiology and 
behavior, this thesis aimed to look more closely at ADHD symptomatology and related physiology 
(part 1) and subsequently whether it is possible to train brain functioning enduringly to improve 
behavior and cognition with neurofeedback in ADHD patients (part 2). 
 
Two of a kind: ADHD and ASD+ADHD 
The first part of this thesis indicates that whereas there is behavioral overlap and overlap in cardiac 
activity between adolescents with ADHD and adolescents with combined ASD+ADHD, there are 
differences in brain activity. These differences are of importance, because this may indicate that 
treatments developed for ADHD work differently in adolescents with ASD+ADHD compared to 
adolescents with ADHD. 
The assumption for the cardiac reactivity was that ADHD is associated with signs of increased 
parasympathetic activation, whereas ASD is associated with signs of increased sympathetic activation. 
Accordingly, it was expected that adolescents with ASD+ADHD would show signs of more 
sympathetic and less parasympathetic activation than ADHD adolescents. However, cardiac activity 
and task-related cardiac adaptation were similar for the adolescents with ASD+ADHD and the 
adolescents with ADHD. A possible rational for these findings is that there are psychophysiological 
constructs related to the ADHD symptomatology, responsible for the overlap in cardiac activity 
between ADHD and ASD+ADHD.  
Interestingly, regarding brain functioning, there was some overlap between ADHD and 
ASD+ADHD adolescent, but some differences emerged as well. The most prominent finding was that 
adolescents with ADHD had increased levels of theta activity, with their eyes open and while 
performing a task compared to adolescents with combined ASD+ADHD. Furthermore, for 
adolescents with ADHD, theta in resting condition with eyes open was negatively related to attention 
task performance. In contrast, adolescents with combined ASD+ADHD did not show this relation. 
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Elevated theta activity is one of the most robust finding in ADHD (Cortese, 2012; Loo & Makeig, 
2012; Snyder & Hall, 2006). Considering theta (4-7 Hz) has been negatively related to vigilance 
(Banaschewski & Brandeis, 2007), this may indicate that elevated theta and decreased vigilance are 
better explanations for attentional problems in adolescents with ADHD than in adolescents with 
ASD+ADHD. The results suggest that attentional problems in ASD+ADHD may result from other 
brain dysfunctions, such as abnormal neuronal connectivity (Billeci et al., 2013; Coben, Clarke, 
Hudspeth, & Barry, 2008) and top-down processing problems (Gomot & Wicker, 2012), rather than 
from frontocentral underarousal per se. The ERP outcomes point in a similar way to processing 
problems in ASD. Stimulant-free adolescents with ASD+ADHD had a smaller N2 to target stimuli, 
than stimulant-medicated adolescents with ASD+ADHD. There was no such difference between 
stimulant-free and stimulant-medicated adolescents with ADHD. The smaller N2 to target stimuli 
hints that the stimulant-free adolescents with combined ASD and ADHD have more problems with 
stimuli discrimination.  
It was expected that stimulant medication partly ‘normalizes’ psychophysiology in ADHD. 
Consequently, the expectation was that the stimulant-medicated adolescents would show less 
neurocognitive and physiological signs usually associated with ADHD than the stimulant-free 
adolescents. Indeed, stimulant-medicated adolescents showed faster reaction times and reaction time 
was less variable than in stimulant-free adolescents, irrespective of diagnosis. In addition, stimulant-
medicated adolescents showed in the cardiac measures a higher LF/HF ratio in resting condition 
compared to stimulant-free adolescents. The LF/HF ratio during performance of an auditory oddball 
task however did not differ in respect to stimulant use. Accordingly, adaptation of LF/HF ratio, that is 
the increase of LF/HF ratio typically seen from rest condition to task condition, was decreased. 
Whereas decreased parasympathetic activation is generally viewed as a shift to normalization, a 
decrease in autonomic modulation could be less favorable. It remains unclear what the implications are 
for everyday life when stimulant-medicated youngsters are less able to shift physiologically between 
rest conditions and demanding cognitive activities. 
It is remarkable that stimulant-medicated and stimulant-free adolescents did not differ in the 
amount of theta or beta activity. Decreased theta and increased beta after stimulant medication use is 
typically seen in youngsters with ADHD after stimulant medication use (Clarke, Barry, Bond, 
McCarthy, & Selikowitz, 2002; Clarke et al., 2003; Hermens et al., 2005; Loo & Barkley, 2005). 
However, although stimulant medication partly normalizes theta and beta power, children with ADHD 
do not reach similar theta and beta levels as TD children (Clarke et al., 2002; Clarke et al., 2003). 
Baseline differences in age between adolescents on and off stimulant medication in our sample may 
have contributed to the lack of effects of stimulant medication: the stimulant-free adolescents were, on 
average, older than stimulant-medicated adolescents. Since aging (Segalowitz, Santesso, & Jetha, 2010) 
as well as using stimulant medication (Clarke et al., 2002; Clarke et al., 2003; Hermens et al., 2005; Loo 
& Barkley, 2005) results in decreased theta power, the two effects may have cancelled each other out. 
In line with the review by Segalowitz et al. (2010) the current study found a clear maturation effect, 
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with older adolescents displaying lower absolute power across all frequency bands, particularly in the 
posterior region, and increased relative beta.  
Similarly, stimulant medication appears to regulate ERP activity, with increased N2 (Pliszka et 
al., 2007) and P3 (Groom et al., 2010; Hermens et al., 2005) amplitudes after stimulant medication use 
in adolescents with ADHD. In line with these outcomes, we found a larger N2 amplitude in stimulant-
medicated than in stimulant-free adolescents with combined ASD+ADHD. Surprisingly, there was no 
such difference for stimulant medication use in adolescents with ADHD. Furthermore, like the study 
of Groen et al. (2008), we did not find larger P3 amplitudes for stimulant-medicated compared to 
stimulant-free adolescents.  Note that whereas the studies that found differences in P3 amplitude 
looked at youngsters with ADHD on and off stimulant medication in a within subject design (Groom 
et al., 2010; Hermens et al., 2005), whereas our study and the study of Groen et al. (2008) analyzed 
differences between subjects. By controlling for individual differences with a within subject design 
differences of stimulant medication use might be better demonstrable than differences between two 
separate patient groups. For the peak latencies we did find differences between stimulant-medicated 
and stimulant-free adolescents dependent on the kind of diagnosis. The N1 peak latency was longer in 
stimulant-medicated adolescents compared to stimulant-free adolescents with combined 
ASD+ADHD. An opposite pattern was observed for the adolescents with ADHD, where N1 peak 
latency was shorter in stimulant-medicated than in stimulant-free adolescents. Shorter latencies are 
generally seen as an indication of more efficient information processing. Nonetheless, the results also 
showed that prolonged central N1 latency was associated with larger N1 amplitudes. In addition, long 
N1 latency was related with less reaction time variability in adolescents with combined ASD+ADHD. 
These results suggest that the later N1 peak is related with a more consistent reaction to target stimuli, 
especially for adolescents with combined ASD+ADHD.  
 The studies in the first part of this thesis demonstrated differences between adolescents with 
ADHD and combined ASD+ADHD. The differences were found in a clinical sample of adolescents 
recruited with clinical DSM-IV ADHD symptoms. Stimulant medication use was allowed and 
continued on the assessment days. Accordingly, the sample resembles clinical practice but is also 
heterogeneous in nature with respect to diagnosis (ADHD or combined ASD+ADHD), stimulant 
medication use and age. Further systematic research on the psychophysiological aspects of ADHD and 
ASD+ADHD and their implications is therefore warranted. Replication of these psychophysiological 
results with a larger sample size are needed in a randomized controlled trial, ideally with a controlled 
stimulant medication titration trial including physiological baseline measures with stimulant-free 
adolescents with ADHD, ASD+ADHD, ASD. Such a titration trial would control for the baseline 
differences in stimulant medication use and age that were observed in the current study. Adolescents 
continued stimulant medication on the day of assessment as described by their physician. Accordingly, 
initial differences in stimulant medication use could not be controlled for. In addition, the stimulant-
medicated adolescents in this study were on average younger than the stimulant-free adolescents. 
Although we controlled for age statistically, it is possible that stimulant medication use and maturation 
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may affect psychophysiological measures similarly. Furthermore, the diagnostic assignments in this 
study were based on clinician’s decisions using DSM-IV (American Psychiatric Association, 2000) 
criteria; whilst this increased the ecological validity of the study, information about specific diagnostic 
aspects of ASD were not available. Including diagnostic interviews such as the Autism Diagnostic 
Interview (Lord, Rutter, & Le Couteur, 1994) or the Autism Diagnostic Observation Schedule (Lord et 
al., 1989) in future research, could give more detailed information about specific characteristics of 
ASD. Moreover, inclusion of a control group of typically developing adolescents would make it 
possible to determine whether psychophysiological patterns in the diagnostic groups differ from those 
of TD adolescents.  
In conclusion, whereas behavioral and autonomic physiological measures seem to overlap 
between adolescents with ADHD and combined ASD+ADHD, the results described in the first part 
of this thesis indicate that there might be differences in underlying brain mechanisms related to 
ADHD symptomatology. Clinical implications of these physiological differences in reaction to 
stimulant medication use should be further investigated in larger groups of participants and more strict 
research designs to provide targets for optimizing treatment of ADHD in ASD. 
 
Neurofeedback: ingredients of effectiveness 
In the second part of the thesis we investigated the additional value of neurofeedback to treatment as 
usual to reduce ADHD symptoms and enhance neurocognitive functioning for adolescents with 
ADHD and comorbid disorders. No additional direct or long-term effects of neurofeedback over 
treatment as usual were found to improve behavior or neurocognitive functioning in adolescents with 
ADHD. Accordingly, we concluded that the results do not support implementation of theta/SMR 
neurofeedback as additional treatment to enduringly improve behavior or enhance neurocognitive 
functioning for adolescents with ADHD and comorbid disorders in clinical practice. 
 A meta-analysis concluded in 2009 that neurofeedback for the treatment of ADHD 
“efficacious and specific” is (Arns, de Ridder, Strehl, Breteler, & Coenen, 2009). The estimated effect 
sizes vary between medium for hyperactivity and large for inattention and impulsivity reduction (Arns 
et al., 2009). In the years thereafter, this non-pharmacological intervention for ADHD received 
increasing interest. This resulted in several reviews in 2012, indicating that neurofeedback is a 
“probably effective” treatment for ADHD (Gevensleben, Rothenberger, Moll, & Heinrich, 2012; 
Lofthouse et al., 2012; Moriyama et al., 2012). Another review was less positive with regard to 
theta/beta neurofeedback, stating that “The state of the published, peer reviewed literature on 
theta/beta training, as it currently stands, does not support theta/beta training even as an adjunct 
treatment” (Loo & Makeig, 2012). A new meta-analysis in 2013 showed that effectiveness of 
neurofeedback in improving behavior in ADHD decreased to non-significant levels in the case of 
probably blinded assessment (Sonuga-Barke et al., 2013). Similarly, results of a systematic review did 
not support the effectiveness of neurofeedback in improving neurocognitive functioning in ADHD 
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(Vollebregt, van Dongen-Boomsma, Buitelaar, & Slaats-Willemse, 2013). Consequently, effectiveness 
estimations of neurofeedback thus far range from “efficacious and specific” to not effective.  
Considering the wide range of effectiveness estimations within the last four years, it is 
important to ask how these differences originated. Studies into the effectiveness of neurofeedback for 
the treatment of ADHD have been hampered by many methodological problems. Not only with 
regard to the designs of the studies that vary greatly, but also with regard to the proposed 
neurofeedback training protocol. To narrow the focus of the current discussion, only studies that 
applied frequency -mainly theta/beta- training protocols to improve functioning in patients with 
ADHD are discussed in more detail.  
 The first non-randomized studies (e.g. Fuchs, Birbaumer, Lutzenberger, Gruzelier, & Kaiser, 
2003; Monastra, Monastra, & George, 2002) all showed positive effects for neurofeedback. However, 
these non-randomized studies could not control for non-specific effects. For example, parents with a 
preference for an intensive non-pharmacological treatment like neurofeedback, might also be more 
likely to encourage changes of the child with ADHD in daily life. Typical neurofeedback training 
consists of 20 to 40 sessions. Those parents able to bring their child to the therapy for an extended 
period of time, multiple times a week, might overall be better able to give their child a more structured 
and predictable surrounding. In addition, the amount of time invested in the treatment by the child, 
therapist and parents, might make parents more inclined to see and report positive changes in the 
behavior of their child. Besides various non-specific effects of parent-informed behavioral assessment, 
maturation and practice effects are likely to result in improved performance on neurocognitive tests in 
children.  
 To control for non-specific investment and preference effects, studies with a randomized 
controlled trial (RCT) design were implemented. Parents were no longer able to choose a treatment of 
their preference, as in the aforementioned studies. Rather, parents and children could choose to 
participate in a study, after which they were randomized to a specific treatment. In one of the first 
large RCT studies, randomized stimulant-free children received either neurofeedback (n=59) or 
computerized attention training (n=35) (Gevensleben, Holl, Albrecht, Vogel, et al., 2009). The children 
received an equal number of training sessions irrespective of treatment allocation. Accordingly, the 
study simultaneously prevented a bias resulting of investment and/or preferences of the parents. 
Furthermore, the children receiving neurofeedback improved more in behavior as reported by parents 
and teacher than the children receiving computerized attention training (Gevensleben, Holl, Albrecht, 
Vogel, et al., 2009). Six-months post-treatment, parents still reported better behavior for the children 
who had received neurofeedback than the children who had received the attention training 
(Gevensleben et al., 2010). Unfortunately, only 70% of the teacher reports was received at follow-up 
and therefore not analyzed (Gevensleben et al., 2010). A limitation for extrapolating these results to 
clinical practice is that it is only applicable to stimulant-free children (Gevensleben et al., 2010; 
Gevensleben, Holl, Albrecht, Vogel, et al., 2009). In case stimulant medication use was indicated, 
children were excluded from trial participation or follow-up analysis. In this way the study introduced a 
 173 
selection bias by excluding children with probably more severe ADHD at the start of the study, and at 
post-treatment, excluding children for whom ADHD symptoms became more severe.  
 Other RCT studies tried to overcome this problem of generalizability by comparing 
neurofeedback with stimulant medication use in children with ADHD. The largest of these studies 
showed similar improvements in attention as reported by parents for neurofeedback (n=30), stimulant 
medication (n=31) or combined neurofeedback and stimulant medication (n=30) (Duric, Assmus, 
Gundersen, & Elgen, 2012). Comparable, a smaller study with an RCT design also showed similar 
improvements in attention for neurofeedback (n=12) and stimulant medication (n=11) (Meisel, 
Servera, Garcia-Banda, Cardo, & Moreno, 2013). In contrast, there is another study showing 
improvement in behavior in stimulant-medicated youngsters (n=15), but not in those receiving 
neurofeedback (n=14). Although these three studies look similar in study design, a major difference 
includes the applied medication protocol. The two studies that show comparable improvements for 
neurofeedback and stimulant medications use, applied medication titration with the daily dosage 
depending on weight, with 1 mg per kg (Duric et al., 2012; Meisel et al., 2013). In contrast, the study 
that found stimulant medication to be superior to neurofeedback, individualized medication use by 
incorporating a double-blind placebo controlled medication trial (Ogrim & Hestad, 2013). Titrating 
stimulant medication based on body weight is applied often in research. However, several studies 
criticize this way of stimulant titration in ADHD (Greenhill et al., 2002; Rapport & Denney, 1997). 
Accordingly, it might be that stimulant medication did not reach an optimal effect in the first two 
studies. Further research, comparing neurofeedback with stimulant medication, titrated with a stepwise 
double blind placebo controlled protocol is essential to see if neurofeedback is able to serve as an 
alternative for stimulant medication.  
 To date, double-blinded studies fail to find additional value of neurofeedback over sham-
neurofeedback on behavioral outcomes in children with ADHD (Arnold et al., 2013; Perreau-Linck, 
Lessard, Levesque, & Beauregard, 2010; van Dongen-Boomsma, Vollebregt, Slaats-Willemse, & 
Buitelaar, 2013). In addition, none of the double-blinded studies found additional improvements on 
neurocognitive measures for neurofeedback over sham-neurofeedback in children with ADHD 
(Arnold et al., 2013; Vollebregt et al., 2013) and healthy students with ADHD features (Logemann, 
Lansbergen, Van Os, Bocker, & Kenemans, 2010). The results of these blinded studies underline that 
effects found in non-blinded studies might also resemble non-specific effects, instead of specific 
effects of neurofeedback.  
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 Neurofeedback protocols used in RCT studies have been debated. For example, it is 
hypothesized that automatic thresholds might be less effective than manual adapted threshold 
(Lansbergen, van Dongen-Boomsma, Buitelaar, & Slaats-Willemse, 2011). Nevertheless, comparing 
neurofeedback with automatic versus manual adapted thresholds did not result in differences on 
behavioral outcomes (van Dongen-Boomsma et al., 2013). Furthermore, it is assumed that explicit 
learning strategies are necessary for neurofeedback to be effective (Lansbergen et al., 2011). However, 
introducing more active learning strategies, did not result in more positive outcomes for 
neurofeedback in one study (van Dongen-Boomsma et al., 2013). Another consideration is the way in 
which feedback is provided to the youngsters: movies (i.e. Duric et al., 2012; Ogrim & Hestad, 2013; 
van Dongen-Boomsma et al., 2013) or complex computer game graphics (i.e. Arnold et al., 2013) 
might distract from the actual neurofeedback training. Comparing neurofeedback with simple graphics 
(n=11) to attractive computer games (n=11) did not confirm this theory (Palsson, Pope, Ball, Turner, 
& Nevin, 2001, March). The current study used simple graphics as feedback (see  Figure 1). Despite 
graphical differences between our study and Duric et al. (2012), which used movies or video games, 
both studies failed to find evidence for additional value of neurofeedback. 
 EEG frequency training aims to inhibit or reinforce particular frequency bands. Different 
protocols have been applied across different studies. The “Lubar” protocol trains to inhibit theta and 
reinforce SMR or beta activity, in a relaxed but focused state (Lubar, 2003; i.e. the current study). 
Accordingly, controlling for muscle tension, which is mostly reflected in the higher frequency bands, is 
important. Other studies trained theta/beta while correcting for eye movements (i.e. Gevensleben, 
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Holl, Albrecht, Vogel, et al., 2009; note that theta/beta training was comined with training of slow 
cortical potentials). Finally, some studies used individualized training protocols (i.e. Lansbergen et al., 
2011) that mostly amounted to training of theta/SMR (i.e. van Dongen-Boomsma et al., 2013). It 
might be that effectiveness of neurofeedback depends on the applied training protocol. However, at 
this moment training protocols are used alternately in clinical practice as well as in research. There is 
no consensus on the exact kind of protocol to apply for the treatment of ADHD. Therefore, 
additional knowledge about specific working mechanisms of neurofeedback on the brain is necessary 
before neurofeedback protocols can be adapted appropriately for the treatment of psychiatric 
disorders. 
 Neurofeedback intends to train EEG-activity. Accordingly, it is remarkable that robust 
changes in EEG-activity have not yet been found. In the study of Gevensleben, Holl, Albrecht, 
Schlamp, et al. (2009), the authors noted a linear decrease from frontal to parietal in the difference 
between pre and post theta in the neurofeedback group, whereas the attention training group did not 
show such an effect. Notwithstanding the changes in patterns of difference scores, the study did not 
report on significant decreased theta from pre to post training for specific electrode positions. 
Especially, significant decreased theta at Cz would have been expected since the theta/beta protocol 
with electrode placement on Cz was applied. In addition, no differences between treatment allocations 
in beta were found, whereas considering the protocol, increased beta was expected for the children 
receiving neurofeedback. In contrast, beta decreased over time, mainly frontal, as a function of age and 
intelligence, irrespective of received treatment. Similarly, another neurofeedback study that looked at 
post-treatment changes in frequency bands did not demonstrate significant changes compared to the 
pre-treatment EEG (Kropotov et al., 2007). It can be reasoned that changes in brain activity are of 
minor importance compared to the aim of neurofeedback to achieve behavioral improvement. 
However, neurofeedback is based on the assumption that ADHD symptoms originate from under or 
over activity in specific brain areas. This over or under activity is measured by an EEG recording in 
resting conditions with eyes open and eyes closed and this recording is used to determine the 
applicable training protocol. Consequently, it seems reasonable to expect changes in EEG activity after 
the training. An explanation for the absence of significant EEG changes from pre- to post-treatment is 
provided by the fact that these EEG recordings take place during resting conditions (Arns et al., 2009; 
Gevensleben, Holl, Albrecht, Schlamp, et al., 2009). EEG recordings in a resting state seem to 
contradict with the assumption that neurofeedback intends to train the brain to be more flexible and 
better able to regulate activation states during task performance. Potentially, changes in brain activation 
could be most pronounced during task performance. Indeed, during the performance of an attention 
task, differences were found in event related potentials (Kropotov et al., 2007; Wangler et al., 2011). At 
this moment, other large RCT studies have not (yet) looked at changes in frequency bands after the 
intervention period. Therefore, exploring differences within frequency bands between intervention 
conditions is warranted to determine whether it is possible to train frequency bands in youngsters with 
ADHD. 
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 Stimulant medication use and comorbidity of ASD did not affect the outcomes in our study. 
In the first part of this thesis, differences in stimulant medication and diagnoses were described. We 
saw that during resting with eyes open and during task performance the adolescents with ADHD had 
significant more theta than the adolescents with combined ASD+ADHD. Elevated theta and 
decreased beta activity in ADHD (Cortese, 2012; Loo & Makeig, 2012; Snyder & Hall, 2006) is 
associated with decreased vigilance and decreased attention (Banaschewski & Brandeis, 2007), 
respectively. Accordingly, neurofeedback protocols aim to decrease theta and increase beta and 
subsequently improve behavior. Since the adolescents with ASD+ADHD display less theta activity 
than adolescents with ADHD in the first place, improvements in behavior by decreasing theta activity 
(if possible) using neurofeedback would probably be less pronounced in adolescents with 
ASD+ADHD than in adolescents with only ADHD. However, in the current study improvements in 
cognition and behavior were similar for both diagnostic groups. Similarly, stimulant-medicated 
adolescents generally display less theta activity than stimulant-free youngsters with ADHD (Clarke et 
al., 2002; Clarke et al., 2003; Hermens et al., 2005; Loo & Barkley, 2005) and stimulant medication is 
effective in reducing ADHD symptoms (Faraone & Buitelaar, 2010; Greenhill et al., 2001) and 
improving neurocognitive functioning (Coghill et al., 2013) in youngsters with ADHD. Consequently, 
expected improvements with neurofeedback would be smaller in stimulant-medicated than in 
stimulant-free adolescents. The current study, however, did not find such differences in improvement 
for stimulant-medicated and stimulant-free adolescents who had received neurofeedback.  
 The main question of the second part of this thesis was if neurofeedback has additional value 
to treatment as usual in reducing ADHD symptoms in adolescents with ADHD and comorbid 
disorders. The current study found similar improvements in behavior and neurocognitive functioning 
direct after the intervention period and at one-year follow-up, irrespective of received treatment. The 
absence of long-term additional effects of neurofeedback in the current study, combined with the 
absence of specific effects of neurofeedback over sham neurofeedback (Arnold et al., 2013; Perreau-
Linck et al., 2010; van Dongen-Boomsma et al., 2013; Vollebregt et al., 2013) and the intensity of the 
training with a large number (20 to 40) of training sessions (Loo & Makeig, 2012), do not support 
implementation of theta/SMR neurofeedback as treatment for adolescents with ADHD and comorbid 





The main conclusions of this thesis are: 
1. Results suggest differences in underlying brain functioning related to ADHD symptomatology 
between adolescents with ADHD and adolescents with combined ASD+ADHD 
2. Theta/SMR neurofeedback showed no additional effect over treatment as usual on behavior 
or neurocognitive functioning in adolescents with ADHD and comorbid disorders.  
Taken together the studies in this thesis suggest that more research is needed into the 
psychophysiology underlying ADHD symptomatology in combined ASD+ADHD as well as ADHD. 
Understanding of psychophysiological mechanisms underlying ADHD symptomatology might help to 
develop or improve interventions for specific diagnostic groups such as adolescents with combined 
ASD+ADHD.  
 Neurofeedback has been proposed as an intervention that is potentially effective in reducing 
ADHD symptomatology. However, in our study, theta/SMR neurofeedback showed no additional 
effects over treatment as usual on behavior or neurocognitive functioning. As such, the absence of 
immediate or long-term additional effects of neurofeedback does not support implementation of 
theta/SMR neurofeedback as treatment for adolescents with ADHD and comorbid disorders in 
clinical practice. These results denote that using knowledge of presumed psychophysiological 
correlates of ADHD symptomatology for development of interventions to enduringly induce clinical 
relevant behavioral improvements is an even larger challenge than the arduous search for 
psychophysiological correlates of ADHD as such.   
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INTRODUCTIE 
Aandachtsproblemen behoren tot de kernsymptomen zowel bij adolescenten met een 
aandachtstekortstoornis met hyperactiviteit (Attention Deficit /Hyperactivity Disorder; ADHD), als 
bij adolescenten met een combinatie van autisme spectrum stoornissen (ASS) en ADHD 
(ASS+ADHD). Het is nog niet bekend tot op welke hoogte psychofysiologische constructen die 
eerder gerelateerd werden aan aandachtsproblemen op dezelfde manier voorkomen bij jongeren met 
ADHD en bij jongeren met een combinatie van ASS+ADHD. Het is daardoor onduidelijk of huidige 
behandelingen, die effectief zijn gebleken in het verminderen van ADHD-symptomen bij jongeren met 
ADHD, mogelijk een ander effect hebben op psychofysiologische parameters bij jongeren met 
ASS+ADHD en als gevolg daarvan eventueel minder effectief zijn.  
Neurofeedback wordt gezien als een interventie die potentieel effectief is in het verminderen 
van ADHD-symptomen. Neurofeedback heeft als doel om hersenactiviteit aan te passen door 
operante conditionering en gelijktijdig ADHD-symptomen te verminderen (in het bijzonder het 
verbeteren van aandacht). Huidige resultaten zijn echter inconsistent en grote gerandomiseerde 
gecontroleerde studies zijn schaars. Daarnaast is nooit specifiek onderzocht of neurofeedback 
toegevoegde waarde heeft bovenop bestaande standaardtherapieën (in het Engels wel ‘care as 
usual’genoemd) voor adolescenten met ADHD en bijkomende stoornissen. Dit proefschrift bestaat 
daarom uit twee delen. Het eerste deel richt zich op de psychofysiologische overlap en verschillen 
tussen adolescenten met ADHD en gecombineerde ASS+ADHD. Het tweede deel richt zich op de 
vraag of het mogelijk is met neurofeedback, gegeven bovenop de al geboden standaardbehandeling, 
het gedrag en neurocognitief functioneren te verbeteren bij deze adolescenten.  
 
ADHD en Autisme Spectrum Stoornissen 
In de 18de eeuw was Sir Alexander Crichton de eerste die een stoornis beschreef die lijkt op de huidige 
aandachtstekortstoornis met hyperactiviteit (ADHD) (Lange, Reichl, Lange, Tucha, & Tucha, 2010). 
Heden ten dage wordt  ADHD gedefinieerd als een frequent voorkomend patroon van 
aandachtsproblemen en/of hyperactiviteit en impulsiviteitssymptomen welke interfereren met bij de 
ontwikkeling passende vaardigheden in het sociale, academische of werkzame leven (American 
Psychiatric Association, 2013). ADHD is de meest voorkomende neuropsychiatrische 
ontwikkelingsstoornis met een wereldwijde prevalentie van rond de 5% (Polanczyk, de Lima, Horta, 
Biederman, & Rohde, 2007; Willcutt, 2012). Bijkomende neuropsychiatrische stoornissen zoals 
leerstoornissen, gedragsstoornissen, depressie en angst worden vaker gezien bij jongeren met ADHD 
dan bij jongeren zonder ADHD (Larson, Russ, Kahn, & Halfon, 2011). Bij autisme spectrum 
stoornissen (ASS), welke gekarakteriseerd worden door aanhoudende problemen in de sociale 
interactie, communicatie en/of het voorkomen van stereotype gedrag, interesses en activiteiten 
(American Psychiatric Association, 2013), variëren de schattingen van gelijktijdig voorkomen van 
ADHD tussen 30% tot 78% (Gjevik, Eldevik, Fjaeran-Granum, & Sponheim, 2011; Lee & Ousley, 
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2006; Simonoff et al., 2008). Ondanks de observatie dat ADHD vaak gelijktijdig met ASS lijkt voor te 
komen, kon ADHD tot voor kort volgens het psychiatrische classificatiehandboek de DSM-IV 
(American Psychiatric Association 2000) niet geclassificeerd worden als een bijkomende stoornis naast 
ASS. De ADHD-symptomen werden gezien als onderdeel van ASS in plaats van als een bijkomende 
stoornis. Om te voorkomen dat patiënten met ASS en ADHD-symptomen niet in aanmerking komen 
voor mogelijke effectieve behandeling van ADHD (American Psychiatric Association, 2012), stellen de 
nieuwere classificatierichtlijnen in de DSM-V nu dat wanneer aan zowel de criteria van ASS als aan de 
criteria van ADHD wordt voldaan, beide diagnoses gesteld behoren te worden (American Psychiatric 
Association, 2013).  
Op dit moment bestaat de standaardbehandeling voor ADHD-symptomen uit medicatie 
en/of gedragstherapie. Bewijs voor de effectiviteit van niet-farmacologische interventies zoals 
gedragstherapie is beperkt (Sonuga-Barke et al., 2013). Gedragstherapieën lijken effectief in het 
verminderen van ADHD-problemen wanneer ze geëvalueerd worden door ouders of andere mensen 
die zich bewust zijn van de gegeven behandeling (Sonuga-Barke et al., 2013). De effecten lijken echter 
te verdwijnen wanneer beoordeeld door mensen die niet op de hoogte zijn van de gegeven behandeling 
(Sonuga-Barke et al., 2013). Stimulantia zijn effectief in het verminderen van ADHD-klachten bij 
jongeren met ADHD (Faraone & Buitelaar, 2010; Greenhill et al., 2001). Voor de behandeling van 
ADHD bij jongeren met een combinatie van ADHD en ASS zijn stimulantia effectief, maar mogelijk 
in mindere mate (Cortese, Castelnau, Morcillo, Roux, & Bonnet-Brilhault, 2012; Research Units on 
Pediatric Psychopharmacology (RUPP) Autism Network, 2005). Daarbij komt dat voorgaande studies 
geen uitsluitsel geven of psychofysiologische correlaten van ADHD verschillend zijn in ASS+ADHD 
en ADHD. Als gevolg hiervan is het niet bekend of stimulantia, welke effectief zijn in de behandeling 
van ADHD (Faraone & Buitelaar, 2010; Greenhill et al., 2001), resulteren in overeenkomstige 
psychofysiologische effecten in gecombineerde ASS+ADHD. Verschillen in psychofysiologie tussen 
ADHD en ASS+ADHD kunnen een indicatie geven of stimulantia mogelijk een andere uitwerking 
hebben in ASS+ADHD en kunnen daardoor mogelijk helpen te verklaren waarom stimulantia minder 
effectief lijken te zijn in ASS+ADHD dan in ADHD.  
 Hoewel stimulantia effectief zijn in het verminderen van ADHD-symptomen bij een groot 
deel van de jongeren met ADHD (Cortese et al., 2012; Faraone & Buitelaar, 2010; Greenhill et al., 
2001; RUPP, 2005), worden dosis-afhankelijke milde bijwerkingen van stimulantia, zoals verminderde 
eetlust, moeite met inslapen en hoofdpijn relatief vaak gerapporteerd (Cortese et al., 2012; Graham & 
Coghill, 2008; RUPP, 2005). Daarbij komt dat een groot deel van de adolescenten boven de leeftijd 
van 15 jaar op eigen initiatief stopt met het nemen van stimulantia, ondanks het aanhoudend karakter 
van de stoornis (Zetterqvist, Asherson, Halldner, Langstrom, & Larsson, 2012). Het ontwikkelen van 
nieuwe aanvullende interventies op de huidige standaard toegepaste behandelingen om ADHD-
symptomen verder blijvend te verminderen, is daarom van belang. In dit opzicht wordt neurofeedback 
gezien als een mogelijk effectieve interventie om ADHD-symptomen te verminderen door het 
aanpassen van de hersenactiviteit van jongeren met ADHD (Lofthouse, Arnold, Hersch, Hurt, & 
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DeBeus, 2012; Moriyama et al., 2012) en ASS (Holtmann et al., 2011). Gezien de assumptie dat 
werkingsmechanismen van interventies zoals stimulantia en neurofeedback gebaseerd zijn op het 
aanpassen van afwijkende fysiologische patronen, is het tevens belangrijk om goed te doorgronden hoe 
fysiologie is gerelateerd aan ADHD-symptomen.  
 
Psychofysiologie en ADHD-symptomen  
Fysiologische maten zijn in eerdere studies gerelateerd aan ADHD-symptomen. Reactiviteit van de 
hartfrequentie is bijvoorbeeld gerelateerd aan verschillende psychologische processen, zoals aandacht, 
inhibitie van gedrag en sociale betrokkenheid (Porges, 2007) en daarmee aan hoofdsymptomen van 
ADHD. Meer specifiek worden indicaties gezien voor verhoogde parasympatische activiteit met een 
tragere hartslag (Negrao, Bipath, van der Westhuizen, & Viljoen, 2011) en meer variabiliteit in het 
hartritme (Borger & van der Meere, 2000; Borger et al., 1999; Negrao et al., 2011) bij jongeren met 
ADHD vergeleken met jongeren zonder ADHD. Verschillen in hersenactiviteit worden gezien in 
elektro-encefalogram (EEG) power spectra in ADHD, die een verhoging van theta activiteit (4-7 Hz; 
golven per seconde; Cortese, 2012; Loo & Makeig, 2012; Snyder & Hall, 2006), en in mindere mate, 
verlaagde beta activiteit (13-30 Hz; Cortese, 2012; Snyder & Hall, 2006) laten zien. Op gedragsmatig 
niveau is verhoogde theta activiteit gerelateerd aan verminderde waakzaamheid en weinig beta activiteit 
gerelateerd aan minder aandacht (Banaschewski & Brandeis, 2007). Zodoende onderschrijven deze 
bevindingen veronderstelde corticale onderactiviteit bij ADHD. Afwijkende, aan stimuli gerelateerde 
hersenactiviteit, ofwel event-related potentials (ERPs), worden ook waargenomen bij jongeren met 
ADHD (Du et al., 2006; Groom et al., 2010; Hermens et al., 2005; Johnstone, Barry, & Clarke, 2013; 
Pliszka et al., 2007). In vergelijking met normaal ontwikkelende jongeren, worden bij jongeren met 
ADHD kleinere amplitudes gezien in ERP-componenten die gerelateerd zijn aan aandachtsprocessen 
(Barry, Johnstone, & Clarke, 2003; Johnstone et al., 2013), zoals de N2, die geassocieerd is met 
oriëntatie en discriminatie van de stimulus (Näätänen, Simpson, & Loveless, 1982), en de P3, die 
geassocieerd is met selectieve aandacht en (werk)geheugen capaciteit (Polich & Herbst, 2000). Alles bij 
elkaar genomen lijkt ADHD samen te gaan met verminderde corticale activatieniveaus, die terug te 
zien zijn in de verschillende fysiologische maten.  
Stimulantia welke effectief zijn in het verminderen van ADHD-symptomen van jongeren met 
ADHD (Faraone & Buitelaar, 2010; Greenhill et al., 2001), blijken ook de eerder genoemde afwijkende 
fysiologische maten gedeeltelijk te ‘normaliseren’. Stimulantia verhogen de hartslag (Hammerness, 
Perrin, Shelley-Abrahamson, & Wilens, 2011), en het hartritme van jongeren met ADHD die 
stimulantia gebruiken lijkt meer op die van normaal ontwikkelende jongeren (Negrao et al., 2011). 
Daarnaast verlagen stimulantia de in ADHD waargenomen verhoogde theta activiteit en verhogen 
tegelijkertijd de beta activiteit (Clarke, Barry, Bond, McCarthy, & Selikowitz, 2002; Clarke et al., 2003; 
Hermens et al., 2005; Loo & Barkley, 2005). Vergelijkbaar lijken stimulantia ERP-componenten te 
beïnvloeden met een vergroting van N2 (Pliszka et al., 2007) en P3 (Groom et al., 2010; Hermens et 
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al., 2005) amplitudes na gebruik van stimulantia door jongeren met ADHD. In het algemeen lijkt het er 
dus op dat stimulantiagebruik door jongeren met ADHD zorgt voor fysiologische waarden die meer 
overeenkomen met fysiologische waarden van normaal ontwikkelende jongeren, hoewel ze geen 
identieke activiteitsniveaus laten zien.  
Zoals eerder aangegeven, is het niet duidelijk of fysiologische patronen bij jongeren met ASS 
en ADHD overlappen met fysiologische patronen zoals waargenomen bij ADHD. Als fysiologische 
waarden overlappen, dan kan dit een indicatie zijn dat interventies die ADHD-symptomen 
verminderen, op eenzelfde manier werken bij jongeren met ASS+ADHD. Als fysiologische waarden 
welke gerelateerd zijn aan ADHD-symptomen echter anders zijn bij jongeren met een combinatie van 
ASS+ADHD, kan dit betekenen dat ADHD interventies mogelijk anders werken of minder effectief 
zijn voor jongeren met ASS+ADHD.  
  
 Neurofeedback: een overzicht 
Neurofeedback is een interventie welke hersenactiviteit poogt aan te passen, door de patiënt feedback 
te geven over zijn eigen EEG activiteit op dat moment. Neurofeedback als een interventie voor 
ADHD is oorspronkelijk afgeleid van onderzoek met katten. In de zestiger jaren trainden Sterman and 
Wyrwicka (1967) hongerige katten om gedrag te onderdrukken en daarmee eten te verdienen. Op het 
moment dat het gedrag werd onderdrukt, werd in het EEG boven de sensorimotor cortex (ongeveer 
op het midden van het hoofd) meer activiteit waargenomen met een frequentie van 12 tot 20 golven 
per seconde (12-20 Hz). De activiteit werd daarom sensorimotor ritme (SMR) genoemd (Roth, 
Sterman, & Clemente, 1967; Sterman & Wyrwicka, 1967). Door de katten te trainen om gedrag te 
onderdrukken, werd zodoende indirect een verhoging in SMR activiteit, met name tussen de 12 tot 
16Hz, getraind (Roth et al., 1967). In een nieuw experiment werden katten niet getraind om gedrag te 
onderdrukken, maar kregen de hongerige katten enkel eten wanneer het EEG meer SMR activiteit 
vertoonde (Sterman, Wyrwicka, & Roth, 1969). Op deze manier probeerden Sterman en collega’s 
(1969) om SMR activiteit meer direct te trainen, in plaats van via het trainen van inhibitie. Merk op dat 
de katten gelijktijdig met de SMR activiteit typisch aan inhibitie gerelateerde houdingen gingen 
vertonen om aan eten te komen. In een daaropvolgend experiment werden drie katten, die getraind 
waren om SMR activiteit te vertonen in het EEG, samen met drie niet getrainde katten vergiftigd met 
monomethylhydrazine in opdracht van de NASA naar de toxische effecten van raketbrandstof 
(Sterman, LoPresti, & Fairchild, 1969). In vergelijking met de niet getrainde katten was er meer 
monomethylhydrazine nodig om epileptische activiteit op te wekken in de op SMR getrainde katten. 
Hieruit werd geconcludeerd dat SMR training protectieve waarde heeft. Hierop volgend werd de 
hypothese gepostuleerd dat het wellicht ook mogelijk is om hersenactiviteit te reguleren door 
opperante conditionering bij mensen.  
Denkend aan de mogelijke protectieve eigenschappen werden de eerste experimenten met 
SMR training met epileptische patiënten uitgevoerd (Sterman & Friar, 1972; Sterman, Macdonald, & 
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Stone, 1974). Na langdurige (meer dan twee of drie maanden) biofeedback training van de SMR 
activiteit, lieten de patiënten een vermindering van epileptische activiteit en meer SMR activiteit zien 
dan voor de training (Sterman et al., 1974). Bij elkaar genomen indiceerde de resultaten dat SMR 
activiteit (12-16Hz) gerelateerd is aan corticale inhibitie (Roth et al., 1967; Sterman & Wyrwicka, 1967; 
Sterman, Wyrwicka, et al., 1969) en dat het mogelijk is het te trainen bij mensen (Sterman & Friar, 
1972; Sterman et al., 1974). Overeenkomstig hiermee redeneerde Lubar en Shouse (1976) dat training 
met het doel SMR activiteit te verhogen ook inhibitieproblemen kan verminderen in kinderen met 
ADHD. De SMR training werd gecombineerd met verlagen van theta activiteit, welke negatief 
gerelateerd is aan waakzaamheid. Na positieve resultaat van een studie met één kind (Lubar  & Shouse, 
1976), volgden andere studies met meer deelnemers. Tot op heden zijn de effecten van neurofeedback 
het meest onderzocht en toegepast bij kinderen met ADHD.  
Het meest toegepaste neurofeedback protocol voor het verminderen van ADHD-symptomen 
is de theta/beta training. Doel van deze training is om minder theta (4-7Hz) en meer SMR (12-15Hz) 
of beta (12-20Hz) activiteit te ontwikkelen (Lofthouse et al., 2012; Loo & Makeig, 2012; Moriyama et 
al., 2012). Dit trainingsprotocol is gebaseerd op de assumptie dat kinderen met ADHD meer theta en 
minder beta activiteit in het EEG laten zien dan normaal ontwikkelende kinderen (Snyder & Hall, 
2006). Theta en beta zijn respectievelijk gekoppeld aan waakzaamheid en aandacht (Banaschewski & 
Brandeis, 2007). De rationale is dan ook dat het verminderen van theta zorgt voor verhoogde 
waakzaamheid en het verhogen van beta de aandacht verbetert.  
In de praktijk begint een neurofeedback trainingsessie met het vastmaken van de elektrodes 
aan de hoofdhuid, meestal op de vertex (Cz; midden op het hoofd) en de referenties mastoïd (achter 
het oor). Het signaal wordt versterkt en naar een computer gestuurd. De speciaal voor neurofeedback 
training ontwikkelende software zet het binnenkomende signaal om en maakt het zichtbaar op de 
monitor van degenen die de neurofeedbacktraining geeft. De trainer kijkt naar het ruwe EEG-signaal 
en naar het signaal uitgesplitst in verschillende frequentiebanden tussen de 4Hz en 32Hz. Verschillende 
frequentiebanden kunnen gelijktijdig getraind worden. In het geval van theta/beta training is de 
software geprogrammeerd met het doel SMR of beta te versterken en theta of andere 
frequentiebanden te onderdrukken. Gebaseerd op het binnenkomende EEG-signaal, worden de 
grenswaarden per frequentieband bepaald. Als het signaal binnen de grenswaarde valt voor elke 
frequentieband, dan wordt het signaal goedgekeurd en wordt de patiënt beloond met positieve 
feedback. Op hetzelfde moment kijkt de patiënt naar een monitor welke een visuele representatie geeft 
van zijn of haar eigen EEG activiteit. De visuele representatie kan worden gegeven in de vorm van een 
film of een spelachtige situatie. In het geval van de film beïnvloedt het EEG signaal de kwaliteit van de 
film –beeld en geluid-. In de spelachtige situatie beïnvloedt de hersenactiviteit de beelden, het geluid en 
de scores. Op deze manier worden de verschillende frequentiebanden versterkt of onderdrukt door 
middel van operante conditionering in ongeveer 20 tot 40 sessies.  
Een speciale vorm van neurofeedback is de training van slow cortical potentials (SCPs) ofwel 
langzame corticale golven. SCPs zijn heel langzame potentialen (<0.1Hz). Een negatieve (naar beneden 
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buigende) hele langzame golf is geassocieerd met verhoogde corticale activiteit en gerelateerd aan meer 
efficiënte reacties in gedrag. Een positieve (omhoog buigende) hele langzame hersengolf is 
geassocieerd met een verlaging van de corticale activiteit en minder efficiënte reacties in gedrag 
(Birbaumer, Elbert, Canavan, & Rockstroh, 1990). Het idee is dat de patiënten leren om controle te 
krijgen over het activiteitsniveau van de hersenen, door zich afwisselend te richten op het verhogen en 
verlagen van de hersenactiviteit. Implementatie van SCP-training komt in de praktijk nog weinig voor, 
gedeeltelijk omdat SCPs moeilijker betrouwbaar te meten zijn.  
 
Effectiviteit van neurofeedback als behandeling bij ADHD  
De eerste niet-gerandomiseerde studies naar de effectiviteit van neurofeedback bij jongeren met 
ADHD vergelijken standaard behandeling, inclusief stimulantia, met neurofeedback, soms als 
aanvullende therapie op de standaard behandeling. In het algemeen lieten deze studies vergelijkbare 
verbeteringen in aandacht zien, zoals gemeten met gedragsvragenlijsten en neurocognitieve testen, 
voor zowel jongeren die neurofeedback training kregen als voor jongeren die stimulantia namen 
(Fuchs, Birbaumer, Lutzenberger, Gruzelier, & Kaiser, 2003; Rossiter & La Vaque, 1995). 
Neurofeedback leek zelfs van aanvullende waarde op het nemen van stimulantia (Monastra, Monastra, 
& George, 2002). Vergeleken met een combinatie van stimulantia en ouder- en school- educatie, lieten 
jongeren die ook neurofeedback kregen meer hersenactiviteit zien, verbeterde aandacht en 
verminderde hyperactief en impulsief gedrag thuis en op school. De studie van Monastra en collega’s 
(2002) toonde dat de jongeren die neurofeedback hadden gekregen, een jaar na de training nog altijd 
minder ADHD-symptomen lieten zien dan de jongeren die alleen de standaard behandeling hadden 
gekregen.   
 De studies die volgden hadden gerandomiseerd gecontroleerde designs (randomized 
controlled trials; RCT) en toonden ook positieve effecten van neurofeedback training. De grootste 
gerandomiseerde studie met 94 kinderen tussen de 8 en 12 jaar liet zien dat neurofeedback (n=59) 
effectiever was in het verminderen van ADHD-symptomen dan gecomputeriseerde aandacht training 
(n=35) tot een half jaar na de behandeling (Gevensleben et al., 2010; Gevensleben, Holl, Albrecht, 
Vogel, et al., 2009). Bij deze studie werd van frontaal naar pariëtaal een steeds sterkere vermindering in 
theta activiteit waargenomen in de groep die neurofeedback had gekregen. De vermindering in theta 
activiteit was tevens gerelateerd aan een vermindering van ADHD-symptomen zoals door de ouders 
gerapporteerd (Gevensleben, Holl, Albrecht, Schlamp, et al., 2009). De studie van Duric en collega’s 
(2012) toonde gelijkwaardige verbetering van aandacht op gedragsvragenlijsten over de tijd voor 
jongeren met ADHD welke waren behandeld met neurofeedback (n=30), stimulantia (n=31) of een 
combinatie van stimulantia en gedragstherapie (n=30). Een kleinere studie met een gerandomiseerd 
design liet eveneens vergelijkbare verbeteringen in aandacht zien voor neurofeedback (n=12) en 
stimulantia (n=11) (Meisel, Servera, Garcia-Banda, Cardo, & Moreno, 2013). Overeenstemmend met 
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de niet gecontroleerde studies, laten deze RCTs gelijkwaardige vooruitgang zien voor neurofeedback 
en stimulantia.  
 Meer recente geblindeerde RCT studies laten echter in het algemeen geen meerwaarde zien 
van neurofeedback ten opzichte van placebo-neurofeedback voor het verminderen van ADHD-
symptomen (Arnold et al., 2012; Perreau-Linck, Lessard, Levesque, & Beauregard, 2010; van Dongen-
Boomsma, Vollebregt, Slaats-Willemse, & Buitelaar, 2013; Vollebregt, van Dongen-Boomsma, 
Buitelaar, & Slaats-Willemse, 2013). De meest optimistische studie is een enkelvoudig geblindeerde 
studie waarbij jongeren met ADHD die neurofeedback training volgden (n=18) meer verbeterden op 
aandacht zoals gerapporteerd door ouders en op neurocognitieve maten zoals reactietijd en 
accuraatheid, dan de jongeren die elektromyografie (EMG) biofeedback training kregen (n=17) 
(Bakhshayesh, Hansch, Wyschkon, Rezai, & Esser, 2011). De andere geblindeerde studies vonden geen 
verschillen tussen neurofeedback en placobo-neurofeedback in vermindering van ADHD-symptomen 
bij jongeren met ADHD (Arnold et al., 2012; Perreau-Linck et al., 2010; van Dongen-Boomsma et al., 
2013). Het aantal deelnemers bij deze onderzoeken was echter relatief klein, met deelnemers ingedeeld 
voor neurofeedback versus placebo-neurofeedback van respectievelijk n=4 tegen n=4 (Perreau-Linck 
et al., 2010), n=25 tegen n=11 (Arnold et al., 2012) en n=22 tegen n=19 (van Dongen-Boomsma et al., 
2013). Het lijkt erop dat eerder gerapporteerde positieve uitkomsten van niet-placebo gecontroleerde 
studies naar de effectiviteit van neurofeedback bij ADHD het resultaat zijn van niet-specifieke 
behandeleffecten zoals motivatie en verwachting bij de jongeren en de ouders, de technologische 
setting met een behoorlijk medische uitstraling en het grote aantal trainingssessies met een therapeut.  
Er zijn minder klinische effectiviteitsstudies uitgevoerd naar de werking van neurofeedback bij 
ASS dan bij ADHD. De meest gebruikte neurofeedback protocollen die bij ASS worden toegepast 
betreffen training van frequentiebanden (Holtmann et al., 2011) gelijkend op de protocollen zoals 
toegepast bij ADHD met inhibitie van theta (4-7 Hz) en versterking van SMR (12-15 Hz) (Coben, 
Linden, & Myers, 2010) of onderdrukking van het Mu ritme (8-13Hz) (Coben et al., 2010; Holtmann et 
al., 2011). De review van Holtmann en collega’s (2011) concludeert dat neurofeedback niet effectief 
lijkt voor ASS kenmerken, maar mogelijk wel effectief kan zijn voor het verminderen van bijkomende 
ADHD-symptomen.  
 Claims over de effectiviteit van neurofeedback voor de behandeling van ADHD lopen uiteen 
van ‘effectief en specifiek’ (Arns, de Ridder, Strehl, Breteler, & Coenen, 2009) en ‘mogelijk effectief’ 
(Lofthouse et al., 2012; Moriyama et al., 2012), tot niet effectief met geblindeerde opzet van de studie 
(Sonuga-Barke et al., 2013). De range van effectiviteitsbeoordelingen is zo breed doordat de meeste 
studies gehinderd zijn door verschillende methodologische tekortkomingen: het grootste deel van de 
studies was niet gerandomiseerd, groepsgrootten waren relatief klein en/of er was niet gecontroleerd 
voor niet-specifieke behandeleffecten. Onlangs gemaakte schattingen zijn daarom conservatiever 
(Gevensleben, Rothenberger, Moll, & Heinrich, 2012; Lofthouse et al., 2012; Loo & Makeig, 2012; 
Moriyama et al., 2012; Sonuga-Barke et al., 2013). Tekortkomingen in de designs van voorgaande 
onderzoeken en missende kennis over mogelijke (negatieve) bijwerkingen zorgen ervoor dat er geen 
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harde conclusies kunnen worden getrokken. Meer gecontroleerd onderzoek is daarom nodig om te 
kijken of er specifieke patiëntgroepen zijn die profiteren van neurofeedback en of dit afhankelijk is van 
het soort toegepaste neurofeedback training protocol (Gevensleben et al., 2012; Lofthouse et al., 2012). 
Verder is het van belang dat er onderzoek wordt gedaan om te zien of neurofeedback van aanvullende 
waarde is op multimodale behandelprotocollen (Gevensleben et al., 2012). Bovenal is het van belang 
de waarde van neurofeedback in de klinische praktijk te onderzoeken, waar meer heterogene populaties 
van jongeren met ADHD worden gezien. Dienovereenkomstig is het van belang dat jongeren met 
ADHD en bijkomende stoornissen, zoals ASS, welke behandeling behoeven voor ADHD-
symptomen, ook tot de studie worden toegelaten, zodat de klinische praktijk zo goed mogelijk wordt 
nagebootst.  
 
De onderwerpen van dit proefschrift  
Dit proefschrift heeft twee hoofdonderwerpen. Het eerste onderwerp van het proefschrift betreft het 
verkennen van psychofysiologie in adolescenten met ADHD en ASS+ADHD en de mogelijke 
klinische implicaties hiervan. Het tweede onderwerp van het proefschrift omvat het onderzoek naar de 
aanvullende waarde van neurofeedback op de huidige standaard toegepaste behandeling om gedrag en 
neurocognitief functioneren van adolescenten met ADHD te verbeteren. Overeenkomstig worden in 
het eerste deel van het proefschrift overlap en verschillen in psychofysiologische maten tussen 
adolescenten met ADHD en adolescenten met een combinatie van ADD+ADHD beschreven. In het 
tweede gedeelte van het proefschrift wordt de aanvullende waarde van neurofeedback op de huidige 
standaard toegepaste behandeling voor adolescenten met ADHD en andere stoornissen onderzocht.  
 
SAMENVATTING 
Deel 1: Psychofysiologie in adolescenten met ADHD en ASS+ADHD  
ADHD is een van de meest voorkomende neuropsychiatrische stoornissen met een prevalentie van rond de 5% 
(Polanczyk et al., 2007; Willcutt, 2012). Daarnaast vertoont een groot aantal jongeren met ASS ook ADHD-
symptomen. Fysiologische maten, zoals reactiviteit van het hart, EEG power spectra en ERP componenten zijn 
gerelateerd aan ADHD-symptomen. In het eerste deel van dit proefschrift is verkend of psychofysiologische 
correlaten van ADHD overlappen of verschillen tussen adolescenten met ADHD en adolescenten met een 
combinatie van ASS en ADHD, met en zonder gebruik van stimulantia.  
Als eerste is er gekeken naar hartactiviteit bij adolescenten met ADHD en adolescenten met 
ASS+ADHD. Afwijkende hartritme activiteit, wijzend op verhoogde parasympatische activiteit zoals lage 
hartslag (Negrao et al., 2011) en meer variabiliteit in het hartritme (Borger & van der Meere, 2000; Borger et al., 
1999; Negrao et al., 2011) lijken gerelateerd aan ADHD. ASS daarentegen is geassocieerd met een verhoging in  
sympathische activiteit (Bal et al., 2010; Daluwatte et al., 2012; Van Hecke et al., 2009). De verwachting was 
daarom dat adolescenten met ASS+ADHD meer tekenen van verhoogde sympathische en minder 
parasympatische activiteit zouden vertonen dan adolescenten met ADHD. De adolescenten met ADHD en de 
adolescenten met ASS+ADHD vertoonden echter geen verschillen op de hartritme maten. Adolescenten die 
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stimulantia namen, toonden verminderde adaptatie van de LF/HF ratio en snellere reactietijden dan adolescenten 
die geen stimulantia namen, onafhankelijk van de diagnose die ze hadden. Deze studie wijst op overlap in 
hartritme activiteit tussen adolescenten met ADHD en adolescenten met ASS+ADHD.  
Als tweede zijn mogelijke overlap en verschillen in theta en beta power spectra tussen adolescenten met 
ADHD en ASS+ADHD verkend. In tegenstelling tot de hartactiviteit, lieten EEG power spectra verschillen zien 
tussen adolescenten met ADHD en adolescenten met ASS+ADHD. Met de ogen open en tijdens het maken van 
een aandachtstaak lieten de adolescenten met ADHD meer theta activiteit zien dan adolescenten met 
ASS+ADHD, ongeacht of ze stimulantia gebruiken. Met de ogen dicht is de theta activiteit gelijk in beide 
groepen. Verhoogde theta tijdens rustcondities (Cortese, 2012; Loo & Makeig, 2012; Snyder & Hall, 2006) is een 
van de meest robuuste bevindingen bij ADHD. Deze verschillen in theta activiteit wijzen erop dat adolescenten 
met ASS+ADHD minder fysiologische kenmerken in het EEG vertonen die normaal geassocieerd worden met 
ADHD, ondanks de overlap in aandachtsproblemen in beide groepen.  
Als derde is gekeken naar stimuli-gerelateerde hersenactiviteit, ERPs, tijdens een auditieve aandachttaak. 
Psychofysiologische indices van hersenfunctioneren, zoals ERP componenten, zijn gerelateerd aan cognitief 
functioneren, zoals aandacht, response selectie, inhibitie en response monitoring (Johnstone et al., 2013). ERP 
componenten verschilden afhankelijk van de gestelde diagnose en van het gebruik van stimulantia. Adolescenten 
met ASS+ADHD die geen stimulantia gebruikten, hadden een kleinere N2 amplitude dan degenenn die wel 
stimulantia gebruikten. Bij adolescenten met ADHD was er geen verschil tussen degenen die wel en geen 
stimulantia gebruikten. De kleinere N2 amplitude suggereert dat adolescenten met ASS+ADHD die geen 
stimulantia gebruikten meer moeite hebben om het verschil waar te nemen tussen twee verschillende stimuli 
(piepjes) dan adolescenten met ASS+ADHD die wel stimulantia gebruiken. Een andere bevinding in dit 
onderzoek was dat adolescenten met ADHD wanneer zij stimulantia gebruikten een vroegere N1 piek lieten zien, 
waar adolescenten met ASS+ADHD wanneer ze stimulantia gebruiken juist een latere N1 piek lieten zien ten 
opzichte van adolescenten die geen stimulantia gebruiken. Deze resultaten tonen dat ERP activiteit afhankelijk is 
van de vastgestelde diagnose, ADHD of ASS+ADHD, en van het gebruik van stimulantia.  
Samengenomen laten de resultaten van het eerste deel van het proefschrift zien dat er ondanks 
gedragsmatige overlap en overlap in hartactiviteit tussen adolescenten met ADHD en adolescenten 
met ASS+ADHD, verschillen zijn in hersenactiviteit. Deze verschillen zijn van belang, omdat het 
indicaties zijn voor de mogelijkheid dat behandeling ontwikkeld voor ADHD anders werkt voor 
adolescenten met ASS+ADHD dan voor adolescenten met alleen ADHD.  
 
Deel 2: De aanvullende waarde van neurofeedback op huidig toegepaste 
behandelingen 
Neurofeedback wordt gezien als een potentieel effectieve behandeling voor het verminderen van 
ADHD-symptomen, voornamelijk aandachtsproblemen. Neurofeedback poogt hersenactiviteit aan te 
passen doormiddel van operante conditionering door het geven van feedback over de EEG activiteit 
van patiënten om zodoende het gedrag te verbeteren. In het algemeen laten jongeren met ADHD 
meer theta (Cortese, 2012; Loo & Makeig, 2012; Snyder & Hall, 2006) en minder beta (Cortese, 2012; 
Snyder & Hall, 2006) activiteit zien in vergelijking met normaal ontwikkelende jongeren. Het meest 
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toegepaste neurofeedback training protocol is daarom de theta/beta training, welke als doel heeft theta 
(4-7Hz) te verminderen en SMR (12-15Hz) of beta (12-20Hz) activiteit te versterken (Lofthouse et al., 
2012; Loo & Makeig, 2012; Moriyama et al., 2012). In het algemeen omvat een complete 
neurofeedback behandeling ongeveer 20 tot 40 sessies (Loo & Makeig, 2012). In het tweede deel van 
dit proefschrift is gekeken naar de waarde van neurofeedback als aanvulling op de huidige standaard 
toegepaste behandelingen om gedrag en neurocognitief functioneren te verbeteren bij adolescenten 
met ADHD en bijkomende stoornissen.  
 Door middel van een multicenter onderzoek met een gerandomiseerd gecontroleerd design, 
zijn 90 mannelijke adolescenten met een DSM-IV diagnose ADHD geloot om al dan niet 
neurofeedback te krijgen naast de standaardbehandeling. Neurofeedback behelsde ongeveer 37 sessies 
theta/SMR-training op Cz (op het midden van het hoofd). De interventieperiode duurde ongeveer 25 
weken. In totaal zijn 71 adolescenten (gemiddelde leeftijd van ongeveer 16 jaar) vergeleken op maten 
van gedrag en neurocognitief functioneren, zowel voor als na de interventieperiode. Zestig 
adolescenten werden op dezelfde maten nogmaals vergeleken één jaar na de interventieperiode.  
 Als eerste is de waarde van neurofeedback als aanvullende behandeling op de momenteel 
toegepaste behandeling op gedragsmaten bekeken direct na de interventieperiode. Gedragsproblemen, 
zoals onoplettendheid en hyperactiviteit en impulsiviteit, waren verminderd voor alle adolescenten met 
ADHD gedurende de interventieperiode. Er waren echter geen verschillen tussen de 45 adolescenten 
die neurofeedbacktraining hadden gevolgd als aanvulling op de standaardbehandeling en de 
adolescenten die alleen standaardbehandeling hadden ontvangen. Het gebruik van stimulantia of de 
aanwezigheid van een ASS diagnose had geen effect op de gerapporteerde vermindering van 
gedragsproblemen met het verstrijken van de tijd. Ook de rapportage van bijwerkingen was gelijk in 
beide groepen. Hoofdpijnfrequentie was afhankelijk van het gebruik van stimulantia: adolescenten die 
geen stimulantia gebruiken, rapporteerden na de interventieperiode een vermindering van het aantal 
keer dat ze hoofdpijn hadden gekregen. De adolescenten die wel stimulantia gebruiken, rapporteerden 
geen verminderingen in hoofdpijnfrequentie. Samenvattend kan gezegd worden dat op basis van het 
gerapporteerde gedrag de combinatie van neurofeedback en standaardbehandeling net zo effectief is 
als alleen standaardbehandeling. Er is geen toegevoegde waarde van neurofeedback op gedrag 
gevonden.  
 Na het bestuderen van effecten op gedrag zijn mogelijke aanvullende effecten van 
neurofeedback op neurocognitief functioneren onderzocht. Voor en direct na de interventieperiode 
werden de adolescenten vergeleken op verschillende neurocognitieve maten: de 'd2 aandacht test', 
'getallen reeksen achteruit', de 'Stroop kleur-woord' test en de 'Tower of London'. Resultaten toonden 
verbetering op maten van aandacht direct na de interventieperiode voor alle adolescenten met ADHD. 
De adolescenten hadden minder tijd nodig om informatie te verwerken en de taak uit te voeren met 
dezelfde accuratesse. Indices van werkgeheugen en planning bleven gelijk. De 45 adolescenten die 
neurofeedbacktraining hadden gekregen als aanvullende behandeling presteerden hetzelfde als de 26 
adolescenten die geen neurofeedback hadden gekregen. Net als bij de gedragsmaten zijn er geen 
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aanvullende effecten van neurofeedback op de standaardbehandeling gevonden voor neurocognitief 
functioneren.  
 Een jaar na de interventie zijn 60 adolescenten nogmaals getest. Deze adolescenten zijn 
wederom vergeleken om te kijken naar de aanvullende waarde van neurofeedback op de 
standaardbehandeling op de lange termijn. Er is gekeken naar vermindering van ADHD-symptomen 
door middel van zelfgerapporteerd gedrag en neurocognitieve maten. Alle adolescenten met ADHD 
rapporteerden 1 jaar na de interventie minder gedragsproblemen dan voor de interventieperiode. De 
adolescenten werden ook sneller in het uitvoeren van de neurocognitieve taken. Er was geen verschil 
in de vooruitgang over de tijd tussen de 41 adolescenten die neurofeedback hadden ontvangen als 
aanvullende behandeling en de 19 adolescenten die geen neurofeedback hadden gevolgd. Evenals de 
resultaten in gedrag en neurocognitief functioneren direct na de interventieperiode, tonen de 
langetermijnresultaten geen aanvullende waarde van neurofeedback. 
 In het tweede deel van dit proefschrift is de aanvullende waarde van neurofeedback op de 
momenteel toegepaste standaardbehandeling bij adolescenten met ADHD onderzocht. Er is geen 
aanvullende waarde van neurofeedback gevonden op gedrag of neurocognitief functioneren bij 
adolescenten met ADHD en bijkomende stoornissen direct na de interventie en een jaar na de 
interventie. De huidige resultaten laten geen robuuste aanvullende waarde van neurofeedback op korte 
en lange termijn zien en ondersteunen daarmee niet het gebruik van theta/SMR neurofeedback als 
aanvullende behandeling om blijvende verbeteringen in gedrag of neurocognitief functioneren van 
adolescenten met ADHD en bijkomende stoornissen te bewerkstelligen in de klinische praktijk. 
 
DISCUSSIE 
Twee van een soort: ADHD en ASS+ADHD  
Het eerste deel van het proefschrift wijst erop dat er, naast overlap in gedrag en hartslag maten bij 
adolescenten met ADHD en adolescenten met ASS+ADHD, verschillen zijn in hersenactiviteit. Deze 
verschillen zijn van belang, omdat het bestaan van verschillen betekenen dat behandelingen die 
ontwikkeld zijn voor ADHD, misschien anders werken voor adolescenten met ASS+ADHD dan voor 
adolescenten met ADHD.  
De veronderstelling voor hartritme activiteit was dat ADHD geassocieerd is met tekenen van 
verhoogde parasympatische activatie, terwijl ASS voorheen geassocieerd is met tekenen van verhoogde 
sympathische activatie. De verwachting was daarom dat de adolescenten met ASS+ADHD meer 
sympathische en minder parasympatische activatie tonen dan adolescenten met ADHD. Hartritme 
maten waren echter gelijk voor de adolescenten met ASS+ADHD en de adolescenten met ADHD. 
Een mogelijke verklaring voor deze bevinding is dat er psychofysiologische constructen zijn welke 
gerelateerd zijn aan de ADHD-symptomen, die verantwoordelijk zijn voor de overlap in hartritme 
activiteit tussen ADHD en ASS+ADHD.  
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In het functioneren van de hersenen zijn er naast overlap ook verschillen gevonden tussen de 
twee diagnose groepen. Het meest opvallende resultaat was dat adolescenten met ADHD meer theta 
activiteit hebben dan adolescenten met ASS+ADHD als ze hun ogen open hebben of tijdens het 
maken van een taak. Daarnaast bleek dat voor adolescenten met ADHD veel theta in rust conditie met 
de ogen open gerelateerd is aan slechtere prestatie op een aandachttaak. Bij adolescenten met 
ASS+ADHD was deze relatie niet aanwezig. Verhoogde theta is een van de meest robuuste 
bevindingen bij ADHD (Cortese, 2012; Loo & Makeig, 2012; Snyder & Hall, 2006). Aangezien theta 
(4-7Hz) een negatieve relatie heeft met waakzaamheid (Banaschewski & Brandeis, 2007), kan dit 
betekenen dat verhoogde theta en verlaagde waakzaamheid een betere verklaring biedt voor 
aandachtsproblemen in adolescenten met ADHD dan in adolescenten met ASS+ADHD. De 
aandachtsproblemen in ASS+ADHD zijn mogelijk het resultaat van ander hersendisfunctioneren, 
zoals abnormale neuronale connectiviteit (Billeci et al., 2013; Coben, Clarke, Hudspeth, & Barry, 2008) 
en problemen met “top-down” verwerking (Gomot & Wicker, 2012)  –een actieve vorm van 
verwerking waarbij voorheen opgedane kennis wordt gebruikt om een inschatting te maken van 
toekomstige doelen -, in plaats van verminderde frontocentrale activiteit op zichzelf. De uitkomsten 
van de ERP componenten wijzen eveneens op problemen met het verwerken van informatie in 
ASS+ADHD. De adolescenten met ASS+ADHD die geen stimulantia gebruiken, lieten een kleinere 
amplitude van de N2 component zien als reactie op stimuli die actie behoeven, dan adolescenten met 
ASS+ADHD die wel stimulantia gebruiken. Dit verschil was niet aanwezig tussen adolescenten met 
ADHD die wel of geen stimulantia gebruiken. De kleinere amplitude van de N2 component op doel 
stimuli geeft een voorzichtige indicatie dat adolescenten met ASS+ADHD die geen stimulantia 
gebruiken, meer problemen hebben met discriminatie van stimuli.  
De verwachting was dat stimulantia normaliserend werken op de psychofysiologische 
karakteristieken van ADHD. Daarom was de verwachting was dat de adolescenten die stimulantia 
gebruiken minder neurocognitieve en fysiologische tekenen vertonen die in het algemeen worden 
geassocieerd met ADHD dan de adolescenten die geen stimulantia gebruikten, ongeacht de diagnose 
(ADHD of ASS+ADHD). De adolescenten die stimulantia gebruikten reageerden inderdaad sneller en 
minder variabel op stimuli dan adolescenten die geen stimulantia gebruikten, onafhankelijk van de 
diagnose. Ook in de hartslag maten is verschil gevonden voor het gebruik van stimulantia: 
adolescenten die stimulantia gebruiken hadden een hogere LF/HF ratio in rust conditie dan 
adolescenten die geen stimulantia gebruikten. Tijdens het uitvoeren van een taak was de LF/HF ratio 
gelijk voor adolescenten die stimulantia gebruikten en zij die dat niet deden. Als gevolg hiervan was de 
aanpassing van de LF/HF ratio, die normaal een verhoging laat zien van rust naar taak condities, 
verminderd voor adolescenten die stimulantia gebruiken. Een vermindering van parasympatische 
activiteit bij ADHD kan in het algemeen worden gezien als een teken van normalisatie. Een 
vermindering van autonome modulatie kan mogelijk minder wenselijk zijn. Het is niet duidelijk wat de 
implicaties zijn voor het dagelijks leven als adolescenten die stimulantia gebruiken minder in 
fysiologisch opzicht kunnen wisselen tussen rust en taken die aandacht vereisen.  
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Het is opvallend dat er geen verschillen waren in theta en beta activiteit afhankelijk van het 
gebruik van stimulantia. In het algemeen wordt er een daling in theta en verhoging van beta gezien bij 
jongeren met ADHD na het gebruik van stimulantia (Clarke et al., 2002; Clarke et al., 2003; Hermens 
et al., 2005; Loo & Barkley, 2005). Hierbij dient opgemerkt te worden dat, ook al worden theta en beta 
beïnvloed door stimulantia, de jongeren met ADHD die stimulantia gebruiken nog altijd niet 
gelijkwaardige niveaus van theta en beta bereiken ten opzichte van normaal ontwikkelende jongeren 
(Clarke et al., 2002; Clarke et al., 2003). Verschillen in leeftijd tussen de adolescenten die wel en geen 
stimulantia gebruiken, hebben mogelijk bijgedragen aan de afwezigheid van verschillen met betrekking 
tot stimulantia gebruik. Gemiddeld genomen waren de adolescenten die geen stimulantia gebruikten 
ouder dan degenen die wel stimulantia gebruikten. Daar ouder worden (Segalowitz, Santesso, & Jetha, 
2010) evenals het gebruik van stimulantia (Clarke et al., 2002; Clarke et al., 2003; Hermens et al., 2005; 
Loo & Barkley, 2005) beide resulteren in verlaging van theta activiteit, is het mogelijk dat de twee 
effecten elkaar in evenwicht hebben gehouden.  
Stimulantia zijn in het algemeen ook van invloed op ERP componenten, welke terug te zien 
zijn in grotere N2 (Pliszka et al., 2007) en P3 (Groom et al., 2010; Hermens et al., 2005) amplitudes na 
het gebruik van stimulantia door jongeren met ADHD. Overeenkomstig met deze veronderstelling 
vonden we grotere N2 amplitudes voor adolescenten met ASS+ADHD die stimulantia gebruikten in 
vergelijking met degenen die geen stimulantia gebruiken. Verrassend genoeg was er geen verschil voor 
het gebruik van stimulantia voor de adolescenten met ADHD. Daarnaast vonden wij, net als de studie 
van Groen en collega’s (2008), geen grotere P3 amplitude voor de adolescenten die stimulantia 
gebruiken dan voor degenen die geen stimulantia gebruiken. Er is echter een duidelijk verschil tussen 
de studies. De studies die een verschil vonden in P3 amplitude vergeleken dezelfde jongeren met 
ADHD, met en zonder stimulantia (Groom et al., 2010; Hermens et al., 2005), terwijl bij de studie van 
Groen en collega’s (2008) en onze studie een groep jongeren die wel stimulantia gebruikte werd 
vergeleken met een groep die geen stimulantia gebruikte. Bij vergelijking van twee verschillende 
(relatief kleine) groepen, zoals bij onze studie zijn er altijd verschillen tussen personen die effect 
hebben op de uitkomsten. Verschillen tussen personen kunnen dan beter gecontroleerd worden 
wanneer er binnen een groep patiënten in verschillende situaties gekeken wordt naar uitkomsten: elke 
patiënt controleert dan als het ware voor zijn eigen variantie. Hierdoor kunnen verschillen voor 
stimulantia gebruik binnen een groep patiënten mogelijk beter worden aangetoond dan verschillen 
tussen twee groepen patiënten.  
Stimulantia hadden eveneens invloed op de latentie tijden van de N1 piek welke afhankelijk 
waren van de diagnose. Adolescenten met ASS+ADHD die stimulantia gebruikten hadden langere N1 
latentie tijden dan degenen die geen stimulantia gebruikten. Een tegenovergesteld patroon zagen we bij 
de adolescenten met ADHD: degenen die stimulantia namen hadden een kortere N1 latentie tijd dan 
degenen die geen stimulantia gebruikten. Kortere latentie tijden worden in het algemeen gezien als een 
indicatie dat informatie efficiënter verwerkt wordt. De resultaten lieten echter zien dat een langere N1 
latentie geassocieerd was met een grotere N1 amplitude. Een latere N1 piek was zelfs gerelateerd aan 
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minder variabele reactie tijden bij adolescenten met ASS+ADHD. Deze resultaten toonden dus dat de 
latere N1 piek gerelateerd is met een meer consistent reactie patroon op doel stimuli, met name voor 
adolescenten met ASS+ADHD. 
 De studies uit het eerste deel van dit proefschrift laten verschillen in hersenactiviteit zien 
tussen adolescenten met ADHD en ASS+ADHD. De verschillen werden gevonden in een klinische 
groep van adolescenten met ADHD-symptomen die voldoende zijn voor een DSM-IV diagnose 
ADHD. Stimulantia gebruik was toegestaan en werd voortgezet op de dagen waarop de jongeren 
gezien werden voor het afnemen van de vragenlijsten, cognitieve testen en fysiologische metingen. Op 
deze manier weerspiegelt de onderzochte groep de klinische praktijk. Dit zorgt er echter ook voor dat 
de onderzochte groep erg heterogeen is met betrekking tot diagnoses (ADHD of ASS+ADHD), 
stimulantia gebruik en leeftijd. Meer systematisch onderzoek naar de psychofysiologische aspecten van 
ADHD en ASS+ADHD en de implicaties voor de klinische praktijk zijn daarom noodzakelijk. 
Replicatie van de psychofysiologische resultaten van de huidige studie, met een grotere groep zijn 
nodig, bij voorkeur opgezet met een gerandomiseerd gecontroleerd design met dubbel-blind placebo-
gecontroleerde titratie van stimulantia en een baseline meting met adolescenten die geen stimulantia 
gebruiken en gediagnosticeerd zijn met ADHD en ASS+ADHD. Daarnaast is een controle groep die 
enkel gediagnosticeerd is met ASS en een groep met normaal ontwikkelende adolescenten van belang 
om te kijken welke psychofysiologische aspecten typerend zijn voor de normale ontwikkeling, welke 
voor ADHD en welke voor ASS.  
Samengevat wijzen de resultaten uit het eerste deel van dit proefschrift erop dat waar gedrag 
en hartritme maten overlappen tussen adolescenten met ADHD en ASS+ADHD, er mogelijk 
verschillen zijn in onderliggend hersenfunctioneren gerelateerd aan ADHD-symptomen. Klinische 
implicaties van deze psychofysiologische verschillen en reactie op het gebruik van stimulantia moeten 
in de toekomst verder worden onderzocht om de behandeling van ADHD als bijkomende stoornis 
van ASS te optimaliseren.  
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Neurofeedback: Ingrediënten van effectiviteit 
In het tweede deel van dit proefschrift hebben we de waarde van neurofeedback als aanvullende 
behandeling om ADHD-symptomen te verminderen en neurocognitief functioneren te verbeteren 
voor adolescenten met ADHD en bijkomende stoornissen onderzocht. Er zijn geen aanvullende 
effecten voor neurofeedback op korte of lange termijn gevonden om gedrag of neurocognitief 
functioneren te verbeteren bij jongeren met ADHD. De resultaten van het huidige onderzoek 
onderschrijven daarmee niet het gebruik van theta/SMR neurofeedback als aanvullende behandeling 
om gedrag of neurocognitief functioneren te verbeteren in adolescenten met ADHD en comorbide 
stoornissen in de klinische praktijk. 
De conclusie van een meta-analyse uit 2009 was dat neurofeedback als behandeling voor 
ADHD “effectief en specifiek” is (Arns et al., 2009). De geschatte effectgrootten varieerden van 
gemiddeld voor hyperactiviteit tot groot voor het verminderen van aandachtsproblemen en 
impulsiviteit (Arns et al., 2009). In de jaren daarna is er steeds meer interesse getoond in deze niet-
farmacologische interventie. Dit resulteerde in verschillende reviews in 2012 die erop wezen dat 
neurofeedback een mogelijk effectieve behandeling is voor ADHD (Gevensleben et al., 2012; 
Lofthouse et al., 2012; Moriyama et al., 2012). Een andere review was minder positief met betrekking 
tot theta/beta neurofeedback, en stelde dat: de staat van de huidige gepubliceerde peer reviewed literatuur over 
theta/beta training, zoals het op dit moment is, niet ondersteunend is voor het gebruik van theta/beta training zelfs niet 
als een aanvullende behandeling (Loo & Makeig, 2012). Een nieuwe meta-analyse gepubliceerd in 2013 laat 
zien dat de effectiviteit van neurofeedback zakt naar niet-significante niveaus wanneer er sprake is van 
een geblindeerde meting (Sonuga-Barke et al., 2013). Overeenkomstig gaven de resultaten van een 
systematische review geen indicaties dat neurofeedback effectief is om neurocognitief functioneren in 
ADHD te verbeteren (Vollebregt et al., 2013). Inschattingen van de effectiviteit van neurofeedback als 
behandeling van ADHD-symptomen lopen dus uiteen van “effectief en specifiek” tot “niet effectief”.  
Kijkend naar de brede range van schattingen met betrekking tot de effectiviteit van 
neurofeedback binnen vier jaar tijd, is het een gepaste vraag om te stellen waar deze verschillen 
vandaan komen. Mogelijk ligt de verklaring in de methodologische problemen die veel studies naar de 
effectiviteit van neurofeedback parten hebben gespeeld. Niet alleen met betrekking tot de grote 
verschillen tussen studies in de opzet van het design, maar ook met betrekking tot het toegepaste 
neurofeedback training protocol. Om het geheel af te bakenen wordt in deze discussie alleen gekeken 
naar de veel toegepaste frequentie–vooral theta/beta- training protocollen die zich richten op patiënten 
met ADHD.  
 De eerste niet gerandomiseerde studies die neurofeedback met andere behandelingen 
vergeleken (e.g. Fuchs et al., 2003; Monastra et al., 2002) lieten positieve resultaten voor neurofeedback 
zien. Deze studies controleerden echter niet voor niet-specifieke behandeleffecten. Zo is het 
bijvoorbeeld mogelijk dat ouders die een voorkeur hebben voor een intensieve niet-farmacologische 
behandeling zoals neurofeedback, wellicht meer aanmoediging bieden aan hun kind met ADHD om te 
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veranderen. In het algemeen bestaat een complete neurofeedback training uit ongeveer 20 tot 40 
sessies. De ouders die hun kind elke week twee of drie keer naar therapie kunnen en willen brengen, 
zijn mogelijk ook beter in staat een meer gestructureerde en voorspelbare omgeving voor het kind te 
scheppen. Daarnaast maakt de geïnvesteerde tijd in de behandeling door het kind, de therapeut en de 
ouders, dat de ouders meer geneigd kunnen zijn om positieve verandering in het gedrag van het kind te 
willen zien. Naast niet-specifieke effecten op gedragsmetingen beïnvloed door vooringenomenheid van 
de ouders, spelen maturatie en oefeneffecten mogelijk een rol bij het waarnemen van verbeteringen bij 
de uitvoer van neurocognitieve taken mettertijd.  
 Om beter te controleren voor deze niet-specifieke effecten van tijdsinvestering en voorkeur, 
zijn er daarna studies met een gerandomiseerd design, zogenaamde randomized controlled trials 
(RCT), uitgevoerd. Ouders kregen niet langer de mogelijkheid om te kiezen voor een specifieke 
behandeling voor hun kind, zoals in de eerste studies. In plaats daarvan konden ouders en kinderen 
enkel kiezen om wel of niet deel te nemen aan een studie. Ze wisten van te voren niet bij welke 
behandeling ze zouden worden ingedeeld. In een van de eerste grote RCT studies werden kinderen 
met ADHD die geen stimulantia gebruiken, ingeloot voor neurofeedback (n=59) of een 
gecomputeriseerde aandacht training (n=35) (Gevensleben, Holl, Albrecht, Vogel, et al., 2009). Beide 
groepen volgden evenveel sessies, waarmee zowel een bias uit verschil in voorkeur als uit verschil in 
investering werd voorkomen. De kinderen die neurofeedback kregen gingen meer vooruit op gedrag 
zoals gerapporteerd door ouders en leerkrachten dan de kinderen die de aandacht training hadden 
gekregen (Gevensleben, Holl, Albrecht, Vogel, et al., 2009). Zelfs zes maanden na de training 
rapporteerden ouders beter gedrag voor de kinderen die neurofeedback volgden dan voor de kinderen 
die aandacht training hadden gekregen (Gevensleben et al., 2010). Helaas was bij deze meting slechts 
70% van de gedragsvragenlijsten van de leerkrachten teruggekomen en waren deze daarom niet 
meegenomen als uitkomstmaat (Gevensleben et al., 2010). Een limitatie van deze studie is dat ze enkel 
betrekking heeft op kinderen met ADHD die geen stimulantia gebruiken. Op het moment dat gebruik 
van stimulantia geïndiceerd was, werden de kinderen niet opgenomen voor deelname in de studie of 
werden ze niet meegenomen voor de metingen na de interventieperiode. Op deze manier introduceert 
de studie een selectie bias, waarbij kinderen met mogelijk een ernstiger vorm van ADHD werden 
uitgesloten aan het begin van de studie en na de start van de studie werden de kinderen die meer last 
kregen van de ADHD-symptomen en dus medicatie nodig hadden uitgesloten.  
 Andere RCT studies hebben geprobeerd dit probleem met generaliseerbaarheid met 
betrekking tot het gebruik van stimulantia te voorkomen door neurofeedback behandeling te 
vergelijken met behandeling met stimulantia. De grootste van deze studies laat een gelijke vooruitgang 
in aandacht zien in gedrag gerapporteerd door ouders voor kinderen met ADHD die behandeld 
werden met neurofeedback (n=30), stimulantia (n=31) of een combinatie van neurofeedback en 
stimulantia (n=30) (Duric et al., 2012). Een kleinere studie laat vergelijkbare resultaten zien met een 
even grote vooruitgang in aandacht voor neurofeedback (n=12) als voor stimulantia (n=11) (Meisel et 
al., 2013). Opvallend is dat er een andere studie is die vooruitgang laat zien bij jongeren met ADHD 
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behandeld met stimulantia (n=15), maar niet voor degenen die neurofeedback kregen (n=14). Ook al 
lijken deze drie studies erg op elkaar in design van de studie, een groot verschil behelst het toegepaste 
medicatie protocol. De twee studies die gelijkwaardige vooruitgang laten zien voor neurofeedback en 
voor stimulantia (Duric et al., 2012; Meisel et al., 2013), hielden een standaard dosis voor medicatie aan 
gebaseerd op gewicht van 1 mg per kg lichaamsgewicht. Daarentegen maakte de studie waarbij 
stimulantia superieur was aan neurofeedback voor gedragsverbetering (Ogrim & Hestad, 2013), 
gebruik van een dubbel-blinde placebo-gecontroleerde titratie van medicatie, waarop vervolgens de 
dosis van de stimulantia individueel werd geoptimaliseerd. Titratie van stimulantia op basis van 
lichaamsgewicht wordt geregeld toegepast in onderzoek. Niet al het onderzoek echter, onderschrijft 
deze wijze van titratie van stimulantia (Greenhill et al., 2002; Rapport & Denney, 1997). Het is daarom 
mogelijk dat in de eerste twee studies stimulantia niet het optimale effect hebben gehad bij de jongeren 
met ADHD en de studie die de stimulantia individueel titreerde daarom als enige vond dat stimulantia 
effectiever zijn in het verminderen van ADHD-klachten dan neurofeedback. Verder onderzoek waarbij 
neurofeedback vergeleken wordt met stimulantia, getitreerd volgens een stapsgewijs dubbel-blind 
placebo-gecontroleerd protocol, is essentieel om te zien of neurofeedback behandeling als een 
gelijkwaardig alternatief van stimulantia kan worden toegepast in de klinische praktijk.  
 Tot op heden heeft geen van de dubbel-blinde onderzoeken verschil gevonden op 
gedragsuitkomsten tussen neurofeedback en placebo-neurofeedback (Arnold et al., 2013; Perreau-
Linck et al., 2010; van Dongen-Boomsma et al., 2013). Tevens is er geen verschil gevonden tussen 
neurofeedback en placebo-neurofeedback op de neurocognitieve maten bij jongeren met ADHD 
(Arnold et al., 2013; Vollebregt et al., 2013) of gezonde studenten met relatief veel ADHD-achtige 
trekken (Logemann, Lansbergen, Van Os, Bocker, & Kenemans, 2010). Deze studies onderstrepen dat 
effecten uit de niet geblindeerde studies ook mogelijk het gevolg zijn van niet aan de behandeling 
gerelateerde specifieke effecten.  
 Neurofeedback protocollen zoals toegepast bij de gerandomiseerde studies zijn veel 
bediscussieerd. Zo is er verondersteld dat het automatisch laten aanpassen van grenswaarden door de 
computer met een bepaald tijdsinterval, mogelijk zorgt voor een minder effectieve training dan 
grenswaarden die handmatig worden aangepast (Lansbergen, van Dongen-Boomsma, Buitelaar, & 
Slaats-Willemse, 2011). Vergelijking van training met automatische grenswaarden en handmatig 
ingestelde grenswaarden resulteerde echter niet in verschillen op gedragsmatige uitkomsten (van 
Dongen-Boomsma et al., 2013). Verder is er gesteld dat het toepassen van expliciete leerstrategieën 
mogelijk noodzakelijk is om neurofeedback effectief te maken (Lansbergen et al., 2011). Het 
introduceren van meer actieve leerstrategieën aan het neurofeedback protocol resulteerde echter 
eveneens niet in meer positieve gedragsmatige uitkomsten voor neurofeedback (van Dongen-
Boomsma et al., 2013). Een andere overweging heeft betrekking op de manier waarop de feedback 
over het EEG aan de jongeren wordt overgebracht: films (i.e. Duric et al., 2012; Ogrim & Hestad, 
2013; van Dongen-Boomsma et al., 2013) of complexe grafische computer spelen (i.e. Arnold et al., 
2013) zijn mogelijk afleidend van de eigenlijke neurofeedback training. Een vergelijking van 
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neurofeedback met simpele visuele feedback (n=11) met voor de jongere meer aantrekkelijke grafische 
computer spelen (n=11) bevestigt geen verschil in de manier waarop feedback wordt aangeboden 
(Palsson, Pope, Ball, Turner, & Nevin, 2001, March). De studie beschreven in dit proefschrift maakte 
gebruik van simpele visuele feedback. Ondanks de grafische verschillen tussen onze studie en die van 
Duric en collega’s (2012), welke gebruik maakte van films of video spelen, waren beide studies niet in 
staat om bewijs te vinden voor aanvullende waarde van neurofeedback.  
 EEG frequentie training poogt om verschillende frequentiebanden te onderdrukken dan wel te 
versterken. Verschillende protocollen zijn toegepast in verschillende studies. Het “Lubar” protocol 
traint om theta te onderdrukken en SMR of beta activiteit te versterken, terwijl de patiënt in een 
ontspannen maar geconcentreerde staat is (Lubar, 2003; e.g. de studie uit dit proefschrift). Op deze 
manier wordt er gecontroleerd voor spierspanning welke snel terug te zien is in de hogere 
frequentiebanden. Andere studies passen training van theta/beta toe, met een correctie voor 
oogbewegingen (e.g. Gevensleben, Holl, Albrecht, Vogel, et al., 2009; de theta/beta training in deze 
studie was gecombineerd met training van slow cortical potentials). Als laatste zijn er studies die een 
geïndividualiseerd training protocol toepassen (i.e. Lansbergen et al., 2011) wat in de meeste gevallen 
neerkwam op training van theta/SMR (i.e.van Dongen-Boomsma et al., 2013). Het is mogelijk dat de 
effectiviteit van neurofeedback afhangt van het toegepaste training protocol. Op dit moment worden 
training protocollen echter afwisselend toegepast in de klinische behandel centra en in 
wetenschappelijk onderzoek. Er is geen consensus over de vorm van het trainingsprotocol de manier 
waarop deze uitgevoerd moet worden bij ADHD. Aanvullende kennis over specifieke 
werkingsmechanismen van neurofeedback op de hersenen is noodzakelijk, voordat neurofeedback 
protocollen op de juiste wijze kunnen worden aangepast voor de behandeling van psychiatrische 
stoornissen.  
 Neurofeedback heeft de intentie om EEG activiteit te trainen. Het is daarom opmerkelijk dat 
er nog geen robuuste veranderingen in EEG activiteit zijn gevonden na neurofeedback training. De 
studie van Gevensleben en collega’s (2009) toont voor de jongeren die neurofeedback hebben 
gekregen een patroon waarbij het verschil in theta tussen de voor- en nameting lineair toeneemt van de 
voorkant van het hoofd naar de achterkant. Bij de groep die de aandacht training kreeg was dit patroon 
niet te zien. Ondanks het verschil in patroon van verschilscores, laat de studie geen verschil zien in 
frequentiebanden op specifieke elektroden. In het bijzonder ligt een significante daling in theta 
activiteit op Cz in de lijn der verwachting, bij uitvoer van een theta/beta training protocol met een 
elektrode geplaatst op Cz. Tevens waren er geen verschillen in beta tussen de jongeren die 
neurofeedback hadden gevolgd en de jongeren die aandacht training hadden gevolgd. Het theta/beta 
protocol is er op gericht om beta te verhogen en dus mag verwacht worden dat beta hoger is na de 
training dan voor de training. In tegenstelling daarmee verminderde beta mettertijd, vooral aan de 
voorkant van het hoofd. Deze vermindering was gerelateerd aan leeftijd en intelligentie en was 
onafhankelijk van de gekregen behandeling. Een andere studie die keek naar verschillen tussen voor en 
na neurofeedback training in frequentiebanden, kon eveneens geen verschillen in de frequentiebanden 
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vinden (Kropotov et al., 2007). Natuurlijk kan gezegd worden dat de verandering in hersenactiviteit 
ondergeschikt is aan het doel van de training om gedrag te verbeteren. Neurofeedback is echter 
gebaseerd op het idee dat (ADHD-) problemen voortkomen uit onder- of overactieve specifieke 
gedeelten van de hersenen. Deze over- of onder-activiteit wordt gemeten met een EEG opname in 
rust conditie met de ogen open en met de ogen dicht. Deze EEG opname kan vervolgens gebruikt 
worden om er een (individueel) training protocol op te baseren. Het lijkt logisch om veranderingen te 
verwachten na een interventie die frequentiebanden traint. Een mogelijke verklaring voor de 
afwezigheid van significante veranderingen in de frequentiebanden na de training is dat deze EEG 
opname plaatsvindt in rust condities (Arns et al., 2009; Gevensleben, Holl, Albrecht, Schlamp, et al., 
2009). EEG opname in rust conditie lijkt in tegenspraak met de assumptie dat neurofeedback de 
hersenen probeert te trainen om meer flexibel en beter in staat te zijn hersenactiviteit te reguleren 
tijdens het uitvoeren van taken. Mogelijke veranderingen in hersenactivatie zijn dan onvermijdelijk 
duidelijker aanwezig tijdens het uitvoeren van taken. Het is inderdaad zo dat tijdens het uitvoeren van 
een aandacht taak verschillen zijn gevonden in ERP componenten (Kropotov et al., 2007; Wangler et 
al., 2011). Op dit moment hebben de andere grote gerandomiseerde studies (nog) niet gekeken naar 
veranderingen in de frequentiebanden voor jongeren die neurofeedback hebben gekregen en jongeren 
in de controle condities. Resultaten en verschillen van de frequentiebanden tussen de 
interventiegroepen zijn van belang om te kijken of het daadwerkelijk mogelijk is om frequentiebanden 
te trainen bij jongeren met ADHD.  
 Beide groepen adolescenten verbeterden evenveel op metingen van gedrag en neurocognitief 
functioneren. Het gebruik van stimulantia en het aanwezig zijn van comorbiditeit in de vorm van ASS 
bleek geen effect te hebben op de uitkomsten. In het eerste gedeelte van dit proefschrift hebben we 
verschillen beschreven met betrekking tot stimulantia en de aanwezigheid van een ASS diagnose naast 
ADHD. Daarbij kwam naar voren dat met ogen open en tijdens het uitvoeren van een taak de 
adolescenten met ADHD significant meer theta vertoonden dan adolescenten met een combinatie van 
ASS en ADHD. Een verhoging van theta en verlaging van beta activiteit bij ADHD (Cortese, 2012; 
Loo & Makeig, 2012; Snyder & Hall, 2006) is respectievelijk geassocieerd met verminderde 
waakzaamheid en verminderde aandacht (Banaschewski & Brandeis, 2007). Neurofeedback 
protocollen pogen daarom vaak om theta te verlagen en beta te verhogen. Als adolescenten met 
ASS+ADHD in beginsel minder theta activiteit vertonen dan adolescenten met ADHD, dan volgt daar 
logischerwijs uit dat vooruitgang van gedrag door het verlagen van theta activiteit door neurofeedback 
-indien mogelijk- minder duidelijk naar voren komt in adolescenten met ASS+ADHD, dan in 
adolescenten met ADHD zonder ASS comorbiditeit. Bij de huidige studie waren vooruitgang in 
cognitie en gedrag echter even groot voor beide diagnostische groepen. Evenzo laten jongeren met 
ADHD die stimulantia gebruiken minder theta activiteit zien dan jongeren met ADHD die geen 
stimulantia gebruiken (Clarke et al., 2002; Clarke et al., 2003; Hermens et al., 2005; Loo & Barkley, 
2005) en zijn stimulantia effectief voor het verminderen van ADHD-symptomen (Faraone & Buitelaar, 
2010; Greenhill et al., 2001) en voor het verbeteren van neurocognitief functioneren (Coghill et al., 
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2013) bij jongeren met ADHD. Derhalve zouden verwachte verbeteringen door neurofeedback minder 
groot kunnen zijn bij jongeren die stimulantia gebruiken dan bij jongeren die geen stimulantia 
gebruiken. De resultaten van de huidige studie laten deze verschillen echter niet zien.  
 De hoofdvraag was of neurofeedback van aanvullende waarde is op de momenteel toegepaste 
standaard behandeling voor het verminderen van ADHD-symptomen bij jongeren met ADHD en 
bijkomende stoornissen. De huidige studie vond vooruitgang in gedrag en neurocognitief functioneren 
voor adolescenten met ADHD en comorbide stoornissen, direct na de interventieperiode en 1 jaar na 
de interventieperiode, onafhankelijk van de ontvangen behandeling. De afwezigheid van aanvullende 
lange termijn effecten van neurofeedback, gecombineerd met de afwezigheid van specifieke effecten 
van neurofeedback ten opzichte van placebo-neurofeedback (Arnold et al., 2013; Perreau-Linck et al., 
2010; van Dongen-Boomsma et al., 2013; Vollebregt et al., 2013) en de intensiviteit van de behandeling 
met een groot aantal (20 tot 40) benodigde training sessies (Loo & Makeig, 2012), ondersteunen de 
implementatie van theta/SMR neurofeedback als behandeling voor adolescenten met ADHD en 
bijkomende stoornissen in de klinische praktijk niet.  
 
CONCLUSIE 
De hoofdconclusies van dit proefschrift zijn: 
1. Resultaten suggereren dat er verschillen zijn in onderliggende hersenmechanismen gerelateerd aan 
ADHD-symptomatologie tussen adolescenten met ADHD en adolescenten met een combinatie van 
ASS en ADHD. 
2. Theta/SMR neurofeedback laat geen aanvullend effect zien op de standaard behandeling om gedrag en 
neurocognitief functioneren te verbeteren bij adolescenten met ADHD en bijkomende stoornissen.  
Samengenomen suggereren de studies uit dit proefschrift dat meer onderzoek nodig is naar de 
onderliggende psychofysiologie van ADHD-symptomatologie bij de combinatie van ASS+ADHD en 
ADHD. Begrip van psychofysiologische mechanismen die ten grondslag liggen aan ADHD-
symptomatologie kan mogelijk helpen bij het ontwikkelen of verbeteren van interventies voor 
specifieke diagnostische groepen, zoals adolescenten met een combinatie van ASS+ADHD.  
Neurofeedback was voorgesteld als een mogelijk effectieve interventie voor het verminderen van 
ADHD-symptomatologie. Theta/SMR neurofeedback had in dit onderzoek echter geen aanvullende 
waarde op de huidige standaard behandeling om gedrag of neurocognitief functioneren te verbeteren. 
De afwezigheid van aanvullende effecten op korte en langere termijn ondersteunen aldus niet de 
implementatie van theta/SMR neurofeedback als behandeling voor adolescenten met ADHD en 
bijkomende stoornissen in de klinische praktijk. Deze resultaten wijzen erop dat het gebruik van kennis 
over mogelijk onderliggende psychofysiologische mechanismen aan ADHD-symptomatologie voor de 
ontwikkeling van interventies om blijvende klinisch relevante gedragsveranderingen te bewerkstelligen 
een nog grotere uitdaging is dan de reeds complexe zoektocht naar psychofysiologische correlaten op 
zichzelf. 
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Het dankwoord,  na zoveel jaren van data verzameling en een eindspurt om de data van al die jaren te 
verwerken, is nu de tijd dat alles bij elkaar komt. Dit alles was niet mogelijk geweest zonder de inzet, 
steun en het advies van velen. De bijdrage van iedereen was op eigen wijze onmisbaar voor het 
onderzoek.  De volgorde van dit dankwoord is als zodanig arbitrair.  
 Als eerste wil ik alle adolescenten ofwel alle jongens bedanken die hebben meegewerkt aan 
deze studie. Wat hebben jullie veel tijd en energie geïnvesteerd in het onderzoek. De lange testsessies 
met uitgebreide interviews, vragenlijsten en opdrachten, doorliepen jullie meerdere keren. Soms werd 
er gezucht bij de zoveelste vragenlijst, maar gelukkig werd er ook veel gelachen. Het voelde als een 
voorrecht dat jullie zo open waren en me een inkijk gaven in jullie leefwereld en geschiedenis. EEG en 
haargel gaan niet goed samen. Een deel van jullie kwam daarom met pet op binnen, nog een beetje 
nukkig bij het gebrek aan koffie of nicotine en als klap op de vuurpijl moest de mobiele telefoon ook 
nog worden uitgezet. Daar zit je dan met allemaal draadjes die naar je hoofd lopen en elektroden die 
op je zijn vastgeplakt en dat om 10 uur in de ochtend! Wie verzint dat nou? Waarom kan dat niet in de 
middag? Tja, ehmm, sorry jongens, dat was ik dus... En wat was ik blij dat jullie ondanks dat, meerdere 
keren zijn afgereisd naar Eindhoven en uiteindelijk op het doolhofachtige terrein het juiste gebouw 
wisten te vinden. Ongelofelijk dat het grootste deel van jullie bijna 40 sessies aan 
neurofeedbacktrainingen heeft doorlopen, twee à drie keer in de week. Energie haalde ik uit jullie 
creativiteit en doorzettingsvermogen. Jullie lieten me onder andere zelfgemaakte of gemixte muziek 
horen, vertelden over (de ontwikkeling van) computerspellen en jullie leerden me hoe via 'hand-klap-
gebaren' afscheid te nemen van elkaar. Bedankt jongens dat ik zoveel van jullie heb mogen leren en dat 
jullie zo goed hebben meegewerkt! 
 Ook alle ouders wil ik bedanken voor het invullen van vragenlijsten, soms twee keer per 
meting, omdat een deel van de post in Nederland nog met gedesoriënteerde postduiven lijkt te gaan. 
En natuurlijk ook bedankt voor de ritjes die jullie gemaakt hebben naar trainingen en metingen, voor 
het herinneren en motiveren van jullie zoons aan hun afspraken.  
 Prof. dr. Chijs van Nieuwenhuizen, beste Chijs, bedankt voor het mogelijk maken van het 
project en dat je me het vertrouwen hebt gegeven om het project uit te voeren. Alpha, beta en gamma 
hebben verschillende golflengten, de truc is om de coherentie te (h)erkennen en er op in te spelen. 
Onze discussies hebben mijn blik verbreed en me geleerd mogelijkheden te zien en te creëren. 
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 Dr. Ilja L. Bongers, beste Ilja, ook jou wil ik graag bedanken voor het mogelijk maken van het 
project. Met veel nauwkeurigheid en geduld heb je onder andere mijn grote hoeveelheden aan SPSS 
output en tabellen naast elkaar gelegd, je hebt alles voor me gecheckt en dubbel gecheckt, zodat we er 
zeker van waren dat alles in goede orde de deur uit kon. Dankjewel voor al je inzet de afgelopen jaren.  
 Dr. Arne Popma, beste Arne, wat was ik blij dat je met enthousiasme reageerde op het verzoek 
of je copromotor van me wilde worden. Je hebt me geleerd om mijn gedachten te structuren tot een 
helder verhaal, op momenten van grote drukte bracht je me rust en je hebt me steeds opnieuw 
uitgedaagd om met een andere blik naar zaken te kijken: wat fijn om met jou te mogen sparren. 
Bedankt voor alles wat je voor me gedaan hebt! 
 Dr. Geert J.M. van Boxtel, beste Geert, tijdens mijn bachelor heb ik je leren kennen en niet 
lang na mijn uitstap naar de universiteit van Leiden, ben ik weer bij je langsgekomen. Mijn verzoek was 
kort in verwoording: Wil jij mij zoveel als mogelijk leren over EEG? Even keek je me verbaasd aan, 
om vervolgens meteen tot actie over te gaan. Je hebt me wegwijs gemaakt in de wonderlijke wereld van 
EEG. Al snel was ik gefascineerd door al die golven en de mogelijke klinische implicaties. Ik ben je 
dankbaar dat je jouw kennis met me hebt willen delen. 
 Ir. Adrianus J.M Denissen, beste Ad, waar te beginnen als je een interventie wilt onderzoeken 
gebaseerd op EEG, maar je hebt nog geen apparatuur om EEG metingen op te nemen? Dankzij jouw 
altijd proactieve houding was dit probleem binnen een week opgelost. En ook daarna heb je me steeds 
opnieuw technische ondersteuning geboden: een halve seconde erbij, een halve seconde eraf. Altijd 
vrolijk hielp je me om de data zo optimaal mogelijk te krijgen, dankjewel voor de fijne samenwerking.  
 Graag wil ik ook de leden van de leescommissie bedanken: prof. dr. Eco de Geus, prof. dr. 
Robert Vermeiren, prof. dr. Chantal Kemner, dr. Dorine Slaats-Willemse, prof. dr. Henk Garretsen en 
prof. dr. Jaap Oosterlaan. Beste Jaap, als ik bij kruispunten kom maak je tijd vrij om me te informeren 
over de verschillende richtingen. Bedankt voor het meedenken en je heldere adviezen. 
 We hadden nooit zoveel jongens kunnen bereiken zonder de intensieve samenwerking met 
GGzE, GGz Breburg en de Reinier van Arkel groep. Vanuit alle lagen van de instellingen hebben 
mensen een bijdrage geleverd. Behandelaren hebben jongens aangemeld en interventiekeuzelijsten 
ingevuld. Heel erg bedankt voor jullie hulp! Zelfs op de momenten van reorganisaties en grote drukte, 
vonden jullie de tijd om de benodigde informatie door te sturen. Als ik iedere psycholoog, psychiater 
en sociaal psychiatrische verpleegkundige bij naam noem, wordt dit een zeer lange lijst en doe ik 
iedereen te kort voor de inzet die ze hebben getoond. Wel wil ik per instelling 1 persoon uitlichten die 
ik extra dankbaar ben voor het enthousiasme waarmee ze het onderzoek ondersteunden: Voor GGz 
Breburg is dat Hans Willemsen, voor GGzE is dat Rina Kerkhof en voor de Reinier van Arkel Groep 
is dat René Berende. Naast alle behandelaren wil ik ook graag de secretaresses bedanken voor onder 
andere het aannemen van de vele telefoontjes van jongens die afspraken wilden verzetten of niet meer 
wisten waar ze wanneer moesten zijn. Wendy Kneepkens, beste Wendy, graag wil ik je "significant" 
bedanken voor al je werk en gezelschap. Hans Donkers, beste Hans, als huismeester heb je jarenlang 
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zorg gedragen voor handdoeken, theedoeken, batterijen, stofzuigen en als er stagiaires moesten 
oefenen liet je je zelfs volplakken met electroden: dankjewel!  
 Ook voor de praktische uitvoering van het project ben ik dank verschuldigd aan alle 
onderzoeksassistenten en stagiaires, voor het geven van trainingen, het afnemen van testen en het 
invoeren, controleren en nog eens checken van alle data. Marilyn Peeters, jou wil ik in het bijzonder 
bedanken, als onderzoeksassistent heb je mij in alle jaren van het onderzoek ondersteund. Vele 
neurofeedbacktrainingen heb je gegeven. Je was altijd betrokken bij de jongens en zij waren erg op jou 
gesteld. Zonder jouw inzet, waren we nooit zover gekomen. Rebekka te Marvelde, in eerste instantie 
kwam je voor een stage van een halfjaar en zonder aarzeling gaf je daarna aan graag nog een halfjaar 
langer te blijven om me te helpen bij het laatste deel van de nametingen. Carlijn Berghout, lieve Carlijn, 
onze vrijdagmiddaguitjes bij andere onderzoeksgroepen vormden hoogtepunten in de maand. We 
hebben samen heel het land doorkruist en nu moeten we het hele land doorkruisen om elkaar te 
kunnen zien. Thomas Widdershoven, beste Thomas, als stagiair ben je bij het neurofeedback project 
betrokken, daarna ben je gebleven als onderzoeksassistent en nu ben je mijn paranimf! Zelfs in het 
weekend kon ik op je rekenen om hele datasets nog een keer te checken of gewoon gezellig samen wat 
te drinken. Charlotte Barendregt, lieve Charlotte, wat ben ik blij dat jij mijn collega werd. Veel 
ervaringen hebben we uitgewisseld en soms zijn we samen ontsnapt om even op adem te komen en 
daarna weer fris door te gaan. Fijn dat je mijn paranimf bent. 
 Graag wil ik ook mijn dank uiten naar prof. dr. Y.Y. Gidron en prof. dr. A.J.W. van der Does 
die me begeleid hebben tijdens mijn eerste stappen binnen het interventieonderzoek tijdens mijn 
studie. Dear Yori, your enthusiasm for research was contagious and with a smile I still remember a lot 
of stories about IL-1β. I am grateful that you taught me to believe in my own ideas and to pursue 
them. Beste Willem, bedankt voor de goede inhoudelijke begeleiding en discussies, de ervaring die ik 
heb opgedaan tijdens mijn masteronderzoek heb ik goed kunnen gebruiken de afgelopen jaren.  
 Tijdens de loop van mijn project het ik het geluk gehad vele inspirerende mensen te mogen 
ontmoeten. Een selectie hieruit: Lex van Bemmel, bedankt voor de bezielende gesprekken in de trein 
tussen Eindhoven en Utrecht. Martijn Arns, meer dan eens zitten we op een andere lijn als het over 
neurofeedbackonderzoek gaat: Bedankt voor de discussies en de technische ondersteuning. Graag wil 
ik Jeroen Dewinter bedanken voor de kritische vragen bij nieuwe ideeën en natuurlijk het 
ontspannende wandelweekend. Marjolein Luman en natuurlijk Rosa van Mourik en Katleen Gelade wil 
ik bedanken voor de gesprekken. Mirjam Kouijzer voor de "neurofeedback input", het was gezellig in 
Denver en in Breda.  
 Afgelopen jaar vroegen mijn vrienden weleens of er nog een tijd zou gaan komen dat ik weer 
onder mijn rots vandaan zou kruipen. En kijk het is gelukt, mede dankzij jullie steun. Lieve Esther, 
Vera, Anja, Anne en Suzanne wat ben ik blij dat jullie al zo lang mijn vriendinnen zijn. De afspraken 
met jullie geven me altijd nieuwe energie. Lieve Emel, samen kunnen wij alles! Eric wil ik bedanken 
voor het taalkundig advies. Niek, je was een geweldige acteur. Lieve Marianne, ook al ben je niet meer 
hier, in mijn gedachten ben je nog elke dag bij me en inspireer je me.  
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 Zonder familie ben je nergens en ook hen wil ik graag bedanken. Jeroen, dankjewel voor je 
technisch adviezen en het op verzoek programmeren van een digit span generator die aan al mijn 
mogelijke eisen voldeed. Maartje en kleine Anne, die mij samen altijd vrolijk krijgen. Susan en Nathalie 
voor alle biologische maaltijden aan het einde van lange werkdagen. Mijn ouders, die van elk bezoek in 
Frankrijk een feestje maken. Pauline en Siebe, voor het vertrouwen en de ondersteuning bij onder 
andere de zoveelste verhuizing. Mijn oma voor alle jaren van "mantelzorg" en al mijn tantes en ooms. 
Tineke, bedankt voor al je warmte en steun, wat bof ik toch met jou! 
 Lieve Tieme, het onderzoek heeft ons bij elkaar gebracht. Twee neurofeedbackonderzoeken 
op een kussen. We staan er weinig bij stil, maar wat is het bijzonder als je elkaars fascinatie zo goed kan 
begrijpen. Ik ben je zeer dankbaar voor je steun, zeker tijdens het laatste halfjaar. Niet alleen zorgde je 
voor het huishouden, ook las je kritisch mijn stukken door. Tussen al het werken door, liet je me zien 
wat daadwerkelijk belangrijk is in het leven. Nog elke dag geniet ik van jouw liefde: ik hou van je en 
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